Document:

<Page>

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                                                   EXHIBIT 10.18

                           DEVELOPMENT, MANUFACTURING

                                       AND

                               MARKETING AGREEMENT

                                     BETWEEN

                          BAXTER HEALTHCARE CORPORATION

                                       AND

                                 STERITECH, INC.

                                  APRIL 1, 1996

<Page>

                                TABLE OF CONTENTS

<Table>
<Caption>

                                                                                                               PAGE
<S>                                                                                                            <C>
1.       BACKGROUND...............................................................................................1

2.       DEFINITION OF TERMS......................................................................................1

3.       COOPERATIVE DEVELOPMENT WORK.............................................................................8

         3.1      Period; Objective...............................................................................8

         3.2      Management Board................................................................................9

                  (a)      Constitution...........................................................................9

                  (b)      Project Committees.....................................................................9

                  (c)      Voting.................................................................................9

                  (d)      Disputes..............................................................................10

         3.3      Review Of Budget, Benchmarks; Approved Projects................................................10

                  (a)      The Red Cell Project..................................................................10

                  (b)      The Fresh Frozen Plasma Project.......................................................11

                  (c)      Other Projects........................................................................12

         3.4      Exchange Of Information........................................................................12

         3.5      Cost Sharing...................................................................................12

         3.6      Testing And Regulatory Expenses................................................................13

                  (a)      Testing Expenses......................................................................13

                  (b)      Regulatory Expenses...................................................................13

         3.7      Budget Contingencies...........................................................................14

                  (a)      Exceeding Initial Budget..............................................................14

                  (b)      Reconciliation .Of Expenditures.......................................................14

         3.8      Baxter Participation In 1996...................................................................14

4.       EQUITY PURCHASE.........................................................................................14

         4.1      Baxter Purchase Of Equity In Steritech.........................................................14

         4.2      Option To Purchase Equity In Steritech.........................................................19

         4.3      Standstill By Baxter...........................................................................20

5.       SUPPLY OF STERITECH COMPOUND AND SYSTEM MANUFACTURING...................................................22

         5.1      Steritech Responsibilities.....................................................................22

         5.2      Baxter Responsibilities........................................................................22

         5.3      Instrument Production..........................................................................22

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                        i.
<Page>

         5.4      System Specifications..........................................................................22

         5.5      Steritech Specifications.......................................................................22

         5.6      Source Of Supply...............................................................................22

         5.7      Failure Of Steritech To Meet Baxter Requirements...............................................22

         5.8      System Improvements............................................................................22

6.       MARKETING AND DISTRIBUTION RIGHTS: EXCLUSIVE DISTRIBUTION RIGHTS........................................23

         6.1      Commercialization..............................................................................23

         6.2      Meetings Concerning Marketing..................................................................23

         6.3      Reserved Right To Compete......................................................................23

         6.4      Competing Products.............................................................................23

         6.5      Commencement, Cessation Of Marketing...........................................................23

         6.6      Achievement Of Market Share....................................................................24

         6.7      Supply Of Baxter Goods.........................................................................24

         6.8      Requalification................................................................................24

         6.9      Management Board Access To And Review Of Marketing And Distribution Information................25

7.       REVENUE SHARING.........................................................................................25

         7.1      Revenue Sharing Payments.......................................................................25

         7.2      Baxter Sourcing Steritech Compounds............................................................25

         7.3      Steritech As Seller Of Systems.................................................................25

         7.4      Licensing......................................................................................26

         7.5      Distributor Sales..............................................................................26

8.       PATENTS, KNOW-HOW, LICENSE GRANTS.......................................................................26

         8.1      Steritech Sole Ownership.......................................................................26

         8.2      Baxter Sole Ownership..........................................................................26

         8.3      Joint Patents..................................................................................26

         8.4      License........................................................................................27

         8.5      Steritech Rights...............................................................................27

                  (a)      Decontaminated Products...............................................................27

                  (b)      Other.................................................................................27

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                         ii.
<Page>

         8.6      Cross-License..................................................................................28

         8.7      Excluded Products..............................................................................28

         8.8      Notice Of Sole Rights..........................................................................28

         8.9      Other Agreements...............................................................................28

         8.10     Regulatory Files...............................................................................28

         8.11     Rights Under Government-Sponsored Research.....................................................29

9.       PROSECUTION OF PATENT RIGHTS............................................................................29

         9.1      Steritech Patents..............................................................................29

         9.2      Baxter Patents.................................................................................29

         9.3      Joint Patents..................................................................................29

         9.4      Prior Art; Review And Comment..................................................................29

         9.5      Election Not to Pay Expenses...................................................................29

10.      TRADEMARKS..............................................................................................30

         10.1     Baxter Trademarks..............................................................................30

         10.2     Steritech Trademarks...........................................................................30

11.      CONFIDENTIAL INFORMATION................................................................................30

         11.1     Confidentiality Agreement......................................................................30

         11.2     Use Of Consultants.............................................................................30

12.      CESSATION OF COOPERATIVE DEVELOPMENT WORK...............................................................30

         12.1     Cessation......................................................................................30

         12.2     Cessation Payment..............................................................................31

13.      REPORTS.................................................................................................32

         13.1     Quarterly Sales Reports........................................................................32

         13.2     Cost Of Goods/Base Revenue.....................................................................32

14.      BOOKS AND RECORDS.......................................................................................32

         14.1     Records........................................................................................32

         14.2     Retention......................................................................................33

         14.3     Interest.......................................................................................33

15.      TERM....................................................................................................33

16.      BREACH..................................................................................................33

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF
1934, AS AMENDED.

                                          iii.
<Page>

         16.1     Material Breach................................................................................33

         16.2     Rights On Termination..........................................................................33

17.      REPRESENTATIONS AND INDEMNITIES.........................................................................34

         17.1     Steritech Representations......................................................................34

         17.2     Steritech Indemnification - Representations And Warranties.....................................34

         17.3     Steritech Indemnification - Products...........................................................34

         17.4     Insurance......................................................................................35

         17.5     Baxter Representations.........................................................................35

         17.6     Baxter Indemnification - Representations And Warranties........................................35

         17.7     Baxter Indemnification-Products................................................................35

         17.8     Baxter Insurance...............................................................................36

18.      INFRINGEMENT............................................................................................36

         18.1     Defense Of Third Party Infringement Suits......................................................36

         18.2     Third Party Patent Expenses....................................................................36

         18.3     Suits For Infringement By Others...............................................................36

19.      GENERAL.................................................................................................37

         19.1     Entire Agreement...............................................................................37

         19.2     Relationship Of Parties........................................................................37

         19.3     Senior Baxter Contact..........................................................................37

         19.4     Senior Steritech Contact.......................................................................37

         19.5     Severability...................................................................................37

         19.6     Force Majeure..................................................................................38

         19.7     Notices........................................................................................38

         19.8     Binding........................................................................................38

         19.9     Governing Law..................................................................................38

         19.10    Venue..........................................................................................39

         19.11    Disbursements..................................................................................39
</Table>

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                   iv.
<Page>

                      TABLE OF CONTENTS
<Table>
<Caption>

<S>                             <C>
         Schedule A             Red Cell Budget and Tasks

         Schedule B             FFP Budget and Tasks

         Schedule C             Phase II Platelet Interim Determination Criteria

         Schedule D             Plasma Derivatives Letter

         Schedule E             Confidentiality Agreement

         Schedule F             Baxter Participation 1996

         Schedule G             Stock Purchase Agreement

</Table>

[ ***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                    v.
<Page>

               DEVELOPMENT, MANUFACTURING AND MARKETING AGREEMENT

         THIS AGREEMENT ("Agreement") between BAXTER HEALTHCARE CORPORATION, a
Delaware corporation ("Baxter") with principal offices at One Baxter Parkway,
Deerfield, I1llnois 60015, and STERITECH, INC., a California corporation
("Steritech") with principal offices at 2525 Stanwell Drive, Concord, California
94520, is effective as of the 1st day of April, 1996 ("Effective Date").

1.       BACKGROUND.

         1.1 Steritech has substantial knowledge and expertise in the area of
inactivation of pathogens for the documentation of blood products. Baxter has
substantial knowledge and expertise in the research, development, manufacture
and distribution of healthcare products including those relating to the
collection, preservation, processing, manipulation, storage and treatment of
blood and blood components.

         1.2 The parties are interested in the development and commercialization
of products-and/or systems which provide a customer with instrumentation,
disposables and compounds for use in ex-vivo inactivation of pathogens for the
decontamination of all human blood cells, Protein Preparations and human blood
components intended for human use.

2.       DEFINITION OF TERMS.

         The words appearing in capitalized form throughout this Agreement shall
have the meanings assigned to them in this Section 2.

         APPROVED DISTRIBUTOR means any company, other than a company (or any of
its affiliates) that manufactures blood collection products or any distributor
of blood collection products identified in a letter from Baxter to Steritech of
even date with this Agreement. For the purposes of this definition, an
"affiliate" of a company shall mean an entity controlling, controlled by, or
under common control with such company. "Control" for the purposes of this
definition shall mean fifty percent (50%) ownership.

         ALE has the-meaning set forth in that certain letter dated March 14,
1996 from Kathryn P. Wilke of Steritech to Joseph B. Barrett of Baxter.

         BASE REVENUE means for any Integrated Inactivation Set as of any
measurement date the average net sales price (computed using the same
adjustments as provided in paragraphs (a) and (b) of the definition of Net Sale)
of a comparable set without an Inactivation Package ("Base Set") during the
three full calendar months preceding such date, and in the case of each new
Integrated Inactivation Set, during the three full months preceding the first
sale of such Integrated Inactivation Set ("Initial Base Revenue"). Base Revenue
shall be adjusted, with respect to the sales of each Integrated Inactivation Set
in each quarter commencing with the first full calendar quarter after its first
sale, to

                  (a) an amount equal to the avenge net sales price (computed
using the same adjustments as provided in paragraphs (a) and (b) of the
definition of Net Sales) of a comparable Base Set during three full calendar
months preceding the first day of such calendar quarter, if

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                   1.
<Page>

there exists throughout such period a large blood collection market for such
comparable Base Set, or

                  (b) if there does not exist throughout such period a large
blood collection market for such Base Set, an amount equal to:

                           (w) which bears the same ratio to (x) the average Net
         Sales price for such Integrated Inactivation Set in such quarter

                           as the ratio of (y) the Base Revenue for such Base
         Set during the most recent three full month period in which there
         continuously existed a large clinical market for such Base Set to (z)
         the average Net Sales price for such Integrated Inactivation Set during
         such three full month period (or shorter period since first sale of
         such Integrated Inactivation Set).

Baxter shall provide to Steritech information supporting such average net sales
price within sixty (60) days after the last day of the first calendar quarter in
which the first sale of each Integrated Inactivation Set occurs and sixty (60)
days after the last day of each calendar quarter thereafter. For the purposes of
this definition, a "large blood collection market" shall be deemed to exist for
any Base Set in any three-month period if Baxter has sales of such Base Set into
the blood collection (for transfusion) market of at least twenty-five percent
(25%) of the number of units of such Base Set that were sold in the three-month
period immediately preceding the first sale of the comparable Integrated
Inactivation Set. Baxter shall provide to Steritech within sixty (60) days after
the last day of each calendar quarter information for each such Base Set
evidencing whether or not there exists a large clinical market.

         BASE SET has the meaning set forth in the definition of Base Revenue.

         BAXTER means Baxter Healthcare Corporation and its affiliates,
including, but not limited to, divisions and subsidiaries, and also including
its parent company, Baxter International Inc.. and its affiliates, including,
but not limited to, divisions and subsidiaries. A company shall be considered an
affiliate of Baxter if it is at least forty percent (40%) owned or controlled by
Baxter Healthcare Corporation or Baxter International Inc.

         BAXTER KNOW-HOW means unpatented inventions, data, processes,
compositions, techniques and other technical information proprietary to Baxter,
which is solely owned by Baxter or which Baxter has the right to control the use
of, relating to the Field and any Systems o including methods for manufacture or
use of Systems or portion thereof.

         BAXTER LICENSED KNOW-HOW means all Baxter Know-How in existence as of
the Effective Date or created or acquired during the term of the Cooperative
Development Work.

         BAXTER LICENSED PATENTS means all Baxter Patents in existence as of the
Effective Date of this Agreement, or claiming an invention conceived or
discovery made, or which are acquired, during the term of the Cooperative
Development Work.

         BAXTER NONCASH CONTRIBUTION shall be deemed to be [***] million for the
Red Cell Project, [***] million for the FFP Project and such amount as the
parties may agree for any other

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                        2.
<Page>

Project, PROVIDED that if the parties do not so agree, the Baxter Noncash
Contribution for such Project shall be one-haft of the Initial Budget for the
total Project, the amount of the Baxter Noncash Contribution in each case
being subject to adjustment as provided herein.

         BAXTER PATENTS means all United States and foreign patent applications
and patents that relate to the Field and have claims reading on a System or
portion thereof or methods for manufacture or use thereof, owned by Baxter or
licensed to Baxter with the right to sublicense and claiming an invention
conceived solely by employees and/or agents and/or licensors of Baxter both
prior to the Effective Date and during the term of this Agreement pursuant to
the Cooperative Development Work, including any continuations, divisions,
reissues, re-examinations and all foreign counterparts thereof.

         BULK FORM means Steritech Compounds which are not packaged in final
form.

         COOPERATIVE DEVELOPMENT WORK means the Cooperative Development Work
defined in Section 3.1 of this Agreement.

         COST OF GOODS means, for either party, such party's full cost of
manufacturing or acquiring such items, in accordance with generally accepted
accounting principles, consistently applied ("GAAP") and in accordance with
Baxter's normal accounting policies, all consistently applied. Cost of Goods
shall not include general corporate allocations or other allocations which are
not directly related to manufacture of the item and shall not include
amortization of development expenditures or expenses falling under the category
designated by Baxter "other costs of sales" or similar category, however
designated, unless otherwise agreed by the Management Board. Capital
expenditures for facilities and/or equipment and capitalized manufacturing
start-up costs will be amortized and included in Cost of Goods. In the event any
item is acquired by a party from an affiliate of such party, "cost of
manufacturing or acquiring" shall be deemed to mean such affiliate's cost of
manufacturing or acquiring.

         COST OF GOODS/BASE REVENUE for Steritech means Steritech's Cost of
Goods. For Baxter Cost of Goods/Base Revenue means:

                  (a) in the case in which the Inactivation  Package is sold as
a stand-alone  item,  Baxter's Cost of Goods, or

                  (b) in the case in which the Inactivation Package is sold as
part of an Integrated Inactivation Set in any calendar year, the greater of (i)
Baxter's Cost of Goods for the Integrated Inactivation Set PLUS a percentage of
Baxter's Base Revenue equal to the percentage applied to Net Sales in such
calendar year under the definition of Marketing and Administrative Expenses (for
marketing and administration expenses associated with Base Revenue), or (ii)
Baxter's Base Revenue PLUS Baxter's Cost of Goods for the Inactivation Package.

         DISTRIBUTOR PORTION means, for any Inactivation Package or Integrated
Inactivation Set sold through a distributor, the amount by which Net Sales price
therefrom exceeds the revenues from the sale of such items to the Distributor.

         EUROPE means any of the countries within the definition of Europe, as
such term is defined in the Platelet Agreement.

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                    3.
<Page>

         EXCLUDED PRODUCT has the meaning provided in Section 8.7 of this
Agreement

         FDA means the United States Food and Drug Administration.

         THE FIELD means the use of [***] in each case that are obtained from
[***]. The Field includes [***] for [***]. The Field does not include, however,
any [***] to make, enable, or improve the [***]. The preceding sentence is not
intended, however, to exclude (a) the use of such [***] falling within the
clauses (i), (ii) or (iii) above, or (b) the [***] falling within clauses (i),
(ii) or (iii) above, in which the [***]. (Steritech reserves all rights to [***]
in which the intended use of the [***].) The Field also excludes [***].

         FINAL PROJECT TOTAL BUDGET means the total cost and expense of
developing a System up to and including obtaining Regulatory Approval to market
the System in the countries in which the Management Board determines that
Regulatory Approval should be sought and any other items of cost or expense that
this Agreement expressly requires to be included in Final Project Total Budget.
In the event either party, to the extent permitted under Section 3.6(b) of this
Agreement, elects not to share in the costs of Regulatory Approval of a Project
in a particular country, the Final Project Total Budget shall be adjusted solely
as to such country by adding to the overall Final Project Total Budget the
amount of the incremental expenditures incurred by the party bearing the costs
of Regulatory Approval in such country and such party's cash contribution to the
Project solely as to such country will be increased by adding the amount of such
expenditures to such party's overall cash contribution to the Project.

         INACTIVATION PACKAGE means the package containing the Steritech
Compound as well as the delivery system (consisting of all disposables and
compound removal device, if any, associated with a System).

         INITIAL BUDGET means the budget first approved by the Management Board
for developing a particular Project to Regulatory Approval, which for the
Initial Budget for the Red Cell Project means Regulatory Approval in the United
States and Europe, and for the Initial Budget for the Fresh Frozen Plasma
Project means Regulatory Approval in the United States.

         INSTRUMENT means an instrument or instruments to be developed or
adapted under the Cooperative Development Work and may include associated data
tracking systems.

         INTEGRATED INACTIVATION SET means an integrated set containing an
Inactivation Package and other collection or storage items.

         JOINT PATENTS means all United States and foreign patent applications
and patents claiming an invention conceived or discovery made jointly by
employees and/or agents of both Steritech and Baxter, including any reissues,
re-examinations and all foreign counterparts thereof. Ownership of an invention
or discovery shall conclusively be considered "joint" when one or more employees
or agents from Baxter and one or more employees or agents from Steritech must be
indicated as co-inventors under United States patent laws .on a patent
application for the invention.

         MANAGEMENT BOARD means the Management Board created pursuant to Section
3.2 hereof.

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                     4.
<Page>

         MARKET LAUNCH of a System in a given country is deemed to be the
earlier of (1) the date of first commercial sale following Regulatory Approval
for sale of the System in that particular country or (2) the ninetieth (90th)
day following Regulatory Approval for commercial sale of that System in that
country.

         MARKETING AND ADMINISTRATIVE EXPENSES for a party in any calendar year
is that percentage of such party's Net Sales (minus Base Revenue in the case of
sales of Integrated Inactivation Sets) for costs incurred in marketing, selling
arid administering the Systems, established as follows:

<Table>
<Caption>
             AGGREGATE NET SALES OF SUCH PARTY       PERCENTAGE APPLIED
                   IN SUCH CALENDAR YEAR            TO ALL NET SALES IN
                                                     SUCH CALENDAR YEAR
             ---------------------------------      -------------------
             <S>                                    <C>
             Under [***]                                  [***]
             [***] up to [***]                            [***]
             [***] up to [***]                            [***]
             Over [***]                                   [***]
</Table>

(All dollar mounts in this definition are expressed in U.S. dollars, convened
from foreign currencies in accordance with Section 7.1 hereof). For the purpose
of determining Premium for the first three quarterly Revenue Sharing Payments
for any calendar year, the percentage used as set forth above to compute a
party's Marketing and Administrative Expenses will be based on the party's BONA
FIDE forecast of Net Sales in such calendar year used for its internal
management purposes (which information will be provided to the Management
Board). If actual aggregate annual Net Sales vary from such projections to an
extent that would cause a change in the applicable percentage rate for such
calendar year, such rust three quarterly Revenue Sharing Payments will be
appropriately adjusted retroactively in the final Revenue Sharing Payment for
such calendar year (i.e., the First Revenue Sharing Payment date in the
following calendar year) and additional payments will be made to the receiving
party, or amounts reimbursed from the receiving party, to yield the
actual-Revenue Sharing Payment to which the receiving party is entitled based on
the level of actual Net Sales in such calendar year.

         NET SALES means

                  (a) in the case of the Inactivation Package sold as a
stand-alone item or as part of an Integrated Inactivation Set, the amount
invoiced by Baxter for sales, leases, or licenses of the stand-alone
Inactivation Package or Integrated Inactivation Set, less credits or allowances,
if any, for rejections or returns, customary trade discounts actually given,
less customs and duties paid; less separately invoiced and actually incurred
taxes and other governmental charges that are imposed directly on or measured by
the sale, transfer, transportation, delivery or use of an Inactivation Package;
and less freight paid by Baxter on shipment from Baxter to end users.

                  (b) In the event any Inactivation Package or Integrated
Inactivation Set is bundled (whether or not invoiced separately) and sold at a
discount with other products for whatever reason, including a special
promotional offer, or in the event of any transaction other than a BONA FIDE
arms length transaction exclusively for money, or upon any use of such

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                      5.
<Page>

Inactivation Package or Integrated Inactivation Set for purposes which do not
result in customary sales revenue, such sale or other disposal or use shall be
(unless the parties agree otherwise) deemed to constitute a sale at the then
current average selling price for the Inactivation Package or Integrated
Inactivation Set, as the case may be.

                  (c) In the case of sales by Baxter to a distributor, the Net
Sales shall be computed on the distributor's invoice price to the ultimate
purchaser or user. In the event that Baxter is not able to determine the price
charged by a distributor to the ultimate purchaser or user, such price shall be
the recommended price which Baxter, at the direction of the Management Board,
recommends the distributor to charge to its end customers (which may vary from
territory to territory).

                  (d) In the event Baxter, in accordance with policies
established by the Management Board, supplies Instruments to end users without
charge in return for an increased price of Inactivation Packages to such end
users, Baxter may deduct from Net Sales received from such end users the
depreciation of cost of such Instruments. In the event such Instruments are also
used in connection with products supplied by Baxter other than the Inactivation
Packages or Integrated Inactivation Sets developed under this Agreement, then
the amount of such depreciation to be deducted in any quarter from Net Sales
shall be limited to that portion of the depreciation reasonably allocable to the
use of the Instruments in connection with Inactivation Packages and Integrated
Inactivation Sets, in accordance with policies established by the Management
Board.

                  (e) In the event that the ultimate purchaser or end user is
assessed a charge on a per-inactivation or other usage basis, the amount of such
charge shall be included in Net Sales.

                  (f) If the term "Net Sales" is used in reference to Systems
sold by Steritech, the word "Baxter" in this definition shall be deemed to mean
"Steritech".

         NONCASH CONTRIBUTION means the Baxter Noncash Contribution and/or the
Steritech Noncash Contribution, as the context requires.

         PATENT ROYALTY PAYMENT means a patent royalty payment made to a third
party for manufacture, use or sale of a System or portion thereof.

         PLATELET AGREEMENT means that certain Development, Manufacturing and
Marketing Agreement between the parties dated as of December 10, 1993.

         PREMIUM means the Net Sales price of an Inactivation Package or
Integrated Inactivation Set minus each Party's Cost of Goods/Base Revenue in the
Inactivation Package or Integrated Inactivation Set, and minus Marketing and
Administrative Expenses.

         PROJECT means the Cooperative Development Work performed by the Parties
to develop, obtain Regulatory Approval of, and market a System for a specific
application within the Field.

         PROTEIN PREPARATIONS shall mean all blood derived products in which the
therapeutic component is a protein, such as coagulation factors.

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                      6.
<Page>

         REGULATORY APPROVAL means (1) in the United States, approval from the
FDA for marketing and promotion of the System, or (2) outside of the United
States, an analogous order by a non-U.S. governmental agency which requires
regulatory approval prior to marketing and promotion of a System in such
non-U.S. country.

         REVENUE SHARING Formula means the relative percentage interest of
Baxter and Steritech as set forth in Section 7 hereof.

         REVENUE SHARING PAYMENTS has the meaning set forth in Section 7.1
hereof.

         SPECIFICATIONS FOR STERITECH COMPOUND means the performance, quality
and reliability requirements which the Project Committee and Management Board
agree must be met by a Steritech Compound for such Steritech Compound to be
acceptable for commercial implementation under Section 6. The Management Board
shall prepare written specifications for Steritech Compound. Such specifications
shall include a provision that Steritech Compound be made according to Good
Manufacturing Practices in a facility licensed by the FDA or (if Steritech shall
elect to manufacture Steritech Compound outside the United States) other
applicable regulatory authority.

         STAND-ALONE OR STAND-ALONE, in reference to an Inactivation Package,
means an Inactivation Package that is not integrated with other collection or
storage items, and which may take the form, for example, of a bag and tube set
that may be sterile docked, a syringe or ampule.

         STERITECH means Steritech, Inc., a company organized under the laws of
California and its affiliates, including, but not limited to, divisions and
subsidiaries. A company shall be considered an affiliate of Steritech if it is
at least forty percent (40%) owned or controlled by Steritech.

         STERITECH COMPOUND(S) means any and all psoralen compounds and anchor
linker effector ("ALE") compounds, developed by, licensed to, acquired by or
otherwise commercially accessible to Steritech prior to the Effective Date or in
the course of the Cooperative Development Work but does not include the psoralen
compound that at this time is designated by Steritech as [***].

         STERITECH KNOW-HOW means unpatented inventions, data, processes,
compositions, techniques and other technical information proprietary to
Steritech, which is solely owned by Steritech or which Steritech has the right
to control the use of, relating to the Field and the System, including methods
for manufacture or use of Steritech Compounds and Systems or portions thereof.

         STERITECH LICENSED KNOW-HOW means all Steritech Know-How in existence
as of the Effective Date or created or acquired during the term of the
Cooperative Development Work.

         STERITECH LICENSED PATENTS means all Steritech Patents in existence as
of the effective date of this Agreement, or claiming an invention conceived or
discovery made, or which are acquired, during the term of the Cooperative
Development Work.

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                      7.
<Page>

         STERITECH NONCASH CONTRIBUTION shall be deemed to be [***] million for
the Red Cell Project, [***] million for the FFP Project and such amount as the
parties may agree for any other Project, PROVIDED that if the parties do not so
agree, the Steritech Noncash Contribution for such Project shall be one-haft of
the Initial Budget for the total Project, the amount of the Steritech Noncash
Contribution in each case being subject to adjustment as provided herein.

         STERITECH PATENTS means all United States and foreign patent
applications and patents that relate to the Field and have claims reading on
Steritech Compounds or compositions or formulations thereof, or otherwise
reading on a System or portion thereof, or methods for manufacture or use of
such System or Steritech Compound owned by or licensed to Steritech with the
right to sublicense and claiming an invention conceived solely by employees
and/or agents and/or licensors of Steritech both prior to the Effective Date and
during the term of the Cooperative Development Work, including any
continuations, divisions, reissues, re-examinations and all foreign counterparts
thereof.

         SYSTEM(S) means a product developed pursuant to the Cooperative
Development Work for use in the Field, incorporating one or more Steritech
Compounds, an Instrument, if any, and associated computer software, and any
disposables, delivery system or other components.

         SYSTEM IMPROVEMENTS means those improvements of commercial Systems
approved by the Management Board. The Management Board shall approve and manage
a budget for all System Improvements (System Improvement Costs).

         SYSTEM SPECIFICATIONS means the performance, cost, quality and
reliability requirements as the Management Board agree must be met by a System
in order for the System to be acceptable for marketing and distribution
hereunder.

3.       COOPERATIVE DEVELOPMENT WORK.

         3.1 PERIOD; OBJECTIVE. From the Effective Date, Baxter and Steritech
shall work together to develop and obtain Regulatory Approval for (the
"Cooperative Development Work") and thereafter market Systems in the Field. The
Management Board shall from time-to-time approve specific Projects for the
Steritech Compounds within the Field.

         3.2      MANAGEMENT BOARD.

                  (a) CONSTITUTION. Steritech and Baxter will appoint a five (5)
person Management Board consisting of two (2) senior executives designated by
each company and one (1) independent member chosen by mutual agreement of the
Parties. The purpose of the Management Board will be to facilitate the overall
relationship of the parties under this Agreement and to manage the research,
development and marketing of Projects within the Field. System Specifications
recommended by the Parties shall not be deemed finalized until they are approved
by the Management Board. The Management Board shall meet from time to time as
appropriate, but no less frequently than four (4) times during each calendar
year, alternating between the offices of the parties, unless the parties shall
agree otherwise. The Management Board shall review and approve budgets, resource
allocations, Projects undertaken within the Field, sales and marketing plans and
expenditures.

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                      8.
<Page>

                  (b) PROJECT COMMITTEES. To assist the Management Board in its
work, the Management Board may, from time-to-time, at its sole discretion,
create project committees, including Management Board and non-Management Board
members. A project committee shall only have that authority specifically granted
to it by the Management Board. A project committee may be created to oversee a
Project or a specific aspect or a Project. However, a project committee shall
never have the authority to disperse funds or reimburse expenses.

                  (c) VOTING. All decisions of the Management Board shall be
made by majority vote or written consent, with Baxter and Steritech each having
one vote regardless of the number of representatives attending any meeting. The
independent member shall vote on all deadlocks of the Management Board; however,
the independent member shall not vote on matters pertaining to any dispute
concerning the parties' legal obligations to each other for disbursement of
funds or the reimbursement of expenses under any circumstances. In the event of
a deadlock that may be broken by the independent member, either Baxter or
Steritech may notify the other party and the independent member in writing of
the existence of such deadlock and provide to each the specific resolution that
such party proposes to be adopted by the Management Board. Each party will have
thirty (30) days from such notice to present its position to the independent
member, which shall include at least one meeting at which both parties and the
independent member are present. Either Baxter, Steritech or the independent
member may, by notice to the others, shorten such time period if such party
believes that urgent action is required on the matter at issue. The independent
member shall render his or her vote on such resolution as promptly as possible,
and in no event later than twenty (20) days after such time period. In the event
of a deadlock between the parties on a decision whether to discontinue
Cooperative Development Work on a Project or to reduce funding for a Project,
the independent member shall not break the deadlock and the Project will
continue without reduction of funding level, subject to the right of either
party to cease participation in such Project, as provided in Section 12 hereof.
Any compensation of the independent member shall be by mutual agreement of the
Parties and shall be subject to cost sharing. The independent member shall vote
on all matters in a manner that in the good faith judgment of the independent
member is in Baxter and Steritech's best interests as risk and revenue sharers
under this Agreement (i.e. in the same manner that a corporate director would
vote in the best interests of the shareholders of a corporation). Baxter and
Steritech will indemnify and hold harmless the independent member against any
claim arising from a decision made by the independent member, so long as such
decision was made in good faith. The independent member may be removed and/or
replaced by mutual written consent of Baxter and Steritech.

                  (d) DISPUTES. With regard to the disputes concerning the
parties' legal obligations to each other for disbursement of funds or
reimbursement of expenses, in the event of a deadlock of the Management Board on
these particular issues, if they are unable to reach agreement Within thirty
(30) days of the onset of the deadlock, then the matter shall be finally settled
by arbitration, to be held in Chicago, Illinois, in accordance with the
Commercial Arbitration Rules of the American Arbitration Association ("AAA").
Any such dispute or controversy shall be arbitrated before one arbitrator,
acceptable to both parties. If the parties are unable to agree on an arbitrator,
one shall be selected in accordance with the rules of the AAA. The arbitrator's
decision shall be final and binding upon the parties. The parties shall be
entitled to full discovery in any such arbitration. Each party shall bear one
half of the cost of such arbitration, unless the arbitrator otherwise allocates
such costs. During the period of any

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                      9.
<Page>

arbitration, each party shall pay to the other party any amounts that are or
become due and owing to such other party, other than amounts being contested in
good faith in the arbitration.

In addition, in the event that there is a deadlock on any other issue within the
authority of the Management Board as to which the independent member would be
authorized to break the deadlock, and at that time there is not an independent
member (or for any reason the independent member does not break such deadlock),
either party may apply to the AAA to appoint an individual, in accordance with
the rules of the AAA who will act in the capacity of independent member solely
for the purpose of breaking such deadlock and resolving such issue. Prior to
making such application, a party will provide to the other party ten (10) days'
advance written notice of its intent to do so. During such ten (10) day period,
the parties will use their good faith best efforts to resolve such issue in a
meeting between the chief executive officer of Steritech and the highest ranking
officer of Baxter Biotech or comparable successor division or entity, or failing
such resolution, to agree upon appointment of an independent member. Each party
will in all cases cooperate in providing the independent member such information
as the independent member may request in considering any matter.

         3.3 REVIEW OF BUDGET, BENCHMARKS; APPROVED PROJECTS. The benchmarks,
budget and timetable for all Projects will be reviewable by the Management Board
from time-to-time during the Cooperative Development Work with the intent that
the parties move expeditiously and effectively toward commercialization of any
System.

                  (a) THE RED CELL PROJECT. The Initial Budget for one Project
approved, as of the Effective Date of this Agreement, by the Management Board is
the Red Cell Project, attached hereto as Schedule A. Each party shall perform
the respective tasks set forth on Schedule A.

                           (i) All funding of the Red Cell Project shall be
provided by Steritech, until Regulatory Approval to commence Phase II clinical
trials in the United States or Europe under the Platelet Agreement (the
"Platelet Milestone"), except as provided in Subsection 3.3(a)(ii). Steritech
will use reasonable commercial development efforts to conduct such program in
1996 in accordance with the budget for 1996 on Schedule A, including expenditure
of the amounts called for in such budget for 1996. Upon achievement of the
Platelet Milestone, Baxter shall participate in the Red Cell Project in
accordance with this Agreement, including without limitation the obligation to
share fifty percent (50%) of the costs and expenses of the Cooperative
Development Work incurred on or after January 1, 1997, and to market and sell
the Systems for Red Cells developed under this Agreement. Baxter shall pay to
Steritech on the later of (a) the date of achievement of the Platelet Milestone,
or (b) January 1, 1997, fifty percent (50%) of the amount (if any) expended by
Steritech under the Project budget from January 1, 1997 to the date of payment,
and shall also pay to Steritech on such date, and on the first day of each
calendar year thereafter, the amount by which Steritech's budgeted expenditures
under the then current Project budget for the then current calendar year
(including amounts budgeted to be expended by Steritech on outside expenses)
exceeds fifty percent (50%) of the budgeted expenditures for such period.

                           (ii) Notwithstanding Subsection 3(a)(i), in the event
that, for any reason, the Platelet Milestone is not achieved by September 30,
1997, then Baxter must provide notice of its commitment to participate ("Red
Cell Commitment Notice") in the Red Cell Project,

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                     10.
<Page>

and commence participation in accordance with the terms of this Agreement, by
October 31, 1997 or Baxter shall be deemed to have elected not to participate,
and decontamination systems for Red Cells will thereafter be deemed to be an
Excluded Product. Baxter shall pay to Steritech on the date of the Red Cell
Commitment Notice, fifty percent (50%) of the amount expended by Steritech under
the Project budget from January 1, 1997 to the date of payment, and shall also
pay to Steritech on such date, and on the first day of each calendar year
thereafter, the amount by which Steritech's budgeted expenditures under the then
current budget for the remainder of then current calendar year exceeds Fifty
percent (50%) of the budgeted expenditures for such period. The Commitment
Notice shall evidence Baxter's obligation to participate in and share fifty
percent (50%) of the cost of the Cooperative Development Work on the Red Cell
Project from and after the date of such notice and to market and sell Systems
for Red Cells developed under this Agreement. Steritech's obligation to proceed
with such Cooperative Development Work will be contingent on the negotiation by
Baxter and Steritech of a revision of the equity purchase schedule under Section
4 hereof to provide funding for Steritech to support such Cooperative
Development Work. Nothing in this subsection should be construed as any
expectation that achievement of the Platelet Milestone will be delayed.

                  (b) THE FRESH FROZEN PLASMA PROJECT. The Initial Budget for
one project approved by the Management Board as of the Effective Date of this
Agreement is the Fresh Frozen Plasma Project, attached hereto as Schedule B.
Each Party shall perform the respective tasks set forth on Schedule B.

                           (i) All funding of the Fresh Frozen Plasma Project
shall be provided by Steritech, until Regulatory Approval to commence Phase II
clinical trials in the United States or Europe under the Platelet Agreement (the
"Platelet Milestone"), except as provided in Subsection 3.3(b)(ii). Steritech
will use reasonable commercial development efforts to conduct such program in
1996 in accordance with the budget for 1996 on Schedule B, including expenditure
of the amounts called for in such budget for 1996. Upon achievement of the
Platelet Milestone, Baxter shall participate in the Fresh Frozen Plasma Project
in accordance with this Agreement, including without limitation the obligation
to share fifty percent (50%) of the costs and expenses of the Cooperative
Development Work incurred on or after January 1, 1997, and to market and sell
the Systems for Fresh Frozen Plasma developed under this Agreement. Baxter shall
pay to Steritech on the later of (a) the date of achievement of the Platelet
Milestone, or (b) (i) January 1, 1997, fifty percent (50%) of the amount (if
any) expended by Steritech under the Project budget from January 1, 1997 to the
date of payment, and shall also pay to Steritech on such date, and on the first
day of each calendar year thereafter, the amount by which Steritech's budgeted
expenditures under the then current Project budget for the then current calendar
year (including amounts budgeted to be expended by Steritech on outside
expenses) exceeds fifty percent (50%) of the budgeted expenditures for such
period.

                           (ii) Notwithstanding Subsection 3(b)(i), in the event
that, for any reason, the Platelet Milestone is not achieved by September 30,
1997, then Baxter must provide notice of its commitment to participate ("FFP
Commitment Notice") in the Fresh Frozen Plasma Project, and commence
participation in accordance with the terms of this Agreement, by October 31,
1997 or Baxter shall be deemed to have elected not to participate, and
decontamination systems for Fresh Frozen Plasma will thereafter be deemed to be
an Excluded Product. Baxter shall pay to Steritech on the date of the FFP
Commitment Notice, fifty percent (50%) of the

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                     11.
<Page>

amount expended by Steritech under the Project budget from January 1, 1997 to
the date of payment, and shall also pay to Steritech on such date, and on the
first day of each calendar year thereafter, the amount by which Steritech's
budgeted expenditures under the then current budget for the remainder of then
current calendar year exceeds fifty percent (50%) of the budgeted expenditures
for such period. The Commitment Notice shall evidence Baxter's obligation to
participate in and share fifty percent (50%) of the cost of the Cooperative
Development Work on the Fresh Frozen Plasma Project from and after the date of
such notice and to market and sell Systems for Fresh Frozen Plasma developed
under this Agreement. Steritech's obligation to proceed with such Cooperative
Development Work will be contingent on the negotiation by Baxter and Steritech
of a revision of the equity purchase schedule under Section 4 hereof to provide
funding for Steritech to support such Cooperative Development Work. Nothing in
this subsection should be construed as any expectation that achievement of the
Platelet Milestone will be delayed.

                  (c) OTHER PROJECTS. The budget for each other project shall be
approved by the Management Board. Baxter shall pay to Steritech upon the
approval of the Initial Budget for each such project, and upon each anniversary
of the date thereof, the amount by which Steritech's budgeted expenditures under
the then current budget for the succeeding twelve month period exceeds 50% of
the total then budgeted expenditures for such period.

         3.4 EXCHANGE OF INFORMATION. During the term of the Cooperative
Development Work, the parties shall exchange all material information developed
pursuant to the Cooperative Development Work including the exchange of Baxter
Know-How and information concerning Baxter Patents and Steritech Know-How and
information concerning Steritech Patents relating to the Field. The exchange
shall occur pursuant to Section 11. The Systems shall embody and use such
Steritech Licensed Patents and Steritech Licensed Know-How and Baxter Licensed
Patents and Baxter Licensed Know-How as shall be determined by the Management
Board.

         3.5 COST SHARING. Except as otherwise provided in this Agreement,
commencing January 1, 1997, Baxter will fund fifty percent (50%) and Steritech
will fund fifty percent (50%) of the Cooperative Development Work with respect
to each Project, and Steritech will fund one hundred percent (100%) of the cost
of the Cooperative Development Work, as set forth in the Initial Budget, with
respect to the Red Cell Project and the Fresh Frozen Plasma Project prior to
that date. Funding shall include all costs and expenses incurred in connection
with the Cooperative Development Work. These costs and expenses shall be shared
equally for each Project, fifty percent (50%) paid by Baxter and fifty percent
(50%) paid by Steritech. Cost and expenses shall include only those expenditures
made in accordance with Project budgets approved by the Management Board related
to, research, development, clinical trials, and Regulatory Approval and other
expenses that this Agreement expressly provides shall be subject to cost
sharing. In the event that the funding for the Cooperative Development Work for
any project is not shared equally commencing January 1, 1997, then (except as
otherwise provided in Section 12 or Section 16 hereof) the Revenue Sharing
Formula in Section 7.1 for such Project shall be adjusted such that the
percentage of Premium received by a party will equal the percentage contributed
by such party to the sum of (a) the cash contributed to the Final Project Total
Budget commencing January 1, 1997 (excluding carryovers of 1996 expenditures, as
provided below in this Section), PLUS (b) Noncash Contribution to the Project.
Nothing in this Section 3.5 shall be construed to imply that prior to
achievement of the Platelet Milestone Baxter

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                     12.
<Page>

shall have any obligation to provide funds for Cooperative Development Work.
Capital expenditures for facilities and/or equipment and capitalized
manufacturing start-up costs will not be included in costs and expenses shared.
Steritech agrees to expend on the Red Cell Project and the Fresh Frozen Plasma
Project the respective amounts set forth on Schedules C and D for 1996; PROVIDED
that if such amounts cannot for any reason be spent in 1996, the unexpended
amounts will be carried over and expended in 1997 (without reducing Steritech's
obligations with respect to the 1997 budget).

                  (a) All expenses and costs incurred by the panics in
connection with the Cooperative Development Work commencing January 1, 1997
shall be subject to cost sharing pursuant to Section 3.5. Each party shall
maintain detailed records which accurately identify costs and expenses incurred
and paid in connection with the Cooperative Development Work. for each specific
Project. Each party Shall submit this information to the Management Board on the
on the last business day of February for the period ending December 31, and on
the last business day of August for the period ending June 30 (or such
alternative dates as the Management Board may establish) along with an estimate
of expenses to be incurred during the current six months. Expenses internally
generated because tasks are performed by a party's own staff will be accounted
for on a uniform average cost per full time equivalent basis.

                  (b) All costs with respect to participation on the Management
Board during the Cooperative Development Work, including travel expenses for
meetings and participation on the Management Board, shall be subject to cost
sharing.

         3.6      TESTING AND REGULATORY EXPENSES.

                  (a) TESTING EXPENSES. All expenses incurred in connection with
any testing whose primary function is marketing of the System, rather than
developing the System or obtaining Regulatory Approval of the System, shall be
borne solely by Baxter and shall not be considered expenses subject to cost
sharing, unless the Management Board determines that such expenses should be
considered part of the Cooperative Development Work.

                  (b) REGULATORY EXPENSES. The Management Board shall determine
the countries in which Regulatory Approval will be sought and the timing of
seeking such Regulatory Approval. All expenses incurred to obtain Regulatory
Approval are expenses subject to cost sharing under Section 3.5 and shall be
part of the Final Project Total Budget; PROVIDED, HOWEVER, that either party
may, by notice given to the other party within thirty (30) days after such
Management Board decision with respect to a particular country, elect to not
share in the costs of Regulatory Approval in not more than five (5) countries
outside of North America and Europe, which will result in an adjustment for each
such country of Final Project Total Budget (as further provided in the
definition of "Final Project Total Budget").

         3.7      BUDGET CONTINGENCIES.

                  (a) EXCEEDING INITIAL BUDGET. If the Management Board
establishes a budget for a new Project, or determines that the budget for an
approved Project within the Field must be increased over the previously
established budget for the Project, then Baxter will fund fifty percent (50%)
and Steritech will fund fifty percent (50%) of the new Project budget or of any

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                     13.
<Page>

increase in the previously approved budget. In the event of any new Project
budget or budget increase, however, either party may, by written notice to the
other party, elect to fund less than its full share (50%) of such new Project
budget or budget increase. In such an event, the funding party may, by written
notice to the non-funding party, elect to assume responsibility for the funding
of such unfunded amount, in which event (except as otherwise provided in Section
12 and Section 16 hereof) the Revenue Sharing Formula in Section 7.1 for such
Project will be adjusted such that the percentage of Premium to be received by a
party will equal the percentage contributed by such party to the sum of (i) the
cash contributed to Final Project Total Budget commencing January 1, 1997
(excluding 1996 carryovers as described in Section 3.5), PLUS (ii) total Noncash
Contribution to the Project.

                  (b) RECONCILIATION .OF EXPENDITURES. Unless otherwise agreed,
the Management Board shall reconcile actual cash outlays and expenses approved
by the Management Board with respect to a Project on an annual basis such that
costs have been incurred in the proportion of fifty percent (50%) by Baxter and
fifty (50%) by Steritech, or such other ratio as is established pursuant to
Section 3.7(a). If they are not in such proportion, Steritech will make a cash
payment to Baxter, or Baxter will make a cash payment to Steritech, in order to
achieve such proportion. The payment shall be made in cash within thirty (30)
days following the determination by the Management Board.

         3.8 BAXTER PARTICIPATION IN 1996. In calendar year 1996, Baxter will in
good faith provide non-incremental Baxter resources at no cost to Steritech to
support the program under the Cooperative Development Work. In addition, in such
calendar year Baxter will use good faith efforts to supply other resources to
Steritech at Steritech's request and at Steritech's expense from time to time on
a reasonable time and materials basis to carry out the activities set forth on
Schedule F. To the extent Baxter cannot supply such services with its existing
resources, Baxter and Steritech will consult in good faith concerning Baxter's
adding additional internal resources or using outside services to perform such
activities.

4.       EQUITY PURCHASE.

         4.1 BAXTER PURCHASE OF EQUITY IN STERITECH. Baxter shall purchase
equity in Steritech according to the following terms and schedule:

                  (a)      Purchase six million dollars ($6,000,000.00 U.S.) of
                           Series E Preferred Stock in Steritech at fifteen
                           dollars and seventy-five cents ($15.75 U.S.) per
                           share, Three Million Dollars ($3,000,000 U.S.) of
                           which will be purchased on April 1, 1996 and Three
                           Million Dollars ($3,000,000 U.S.) will be purchased
                           on July 1, 1996.

                  (b)      Purchase five million dollars ($5,000,000.00 U.S.) of
                           Steritech equity upon approval to commence a Phase II
                           study in the United States or Europe in the program
                           under the Platelet Agreement ("Tranche 2 Milestone")
                           consisting of Common Stock at a purchase price equal
                           to open market PLUS twenty percent (20%) if Steritech
                           is publicly traded at the time of such purchase, or
                           if then privately held, Preferred Stock at the lesser
                           of (i) twenty-five dollars and ten cents ($25.10
                           U.S.) per share or

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                     14.
<Page>

                           (ii) fifty percent (50%) premium over last private
                           third-party financing round, PROVIDED THAT this
                           clause (ii) shall apply only if there has been a
                           third-party private financing round of at least
                           five million dollars ($5,000,000) since the date
                           of the last equity purchase by Baxter pursuant to
                           this Section 3.11. Such purchase will be
                           consummated and the purchase price paid not later
                           than January 10, 1997, or within fifteen (15)
                           business days after such Tranche 2 Milestone, if
                           later. As used in this Section 4.1, "open market"
                           means the average closing price of the Steritech
                           stock, as reported in the Wall Street Journal, for
                           the thirty (30) trading days (or lesser number of
                           trading days that Steritech stock is publicly
                           traded) prior to and including the trading day
                           that is two (2) trading days prior to the date the
                           purchase is consummated. A "trading day" is a day
                           when the Steritech stock may be traded on the
                           relevant exchange or over the counter.

                  (c)      Either purchase five million dollars ($5,000,000.00
                           U.S.) of Steritech equity upon the completion of both
                           Phase II Platelet Interim Determination and filing of
                           an IND with the F.D.A. to begin a Phase I study under
                           the Red Cell Project, or comparable filing in Europe
                           under such Project (the "Tranche 3 Milestone") or, at
                           Steritech's election, purchase two million dollars
                           ($2,000,000 U.S.) of Steritech equity upon the
                           completion of the Phase II Platelet Interim
                           Determination ("Tranche 3a Milestone") and purchase
                           three million dollars ($3,000,000 U.S.) upon the
                           approval of an IND by the F.D.A. under the Red Cell
                           Project or comparable approval in Europe under such
                           Project ("Tranche 3b Milestone") consisting of Common
                           Stock at a purchase price equal to open market price
                           PLUS twenty percent (20%) if Steritech is publicly
                           traded at the time of such purchase or, if then
                           privately held, Preferred Stock at the lesser of (i)
                           twenty-five dollars and ten cents ($25.10 U.S.) per
                           share or (ii) fifty percent (50%) premium over last
                           private third-party financing round PROVIDED THAT
                           this clause (ii) shall apply only if there has been a
                           third-party private financing round of at least five
                           million dollars ($5,000,000) since the date of the
                           last equity purchase by Baxter pursuant to this
                           Section 3.11. Such purchase will be consummated and
                           the purchase price paid not later than January 10,
                           1998, or within fifteen (15) days after such Tranche
                           3 Milestone, Tranche 3a Milestone or Tranche 3b
                           Milestone, as the case may be, if later. The purchase
                           price stated in clause (i) above, however, shall be
                           increased from $25.10 to twenty-seven dollars ($27.00
                           U.S.) if both the Tranche 3a Milestone and Tranche 3b
                           Milestone are achieved by January 31, 1998. If a
                           closing under this subparagraph 3(c) has previously
                           occurred at the $25.10 price, the price Per share
                           shall be retroactively increased to $27.00 and Baxter
                           shall promptly make an additional payment to
                           Steritech to yield an effective price of $27.00 per
                           share on such purchase. For the purposes of this
                           Section, the "Phase II Platelet Interim
                           Determination" means a point in the Phase II clinical
                           trials under the Platelet Agreement at which Baxter
                           and Steritech determine that there is sufficient data
                           to determine that such Phase II trials are likely to

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       15.
<Page>

                           have a successful outcome pursuant to the criteria
                           set forth on Schedule C to this Agreement. The point
                           in the Phase II trials at which such determination
                           shall be made shall be included as part of the
                           protocol agreed upon by Baxter and Steritech for the
                           Phase II trials. Baxter and Steritech shall make such
                           determination in good faith.

                  (d)      Purchase five million dollars ($5,000,000.00 U.S.) of
                           Steritech equity upon (i) the approval by the F.D.A.
                           to commence a Phase II study in the United States or
                           comparable approval in Europe under the Red Cell
                           Project, and (ii) the approval of an NDA by the
                           F.D.A. under the Platelet Agreement or comparable
                           approval in Europe under such Agreement ("Tranche 4
                           Milestone") consisting of Common Stock at a purchase
                           price equal to open market price PLUS twenty percent
                           (20%) if Steritech is publicly traded, at the time of
                           such purchase, or if then privately held, Preferred
                           Stock at the lesser of (x) thirty-five dollars
                           ($35.00 U.S.) per share or (y) fifty percent (50%)
                           premium over last private third-party financing round
                           PROVIDED THAT clause (y) shall apply only if there
                           has been a third-party private financing round of at
                           least five million dollars ($5,000,000) since the
                           date of the last equity purchase by Baxter pursuant
                           to this Section 3.11. Such purchase will be
                           consummated and the purchase price paid no later than
                           January 10, 1999, or within fifteen (15) days after
                           such Tranche 4 Milestone, if later. The purchase
                           price stated in clause (x) above, however, shall be
                           increased from $35.00 to the following price per
                           share if the events set forth in clause (ii) above
                           has occurred in both the U.S. and Europe on or before
                           the following dates:

<Table>
<Caption>
                           DATE                           PRICE PER SHARE
                           <S>                            <C>
                           January 31, 1999                   $40.00
                           June 30, 1999                      $38.00
</Table>

                           or if the event set forth in clause (ii) above has
                           occurred in Europe on or before the following date:

                           September 30, 1998                 $36.00

                           If a closing under this subparagraph 3(d) has
                           previously occurred at the $35.00 price, the price
                           per share shall be retroactively increased to the
                           applicable price per share set forth in the above
                           table, and Baxter shall promptly make an additional
                           payment to Steritech to yield such applicable price
                           per share on such purchase. Notwithstanding the
                           foregoing, Steritech may, in its discretion, elect to
                           refrain from selling equity to Baxter, or may elect
                           to sell less than five million dollars ($5,000,000)
                           of equity to Baxter, pursuant to this subsection (d).
                           If, at the time the event set forth in clause (ii)
                           above has occurred, Steritech has not yet achieved
                           the event set forth in clause (i) above, then until
                           completion of the full Tranche 4 Milestone, in the
                           event that Steritech conducts a third-party

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       16.
<Page>

                           equity financing round of at least five million
                           dollars ($5,000,000), then upon Steritech's
                           written request, Baxter will purchase in such
                           round nineteen and nine-tenths (19.9%) (but not
                           exceeding $5,000,000 in purchase price) of the
                           shares being sold in such round on the same terms
                           and conditions as the other investors in such
                           round. The dollar amount purchased by Baxter in
                           such round will reduce the dollar amount required
                           to be purchased under this subsection (d) upon
                           achievement of the Tranche 4 Milestone.

                  (e)      The purchase prices set forth above in Subsections
                           (c), (d) and (e), excluding prices set by open market
                           price, will be appropriately adjusted for stock
                           splits, stock dividends and the like.

                  (f)      The purchases of equity set forth above will be made
                           in accordance with an agreement substantially in the
                           form of the Preferred Stock Purchase Agreement in the
                           form of Schedule G to this Agreement, with
                           appropriate changes to reflect share price, class and
                           series of stock being purchased and to make accurate
                           representations and warranties as of the date of the
                           subsequent equity purchases; such changes shall not
                           affect the equity purchase and sale obligations
                           hereunder. While it is anticipated that the parties
                           will separately execute and deliver such Stock
                           Purchase Agreements and associated documents for
                           subsequent equity purchases, the obligation to
                           purchase and sell equity as set forth in this Section
                           are enforceable obligations upon the signing of this
                           Agreement irrespective of whether there is a separate
                           execution and delivery of such Stock Purchase
                           Agreements and associated documents. It is understood
                           that from and after the date of Steritech's initial
                           public offering or other conversion of Steritech's
                           outstanding Preferred Stock to Common Stock, the
                           shares purchased hereunder will be shares of
                           Steritech Common Stock. Prior to such time, the
                           shares purchased hereunder will be shares of
                           Steritech Preferred Stock. Steritech will use
                           reasonable efforts to provide Baxter fifteen (15)
                           days prior notice of the expected date of achievement
                           of milestones under subparagraphs (b), (c) and (d).

                  (g)      Notwithstanding Subsections (b), (c) and (d) above,
                           in the event that any purchase of equity pursuant to
                           such subsection would cause Baxter to own in excess
                           of twenty and one-tenth percent (20.1%) of issued and
                           outstanding capital stock of Steritech, Steritech may
                           limit such purchase of equity by Baxter to a number
                           of shares of capital stock that would cause Baxter to
                           own not more than twenty and one-tenth percent
                           (20.1%) of such issued and outstanding capital stock.

                  (h)      Notwithstanding subsections (b), (c) and (d) above,
                           in the event that any purchase pursuant to such
                           subsection would cause Baxter to own in excess of
                           nineteen and nine-tenths percent (19.9%) of issued
                           and outstanding capital stock of Steritech, Baxter
                           may limit such purchase of equity to a number of
                           shares of capital stock that would cause Baxter to
                           own not more

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       17.
<Page>

                           than nineteen and nine-tenths percent (19.9%) of
                           the issued and outstanding capital stock of
                           Steritech; PROVIDED that in each such instance,
                           upon the written request of Steritech, Baxter
                           shall pay to Steritech as a research and
                           development payment an amount equal to the
                           difference between five million dollars
                           ($5,000,000 U.S.) and the dollar amount of capital
                           stock being purchased. Such research and
                           development payment will be made to Steritech on
                           the date for consummation of purchase of such
                           capital stock. Unless Steritech notifies Baxter,
                           as set forth below, that Steritech elects to repay
                           to Baxter the amount of such research and
                           development payment, such research and development
                           payment will be treated as if Baxter had made an
                           additional contribution of cash to the Final
                           Project Total Budget for the purposes of the
                           fourth sentence of Section 3.5 (allocated among
                           then ongoing Projects in proportion to the size of
                           the then approved budget for each Project). (Such
                           research and development payment shall not,
                           however, change the actual approved budget for any
                           Project nor Steritech's contribution thereto.)
                           Steritech must notify Baxter in writing at the
                           time of such research and development payment
                           whether or not Steritech elects to repay to Baxter
                           the amount of such research and development
                           payment. If Steritech notifies Baxter that
                           Steritech elects to repay such amount, Steritech
                           will, if such amount is not earlier, repaid, pay
                           to Baxter fifty percent (50%) of the Revenue
                           Sharing Payments received by Steritech hereunder,
                           until such amount is repaid. In the event that
                           Baxter makes any such research and development
                           payment to Steritech pursuant to this subsection
                           (h), Steritech will grant to Baxter a warrant to
                           purchase capital stock of Steritech on the
                           following terms: (i) the exercise price will be
                           the price per share to Baxter established under
                           subsection (b), (c) or (d) above (i.e., the
                           subsection applicable to the then current Baxter
                           equity purchase); (ii) the term of the warrant
                           shall extend until two (2) years following market
                           launch in the U.S. or Europe of the first product
                           developed under the Platelet Agreement, but not to
                           exceed seven (7) years from the date such research
                           and development payment was made, subject to
                           earlier termination in the event of merger or
                           acquisition of Steritech; and (iii) the number of
                           shares subject to the warrant shall be equal to
                           ten percent (10%) times the amount of such
                           research and development payment divided by such
                           exercise price. The number of shares subject to
                           the warrant will be appropriately adjusted from
                           time to time for stock splits, stock dividends and
                           the like. Repayment of the amount of the research
                           and development payment will not terminate the
                           warrant.

         4.2 OPTION TO PURCHASE EQUITY IN STERITECH. Steritech grants to Baxter
the following options to purchase equity in Steritech according to the following
terms and schedule:

                  (a)      The Investors' Rights Agreement grants to Baxter the
                           option to participate in other non-public sale of
                           equity in Steritech by purchasing up to nineteen and
                           nine tenths percent (19.9%) of the Equity Securities
                           sold in such

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       18.
<Page>

                           offering, as such term is defined in and in
                           accordance with the terms of the Investors' Rights
                           Agreement; and

                  (b)      Steritech agrees that in the event of an initial
                           public offering of equity in Steritech, Baxter has
                           the option of acquiring nineteen and nine-tenths
                           percent (19.9%) of the shares offered to the public
                           at the initial public offering price, net of
                           underwriter discount. The terms and conditions of
                           such a sale to Baxter shall be identical to those
                           terms sold to the public at the initial public
                           offering; PROVIDED that the shares will be subject
                           the same to lock-up provisions agreed to by officers,
                           directors and major shareholders. Such option shall
                           be exercised as follows:

                           At such time as Steritech shall begin serious efforts
                           toward undertaking its initial public offering,
                           Steritech will so notify Baxter in writing. Steritech
                           shall not have any liability arising from any notice
                           or alleged failure to give timely notice under this
                           Section, nor shall any dispute concerning such notice
                           in any way limit or delay Steritech's ability to
                           conduct its initial public offering or expend any
                           rights of Baxter.

                           In order to guarantee its participation in the
                           offering Baxter must provide notice to Steritech
                           within fourteen (14) days prior to the- anticipated
                           filing date of the registration statement for the
                           initial public offering, stating the percentage of
                           such offering, not exceeding nineteen and nine-tenths
                           percent (19.9%), that Baxter will commit to buy (the
                           "commitment notice") (Baxter may also specify a
                           maximum dollar amount of shares it will purchase,
                           which may reduce the percentage of the offering that
                           Baxter would otherwise receive.) In the event that
                           Baxter is unable to provide such commitment notice
                           within such fourteen day period, but notifies
                           Steritech within such period that it is strongly
                           interested in participating in the offering,
                           Steritech will make all reasonable efforts to include
                           Baxter in the offering up to the limits specified
                           above, PROVIDED that Steritech will not, in such
                           regard, be obligated to take any action that would
                           delay or otherwise interfere with the offering. In
                           the event the offering is withdrawn, the above
                           procedure will be reinstituted at the time Steritech
                           elects to proceed with a new offering. In the event
                           that the registration statement does not become
                           effective within ninety (90) days after the date of
                           filing of the registration statement, Baxter may by
                           written notice give within seven (7) days thereafter,
                           withdraw its commitment notice.

         4.3 STANDSTILL BY BAXTER. Baxter agrees that it will not at any time,
nor will it permit any of its Affiliates to, without the prior written consent
of Steritech:

                  (a) (i) acquire, directly or indirectly, by purchase or
otherwise, of record or beneficially, other than by the transactions set forth
in Sections 4.1 and 4.2 of this Agreement, any securities of Steritech or rights
or options to acquire any securities from any holder of such securities if after
such acquisition (and giving effect to the exercise of any such rights or
options) Baxter and its Affiliates would own capital stock of Steritech having
twenty and one-tenth

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       19.
<Page>

percent (20.1%) or more of the voting power of the outstanding capital stock
of Steritech; PROVIDED, HOWEVER, that neither (1) the purchase of shares of
Common Stock pursuant to Sections 4.1 or 4.2 of this Agreement or (2)
subsequent reductions in the number of shares of outstanding capital stock of
Steritech (or rights or options therefor) shall be deemed to have caused a
violation of this Section 4.3(a);

                           (ii) To the extent Baxter and/or its Affiliates owns,
beneficially or of record, securities of Steritech constituting twenty and
one-tenth percent (20.1%) or more of the voting power of the outstanding capital
stock of Steritech and such securities include securities of Steritech other
than those purchased pursuant to Sections 4.1 or 4.2, Baxter and/or its
Affiliates shall be deemed to own "Prohibited Securities." Baxter agrees that
neither it nor any of its ,Affiliates shall (and neither it nor any of its
Affiliates shall be entitled to) vote any Prohibited Securities with respect to
any matter subject to the vote or written consent of Steritech's stockholders
(PROVIDED, HOWEVER, that the foregoing shall not be deemed to limit Steritech's
remedies in the event that the excess securities were acquired in violation of
this Section);

                           (iii) Baxter hereby covenants and agrees that it will
provide written notice to Steritech of any purchase, sale or other acquisition
or disposition, on the open market or in private transactions, by Baxter or any
of its Affiliates of any securities of Steritech (or if Baxter or such
Affiliates shall direct any third party to take any such actions on behalf of
Baxter or such Affiliates). Such notice shall be transmitted to Steritech by
facsimile (with telephonic notice) within three (3) business days after any such
transaction on the open market or within ten (10) business days after any such
private transaction, and shall specify the person or entity effecting the
transaction, the date of such transaction, the number of securities and the
price per security with respect to such transaction;

                  (b) solicit proxies with respect to any securities of
Steritech under any circumstances for change in the directors or management of
Steritech or relating to merger or acquisition of the Company or deposit any
securities of Steritech in a voting trust or subject them to a voting agreement
or other agreement of similar effect (other than subjecting shares owned by
Baxter to a revocable proxy);

                  (c) initiate, propose or otherwise solicit any stockholder for
the approval of one or more stockholder proposals at any time, or induce or
attempt to induce any other person to initiate any stockholder proposal for
change in the directors or management of Steritech or relating to merger or
acquisition of the Company; or

                  (d) take any action individually or jointly with any
partnership, Limited partnership, syndicate, or other group or assist any other
person, corporation, entity or group in taking any action it could not take
individually under the terms of this Section 4.3.

         The preceding provisions of this Section 4.3 shall terminate in the
event (i) any Person (defined below) or 13D Group (defined below) other than an
Affiliate of Baxter) shall have commenced a tender offer for a majority of the
outstanding shares of Common Stock (including any other outstanding voting
securities) of Steritech or (ii) Steritech's Board of Directors (the "Board")
shall determine to (A) approve any transaction set forth in clause (i)
immediately preceding, (B) liquidate Steritech or sell all or substantially all
of the assets of Steritech to

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       20.
<Page>

another person, (C) approve a merger or consolidation of Steritech with any
other person that would result in the voting securities of Steritech
outstanding immediately prior thereto continuing to represent less than a
majority of the combined voting power of the voting securities of Steritech
or such surviving entity outstanding immediately after such merger or
consolidation or (D) sell to any person a majority of Steritech's outstanding
voting securities. In the event of any determination by the Board pursuant to
the immediately preceding clause (ii), Steritech shall notify Baxter at least
15 days prior to the final approval of such transaction, and any such Board
determination shall be conditioned upon the notification by Steritech of
Baxter in compliance with this sentence. For purposes of this Section 4.3, a
"13D Group" means any group formed for the purpose of acquiring, holding,
voting or disposing of securities of Steritech that would be required under
the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and the
rules and regulations promulgated thereunder, to File a statement on Schedule
13D with the (United States Securities Exchange Commission) as a "Person"
within the meaning of Section 13(d)(3) of the Exchange Act if such group
beneficially owned sufficient securities to require such a filing. All of the
provisions of this Section 4.3 shall be reinstated and shall apply in full
force according to their terms in the event that: (x) if the preceding
provisions of this. Section 4.3 shall have terminated as a result of a tender
offer, such tender offer (as originally made or as extended or modified)
shall have terminated (without closing) prior to the commencement of a tender
offer by Baxter or any of its Affiliates that would have been permitted to be
made pursuant to the preceding provisions of this paragraph as a result of
such third-party tender offer, (y) any tender offer by Baxter or any of its
Affiliates (as originally made or as extended or modified) that was permitted
to be made pursuant to the preceding provisions of this paragraph shall have
terminated (without closing), or (z) if the preceding provisions of this
Section 4.3 shall have terminated as a result of a Board determination
referred to in the preceding clause (ii), the Board shall have determined not
to take any of such actions (and no such transaction considered by the Board
shall have closed) prior to the commencement of a tender offer by Baxter or
any of its Affiliates that would have been permitted to be made pursuant to
the preceding provisions of this paragraph as a result of the initial Board
determination referred to in the preceding clause (ii), unless prior to such
Board determination not to take any of such actions, any of the events
described in the preceding clause (i) shall have occurred. Upon reinstatement
of the provisions of this Section 4.3, the preceding provisions of this
paragraph shall continue to govern (including, without limitation, those that
provide for the termination of the preceding provisions of this Section 4.3)
in the event that any of the evens described in the preceding clauses (i) or
(ii) shall occur. Upon the closing of any tender offer for, or acquisition by
Baxter or its Affiliates of, any securities of Steritech or rights or options
to acquire any such securities that would have been prohibited by the
preceding provisions of this Section 4.3 but for the provisions of this
paragraph, all provisions of this Section 4.3 shall terminate.

5.       SUPPLY OF STERITECH COMPOUND AND SYSTEM MANUFACTURING

         5.1 STERITECH RESPONSIBILITIES. Steritech shall at all times use
commercially reasonable efforts to supply, or have supplied, Baxter's demand for
the Steritech Compounds used in each System. The Parties shall agree in good
faith upon a forecasting, order, supply and delivery mechanism for the Steritech
compounds.

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       21.
<Page>

         5.2 BAXTER RESPONSIBILITIES. Baxter shall be responsible for all
aspects relating to scale-up, production, marketing and distribution of each
System, but not including manufacturing of the Inactivation compound.

         5.3 INSTRUMENT PRODUCTION. Baxter shall tool and scale up the
production model of any Instrument needed for each System. Baxter shall be
responsible for production and manufacture of the Instrument and associated
software of each System.

         5.4 SYSTEM SPECIFICATIONS. Baxter's manufacture of each System shall be
in accordance with Systems Specifications as finally approved in writing by the
Management Board. Any change in Systems Specifications must be approved in
writing by the Management Board.

         5.5 STERITECH SPECIFICATIONS. Steritech shall supply Steritech
Compounds in Bulk Form to Baxter to be used as a component of a System and
Baxter shall obtain Steritech Compounds to meet its requirements of inactivation
compounds for use in the Field from Steritech. Steritech Compounds shall meet
the Specifications for Steritech Compounds as finally approved in writing by the
Management Board. Any change in specifications for Steritech Compounds must be
approved in writing by the Management Board.

         5.6 SOURCE OF SUPPLY. In the event Baxter recommends that Steritech
change Steritech's source of raw materials or Steritech Compound because of
actual or anticipated irregularity of supply, or failure to meet specifications
and a viable alternative source of supply is available, Steritech will support
Baxter in Steritech's obtaining such alternate source to the extent commercially
reasonable.

         5.7 FAILURE OF STERITECH TO MEET BAXTER REQUIREMENTS. To the extent
that Steritech cannot meet Baxter's requirements for Steritech Compound, Baxter
shall be free to obtain Steritech Compound from a third party. Steritech agrees
to provide the third party that Baxter selects with the necessary information
and Steritech Know-How to allow the third party to make the Steritech Compound.

         5.8 SYSTEM IMPROVEMENTS. During the term of this Agreement, as approved
by the Management Board, the Parties will cooperate in making improvements to
each System to meet changing market needs. The costs for such System
Improvements Inactivation Packages shall be budgeted by the Management Board and
subject to cost sharing pursuant to Section 3.5 and shall be added to the Final
Project Total Budget.

6.       MARKETING AND DISTRIBUTION RIGHTS: EXCLUSIVE DISTRIBUTION RIGHTS.

         6.1 COMMERCIALIZATION. Baxter shall use commercially reasonable efforts
to market and sell Systems developed under this Agreement in those countries of
the world in which the Management Board determines that such Systems should be
marketed and sold.

         6.2 MEETINGS CONCERNING MARKETING. The Management Board shall meet from
time-to-time to discuss and approve marketing strategies in order to optimize
customer acceptance and effective promotion of the System. All final decisions
regarding System marketing, distribution and pricing shall be made by the
Management Board reasonably and in

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       22.
<Page>

good faith. Baxter shall follow the strategies established by the Management
Board. In the event that any product is sold by Baxter for a price less than
the price established by the Management Board for such product, for the
purpose of computation of Net Sales, the product will be deemed to be sold at
the price established by the Management Board.

         6.3 RESERVED RIGHT TO COMPETE. With the exception of psoralens or ALE
compounds, Baxter expressly reserves the right to research, develop and market
inactivation/decontamination products (expressly including
inactivation/decontamination products which compete indirectly or directly with
the Systems developed and marketed under this Agreement) which incorporate
technology owned or licensed by Baxter, and/or third parties to make, use and
sell such inactivation/decontamination products. Nothing herein shall
be-interpreted to limit in any manner such right of Baxter. Baxter shall notify
Steritech in writing if Baxter commences development internally or with a third
party of a competing inactivation or decontamination product in a program in
which Baxter has budgeted at least one million dollars ($1,000,000) in any
twelve (12) month period of research and development expenses (or equity
investment), acquires marketing rights to a competing inactivation or
decontamination product or commences marketing of a competing inactivation or
decontamination product, or riles an application for 510(k) or I.N.D., or
foreign equivalent, for such a competing product.

         6.4 COMPETING PRODUCTS. In the event Baxter markets within a specific
country or territory an inactivation/decontamination product that competes
directly with a specific System developed under this Agreement, Baxter' s rights
under this Agreement shall become co-exclusive with Steritech for the specific
System in that specific country or territory only, allowing Steritech to market,
sell and distribute the System itself within the Specific country or territory
or, if Steritech chooses, through a single Approved Distributor (or Approved
Distributors, so long as only one Approved Distributor is appointed per
geographic region) within the specific country or territory. The sharing of
Premium shall be adjusted according to Section 7.3.

         6.5 COMMENCEMENT, CESSATION OF MARKETING. If (a) according to the
Management Board, Baxter (through its own efforts or those of its distributors)
has not marketed a specific System within a specific country or territory
following Market Launch within a reasonable time, but not less than one year nor
more than three years from Market Launch, or (b)after commencement of marketing
of a specific System in a particular country or territory, Baxter shall cease
marketing (or be prevented from marketing by governmental action concerning
Baxter) of such System in such country or territory in the manner required under
this Agreement, Steritech shall have exclusive rights to market that specific
System in that specific country or territory only, allowing Steritech to market,
sell and distribute the System itself within the specific country or territory,
or if Steritech chooses, through an Approved Distributor (or Approved
Distributors, so long as only one Approved Distributor is appointed per
geographic region) within the specific country or territory. The sharing of
Premium shall be adjusted according to Section 7.3. If, according to the
Management Board, Steritech (through its own efforts or those of its
distributors) has failed to gain a sufficient market share for a particular
System within a specific country or territory within three (3) years after
Steritech has obtained marketing rights in such country or territory, or to gain
or maintain sufficient market share in such country at any time thereafter, or
has ceased marketing of a Specific System in any country or territory,
Steritech's rights under this Agreement shall become co-exclusive with Baxter
for

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       23.
<Page>

that specific System in that specific country or territory, allowing Baxter
to market, sell and distribute the System itself within the specific country
or territory or, if Baxter chooses, through a single Approved Distributor (or
Approved Distributors, so long as only one Approved Distributor is appointed
per geographic region) within the specific country or territory.

         6.6 ACHIEVEMENT OF MARKET SHARE. If, according to the Management Board,
Baxter (through its own efforts and those of its distributors) has not gained a
sufficient market share for a particular System within a specific country or
territory within three (3) years following Market Launch, or has not to gained
or maintained sufficient market share in such country at any rime thereafter,
Baxter' s rights under this Agreement shall become co-exclusive with Steritech
for that specific System in that specific country or territory, allowing
Steritech to market, sell and distribute the System itself within the specific
country or territory or, if Steritech chooses, through a single Approved
Distributor (or Approved Distributors, so long as only one Approved Distributor
is appointed per geographic region) within the specific country or territory.
The sharing of Premium shall be adjusted according to Section 7.3.

         6.7 SUPPLY OF BAXTER GOODS. Baxter shall provide the necessary Baxter
disposables, Blood Pack Units(R), Instruments, or other components necessary for
Steritech, or Steritech's Approved Distributor, to sell Systems under Sections
6.4, 6.5 and 6.6. Steritech shall forecast its needs for such Baxter
disposables, apheresis kits, Blood Pack Unit(R), Instruments or other components
under Sections 6.4, 6.5 and 6.6. Baxter's Cost of Goods/Base Revenue under this
section shall be reimbursed under Section 7.3. Baxter shall not, however, be
obligated to develop, reconfigure, modify, qualify or seek Regulatory approval
for any disposables, apheresis kits, Blood Pack Units(R), Instruments or other
components supplied to Steritech or Steritech's Approved Distributor under this
Section.

         6.8 REQUALIFICATION. In the event Steritech obtains marketing rights
under Section 6.5, 12 or 16, or in the event Baxter does not supply sufficient
goods under Section 6.7 to meet Steritech's needs (without limiting Baxter's
obligation to supply such goods) Steritech may, or may license third parties to,
make, have made, use, sell and have sold products using the Steritech Compounds
or under the Steritech Patents or Steritech Know-How, and under any patents or
know-how under which Steritech is licensed pursuant to Section 8.5(b) hereof,
for the use and in the particular country or countries for which Steritech has
marketing rights, PROVIDED THAT such products are qualified for regulatory
approval on Steritech's or such third party's own system.

         6.9 MANAGEMENT BOARD ACCESS TO AND REVIEW OF MARKETING AND DISTRIBUTION
INFORMATION. A party marketing and distributing products under this Agreement
will provide to the Management Board all information in such party's possession
as the Management Board may reasonably require from time to time to review and
make decisions concerning marketing and distribution, including without
limitation breakdown and substantiation of any data provided pursuant to Section
13 of this Agreement. If the information requested of a party is information
that is not normally collected by the party, and requires substantial additional
expense of such party to collect and provide, such additional expense shall be
borne equally by the parties.

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       24.
<Page>

7.       REVENUE SHARING.

         7.1 REVENUE SHARING PAYMENTS. In consideration of the Cooperative
Development Work to be undertaken and other obligations set forth herein, the
parties agree to share Net Sales as follows: Subject to the provisions of
Sections 3.5, 3.7(a), 7.2, 7.3, 7.4, and 12, no later than sixty (60) days after
the first and all subsequent calendar quarters following the Market hunch of the
System, (a) Baxter shall pay to Steritech, with respect to Net Sales in such
calendar quarter, a sum equal to: (1) Steritech's Cost of Goods/Base Revenue;
and (2) fifty percent (50%) (or such other percentage is established pursuant to
Section 3.5 hereof) of the Premium during such calendar quarter ("Revenue
Sharing Payments"), and (b) Baxter shall retain for itself the balance of the
proceeds of Net Sales of Systems shipped during such Calendar Quarter. On each
such date a party that has received in such calendar quarter a royalty, license
fee or other consideration for licensing r sublicensing rights hereunder shall
pay to the other party the amount due to such party under Section 7.4. The
Revenue Sharing Payments due and payable hereunder shall be computed for each
calendar quarter in the currency in which the sale was made, but shall be
definitively discharged by payment to Steritech in U.S. dollars converted from
such currency using the average of spot rates for such currency for the last
business day of the second and third months of such quarter and of the first
month of the subsequent quarter, as quoted in the Wall Street Journal (or such
other mutually agreeable financial publication of international circulation or
rates published by Baxter's corporate treasury, if mutually agreed).

         7.2 BAXTER SOURCING STERITECH COMPOUNDS. In the event Baxter sources
the Steritech compounds from an alternate source, Baxter shall retain for itself
the Cost of Goods/Base Revenue for the Steritech Compounds in the Systems
shipped during such calendar duration.

         7.3 STERITECH AS SELLER OF SYSTEMS. In the event Steritech, or an
Approved Distributor appointed by Steritech, is the seller of the Systems under
Sections 6.4, 6.5 or 6.6, Steritech shall retain for itself its Cost of
Goods/Base Revenue, and the Marketing and Administrative Expenses, and pay to
Baxter, Baxter's Cost of Goods/Base Revenue and the percentage of Premium
received by each of the parties will equal the percentage contributed by such
party to the sum of (a) cash contributed to the final Project Total Budget, PLUS
(b) Noncash Contribution to the Project, PROVIDED that for the purposes of
computations under this Section, Baxter' s Noncash Contribution shall be reduced
by (i) fifty percent (50%) if such sales are made pursuant to Section 6.4 or
6.6, or (ii) by seventy-five percent (75%) if such sales are made pursuant to
Section 6.5. In the event that Steritech purchases any components from Baxter,
as provided in Section 6.7, Baxter's share of the Premium split shall be not
less than fifty percent (50%) of Baxter's Cost of Goods for such components.

         7.4 LICENSING. In the event either Steritech (pursuant to Section 6.8
hereof) or Baxter (pursuant to Section 8.4 hereof) licenses or sublicenses a
third party to rights arising under this Agreement, all royalties, license fees
and other consideration received from such licensing or sublicensing (excluding
research or development payments) shall be shared by the parties according to
the percentage of the sum of (a) funding by each party in the Final Project
Total Budget (or such lesser amount as shall have been expended by Baxter and
Steritech to enable the parties to license or sublicense the rights hereunder
and to comply with their development obligations under the license or sublicense
agreement), PLUS (b) Noncash Contribution to such

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF
1934, AS AMENDED.

                                25.
<Page>

Project made by each party, PROVIDED that for the purposes of this Section,
Steritech's and Baxter' s Noncash Contributions will be equitably adjusted to
reflect the relative contribution of Steritech Patents and Steritech Know-How
and Baxter Patents and Baxter Know-How to the rights being licensed or
sublicensed, but in all events Baxter's Noncash Contribution shall be reduced
by not less than seventy-five percent (75%). Notwithstanding the foregoing,
Steritech will not have any obligation to pay any royalty, license fee or
other consideration with respect to any licensing by Steritech to third
parties pursuant to the rights of Steritech under. Section 8.5(a) of this
Agreement.

         7.5 DISTRIBUTOR SALES. In the event that either party sells
Inactivation Packages or Integrated Inactivation Sets through a distributor, Net
Sales shall be computed as set forth in paragraph (c) of the definition of Net
Sales, and the Distributor Portion will not diminish the Revenue Sharing Payment
receivable by the other party.

8.       PATENTS, KNOW-HOW, LICENSE GRANTS.

         8.1 STERITECH SOLE OWNERSHIP. Steritech shall own all Steritech Patents
and Steritech Know-How.

         8.2 BAXTER SOLE OWNERSHIP. Baxter shall own all Baxter Patents and
Baxter Know-How.

         8.3 JOINT PATENTS.

                  (a) Baxter shall own, and is hereby assigned, all Joint
Patents specifically reading on materials and configuration of blood bags and
associated tubes and connections, developed under this Agreement. Except as
provided in Section 8.3(b), Steritech shall own, and is hereby assigned, all
other Joint Patents, including without limitation Joint Patents reading on the
compounds, and methods of using or removing compounds, developed under this
Agreement.

                  (b) Steritech shall own, and is hereby assigned, all Joint
Patents specifically reading on the illumination device elements of Instruments
developed under this agreement, including hardware and software associated with
the illumination device elements. Baxter shall own, and is hereby assigned, all
Joint Patents specifically reading on all other elements of Instruments
developed under this Agreement.

                  (c) Within the Field the panics shall use any Joint Patents
solely for the development, sale or licensing of Systems pursuant to this
Agreement.

         8.4 LICENSE. Subject to the terms and conditions of this Agreement, for
Systems whose manufacture, use or sale is covered by a claim of a Steritech
Licensed Patent, or which use Steritech Licensed Know-How, Steritech hereby
grants Baxter an exclusive, paid-up, royalty free (except as provided herein)
license, with the right to sublicense (if such sublicense is approved in advance
by the Management Board), under Steritech Licensed Patents and Steritech
Licensed Know-How to make, have made, sell or have sold such Systems, and to use
such Systems solely for promotion and sale thereof, worldwide, solely for use in
the Field. Notwithstanding the foregoing, for any country or territory where
such marketing rights become co-exclusive or exclusive to Steritech pursuant to
Sections 6.4, 6.5 or 6.6 of the Agreement, such

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF
1934, AS AMENDED.

                                    26.
<Page>

license shall automatically become co-exclusive with Steritech, or the rights
shall revert exclusively to Steritech, as the case may be, for such country
or territory. Except as set forth herein in Section, 5.7, such license shall
exclude the right to make or have made Steritech Compounds. As to Steritech
Compounds, such license shall be limited to the Steritech Compounds that are
selected by the Management Board for a specific Project within the Field.
Notwithstanding anything in .this Section or elsewhere in this Agreement,
Baxter shall not have any license or distribution rights in or to any
Steritech Patent or Steritech Know-How to the extent relating to (a) the
inactivation of bacteria, viruses, parasites or other pathogens through use
of compounds other than psoralens or ALE compounds, or (b) the [***]
inactivation system development at Steritech, or (c) use outside the Field,
except as provided in Section 8.6 of this Agreement.

         8.5      STERITECH RIGHTS.

                  (a) DECONTAMINATED PRODUCTS. Baxter and Steritech have
previously entered into a letter agreement dated January 18, 1996 Re
Non-Exclusive License for Plasma Derivatives a copy of which is attached hereto
as Schedule D (the "Plasma Derivatives Letter"). Baxter and Steritech agree that
the terms of the Plasma Derivatives Letter, rather than this Agreement, shall
apply to all products in the Field where the product to be produced or sold is a
decontaminated blood cell, Protein Preparation on, recombinant equivalent or
blood component or other product, rather than a System containing a disposable
Inactivation Package. The Plasma Derivatives letter will apply to such other
products to the same extent and in the same manner as if such other products
were expressly listed with plasma derivatives in the Plasma Derivatives Letter.
Accordingly, the license set forth in Section 8 is subject to the exclusive
right retained by Steritech in the Steritech Patents and Steritech Know-How to
inactivate pathogens in such products and license others to inactivate pathogens
in such products, including the right to make, have made, use and sell compounds
and other components applicable to such inactivation process; PROVIDED THAT
Steritech shall accord to Baxter the rights set forth in the Plasma Derivatives
letter.

                  (b) OTHER. The license to Baxter set forth above is subject to
the right retained by Steritech to grant licenses to third parties under
Steritech Patents and Steritech Know-How, and exercise other rights, as provided
in Section 6.8 of this Agreement. Baxter further grants to Steritech paid-up,
royalty-free (except as provided herein) license, with right to sublicense (a)
co-exclusive in the Field, to any Baxter Patents or Baxter Know-How developed in
the course of the Cooperative Development Work, and (b) non-exclusive in the
Field to any Baxter Patents or Baxter Know-How otherwise embodied or used within
a System; solely for the purposes of granting licenses and exercising other
rights pursuant to Section 6.8 or exercising Steritech's rights under Section 12
or 16 of this Agreement. The foregoing clause (b) shall exclude, however, any
Baxter proprietary materials or Baxter proprietary configuration of blood bags
and associated tubes and connections, or Baxter proprietary processes to
manufacture any of the same, unless Baxter shall consent in writing to license
of the same to Steritech.

         8.6 CROSS-LICENSE. Steritech hereby grants to Baxter, and Baxter hereby
grants to Steritech, a worldwide, non-exclusive, paid-up, royalty-free license,
with right to sublicense, to make, have made, and use, sell or have sold,
outside the Field, products under any patents and know-how of the granting party
used or embodied in any Instrument or in any compound

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF
1934, AS AMENDED.

                                       27.
<Page>

removal device developed under this Agreement. In addition, Baxter hereby
grants to Steritech a worldwide, non-exclusive, paid-up, royalty-free (except
as provided herein) license, with right to sublicense, under the Baxter
Patents and Baxter Know-How to make, have made, and use, sell or have sold
Instruments in connection with the exercise by Steritech of any rights under
Sections 6.4, 6.5, 6.6, 6.7, 6.8, 8.5 or 12 of this Agreement in the event
Baxter is unable to supply the same to Steritech at a cost to Steritech equal
to or less than the cost from an alternative supplier.

         8.7 EXCLUDED PRODUCTS. The term EXCLUDED PRODUCT means any product in
the Field that Baxter, in its sole discretion, specifically notifies Steritech
in writing that Baxter has no interest in developing and marketing. In the event
that Steritech proposes in writing a product for development under the
Cooperative Development Work, Baxter will consider such proposal in good faith
and will notify Steritech in writing if Baxter has no interest in developing and
marketing such product in the reasonably foreseeable future. Notwithstanding any
other provision of this Agreement, all rights and licenses hereunder as to any
Excluded Product shall revert to Steritech, including without limitation the
right to make, have made, and use, sell and have sold the Excluded Product.
Steritech shall not have any obligation to account to Baxter for any proceeds
from sale of any Excluded Product.

         8.8 NOTICE OF SOLE RIGHTS. After the Effective Date of this Agreement,
a party asserting sole ownership of any patent rights or know-how in the Field
developed pursuant to the Cooperative Development Work shall provide reasonable
notice to the Management Board of its intention to seek patent protection or to
assert proprietary interest in such Know-How. The Management Board shall have
the right to a reasonable opportunity to review and comment on such assertions
prior to patent applications being filed.

         8.9 OTHER AGREEMENTS. Steritech shall not terminate, alter or amend the
terms of the following agreements in a manner that would limit Steritech's or
Baxter's rights under this Agreement without the prior written approval of
Baxter: The Technology Transfer Agreement and the License Agreement between
Steritech and HRI Research, Inc. each dated December 13, 1991. Baxter shall
respond within thirty (30) days of receipt of written proposed changes to such
agreements. Baxter's approval of proposed changes shall not be unreasonably
withheld.

         8.10 REGULATORY FILES. Baxter and Steritech shall each have full access
to all materials filed and correspondence with the FDA and other regulatory
agencies in connection with the Cooperative Development Work and each System,
and shall be entitled to use and rely on such materials with respect to any
regulatory approvals for a product sought by either, whether or not such product
relates to this Agreement. In the event that product registration is in the name
of Baxter in any country and Steritech obtains marketing rights for such product
in such country, then Baxter will, at Steritech's expense, cause the product to
be co-registered in Steritech's name or take other steps so that Steritech may
market and sell the product under such registration.

         8.11 RIGHTS UNDER GOVERNMENT-SPONSORED RESEARCH. Any licenses hereunder
to any "subject invention," if any, as defined in 35 U.S.C. Section 201, shall
be subject to the rights of the United States Government under 35 U.S.C.
Section, 200 et seq.

[***] -- CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF
1934, AS AMENDED.

                                     28.
<Page>

9.       PROSECUTION OF PATENT RIGHTS

         9.1 STERITECH PATENTS. Steritech shall have the right but no obligation
to timely prepare, file, prosecute and maintain, under its exclusive control and
at its expense, Steritech Patents.

         9.2 BAXTER PATENTS. Baxter shall have the right but no obligation to
timely pare, file, prosecute and maintain, under its exclusive control and at
its expense, Baxter patents.

         9.3 JOINT PATENTS. The party to whom a Joint Patent is assigned
pursuant to Section 8.3 hereof shall employ counsel for the purpose of timely
preparing, filing, prosecuting and maintaining the Joint Patents which are
assigned to such party pursuant to such Section 8.3. The other party shall have
the right to approve such counsel, which approval shall not be unreasonably
withheld. Whenever possible, the parties shall file internationally under the
Patent Cooperation Treaty and/or the European Patent Convention in order to
minimize expenses. The reasonable expenses of preparing, filing, prosecuting and
maintaining corresponding Joint Patents in the countries of the United States,
Australia, Canada, the United Kingdom, Germany, Belgium, France, Italy,
Netherlands, and Japan, and all other countries that are agreeable to Baxter and
Steritech, as evidenced in writing shall be borne equally. Unless such other
countries are agreed to by the parties in writing, such other country filings
shall not be made. Baxter shall pay such patent expenses and will deduct
Steritech's share of such expenses from Revenue Sharing Payments otherwise due
Steritech.

         9.4 PRIOR ART; REVIEW AND COMMENT. Each party shall .cooperate with the
other to ensure that all prior art that is pertinent to the examination of a
Joint Patent is brought to the attention of the other party. The parties to this
Agreement shall have the right to review and comment on substantive documents
prepared in connection with the preparation, filing, prosecution and maintenance
of the Joint Patents prior to the filing of such papers; however, such review
and comment shall be performed expeditiously so as not to negatively affect
patent rights.

         9.5 ELECTION NOT TO PAY EXPENSES. If either party elects for any reason
not to pay its share of the reasonable expenses for a particular Joint Patent,
then, at the option of the other party:

                  (a) the joint ownership of that nonpaying party under this
Agreement with respect to that particular patent application or patent shall
immediately terminate and the paying party shall exclusively own that particular
patent or patent application, without affecting the nonpaying party's rights
under all other patent applications and patents; or

                  (b) the application or patent shall be allowed to lapse.

         In the event the paying party elects option (a) above, the nonpaying
party hereby agrees to execute documents necessary to transfer its interest in
such patent or patent application to the paying party.

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF
1934, AS AMENDED.

                                     29.
<Page>

10.      TRADEMARKS.

         10.1 BAXTER TRADEMARKS. Steritech shall make no use of any Baxter
trademark without the prior written approval by Baxter.

         10.2 STERITECH TRADEMARKS. Baxter shall include the Steritech name and
mark (or successor name and mark) in a prominent manner on and on packaging,
literature and promotional material and advertising for the System unless Baxter
makes a good faith determination that the Steritech name cannot be used due to
third party rights. Baxter shall, to the extent practical, provide to Steritech
for review copies of all proposed uses of the Steritech name and mark and
references to Steritech. At Steritech's reasonable request, Baxter shall refer
to the Steritech Compounds by the Steritech trademark that Steritech indicates
is appropriate. Baxter shall include on material bearing such trademarks an
acknowledgment that such trademarks are the property of Steritech. If necessary
in any market to maintain Steritech's rights in the Steritech trademarks, Baxter
shall enter into a registered user agreement regulating its use of the Steritech
trademarks. Except as provided in this Section, no rights to Steritech
trademarks are hereby granted to Baxter.

11.      CONFIDENTIAL INFORMATION.

         11.1 CONFIDENTIALITY AGREEMENT. The use and disclosure of information
designated by either party as confidential shall be governed by the attached
Schedule E Confidentiality Agreement. The Schedule E Confidentiality Agreement
shall survive termination of this Agreement.

         11.2 USE OF CONSULTANTS. The parties contemplate that from time to time
during the term of this Agreement third party technical consultants may be
employed by either party in connection with the development of Steritech
Compounds or Systems. The parties agree that information designated as
confidential may be disclosed to such consultants PROVIDED that the other party
is given reasonable notice of the circumstances and nature of the intended
disclosure and that the disclosure is limited to information necessary to enable
the technical consultant to provide technical consulting services. The
consultant will be required to sign an agreement committing the consultant to
protect such confidential information.

12.      CESSATION OF COOPERATIVE DEVELOPMENT WORK.

         12.1 CESSATION. Either party may unilaterally cease all participation
on a specific approved Project or all Cooperative Development Work under this
Agreement upon ninety (90) days written notice of its intent. At any time
thereafter, the party who did not unilaterally cease participation in the
Cooperative Development Work shall have the right to proceed with the
independent development of such System at its own expense. Should a party so
proceed, the following terms and conditions shall apply:

                  (a)      The Premium Sharing Formula in Section 7.1 will be
                           adjusted. The Premium shall be split between the
                           Parties based on the percentage of the sum of (i)
                           Final Project Total Budget funded by each Party, PLUS
                           (ii) Noncash Contributions to the Project made by
                           each party, adjusted as provided in clauses (b) and
                           (c) below. Such percentage being calculated

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF
1934, AS AMENDED.

                                    30.
<Page>

                           as follows: for purposes of this Section only, after
                           the cessation of funding by one Party, the funds
                           provided by the other Party thereafter to support the
                           Cooperative Development Work shall be considered
                           doubled when calculating the Final Project Total
                           Budget and the corresponding respective percentage
                           funded by each Party. All funds provided by either
                           Party prior to a Party's cessation shall be credited
                           but not doubled.

                  (b)      In the event that Steritech unilaterally ceases all
                           participation, then at Baxter's election by written
                           notice, all marketing rights and licenses of
                           Steritech hereunder to the System(s) developed or
                           being developed under such Project, or under the
                           Development Work, as the case may be shall terminate,
                           and Baxter shall source the Steritech Compounds from
                           an alternative source with the cooperation of
                           Steritech, and the Revenue Sharing Formula in Section
                           7.1 will be adjusted under Sections 7.2 and 12.1(a);

                  (c)      In the event that Baxter unilaterally ceases all
                           participation, then at Steritech's election by
                           written notice, all marketing rights and licenses of
                           Baxter to the System(s) developed or being developed
                           under such Project, or under the Cooperative
                           Development Work, as the case may be, shall terminate
                           and Steritech shall have exclusive rights to market,
                           sell and distribute such System throughout the world.
                           Baxter shall provide the necessary Baxter
                           disposables, apheresis kits. Blood Pack Units(R)or
                           other components necessary for Steritech, or
                           Steritech's Approved Distributor to sell Systems
                           under Section 6.7. Revenue Sharing under Section 7.1
                           shall be adjusted under Sections 7.3, 7.4 and
                           12.l(a).

         12.2 CESSATION PAYMENT. In the event that either party gives notice Of
unilateral cessation of participation on a specific approved Project or all
Cooperative Development Work under this Agreement, such party shall, not later
than twenty (20) days after the date of such notice, pay to the other party an
amount equal to [***] period following the date of such cessation. Such
cessation payment need not be applied by the receiving party to continuation of
work on such Project or Cooperative Development Work. Neither party shall be
entitled to give notice of unilateral cessation of participation on the Red Cell
Project or the Fresh Frozen Plasma Project prior to January 1, 1998 or on any
other Project prior to two years after the approval of the Management Board to
commence the Project, PROVIDED, HOWEVER, that either party shall have the right
to give notice of unilateral cessation of a Project prior to that date if such
party conclude, reasonably and in good faith, based on an unambiguous,
unsuccessful outcome in a critical test in the Project test protocol that there
is no reasonable likelihood that the Project will attain Regulatory Approval.

13.      REPORTS.

         13.1 QUARTERLY SALES REPORTS. Each quarterly payment made under Section
7 shall be accompanied by a full and accurate accounting of all Net Sales of
Systems by Baxter and Steritech, as the case may be, for the calendar quarter.
Each such report shall include at least the

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF
1934, AS AMENDED.

                                      31.
<Page>

following information for each type of System separately as to each of the
following regions: U.S., Europe, Japan, rest of world:

                  (a) The number of stand-alone Inactivation Packages and
Integrated Inactivation Sets sold to third parties by Baxter or Steritech, as
the case may be;

                  (b) The Net Sales, with a breakdown between Net Sales of
stand-alone Inactivation Packages and Integrated Inactivations Sets;

                  (c) Cost of Goods/Base Revenue with a breakdown between
stand-alone Inactivation Packages and Integrated Inactivation Sets;

                  (d) Computation of the Revenue Sharing Payment due to the
other party.

                  (e) Customer published price lists for Systems; and

                  (f) Any deductions from Revenue Sharing Payments.

Each report shall include the certification of the party making the report
attesting to the fact that the report is an accurate and complete accounting of
all information required hereunder.

To the extent Baxter is unable to provide any such information when due, Baxter
will provide to Steritech at such time Baxter's best estimates of such
information, and will provide actual information as soon as it is available,
PROVIDED, HOWEVER, that Baxter will, in any event, provide reports when due of
actual Net Sales and Cost of Goods/Base Revenue.

         13.2 COST OF GOODS/BASE REVENUE. To the extent not provided under
Section 13.1 above, each party will furnish quarterly reports to the other party
on such party's Cost of Goods/Base Revenue for components supplied by such
party.

14.      BOOKS AND RECORDS.

         14.1 RECORDS. Baxter and Steritech shall keep full and accurate books
of account containing all particulars that may be necessary for the purpose of
calculating all amounts owing to either party. Books of account maintained by
the parties shall be kept at their principal place of business. All such reports
and data shall be open for inspection on a confidential basis at all reasonable
times and either party may conduct at its own expense, once every year during
normal business hours through an independent certified public accountant, an
examination of the accounts contemplated above. If any audit shall show that the
selling party underpaid amounts due under this Agreement herein as to the period
subject of the audit, then the party which underpaid shall immediately pay to
the other any such deficiency with interest thereon in o accordance with Section
14.3. If the underpayment shall exceed ten percent (10%) of the amount owed for
any calendar year, the party underpaying shall also reimburse the other for
costs related to such audit.

         14.2 RETENTION. Books and records required to be maintained by the
parties hereunder shall be retained for at least two (2) years from the date of
the payment to which they pertain.

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF
1934, AS AMENDED.

                                   32.
<Page>

         14.3 INTEREST. All payments due hereunder that are not paid when due
and payable hereunder shall bear interest at an annual rate equal to 4% (four
percent) above the U.S. dollar reference rate ("prime rate") charged from time
to time by Bank of America N.T. & S.A. from the date due until paid or at such
lower rate as shall be the maximum rate permitted by law.

15.      TERM.

         This Agreement shall continue so long as any System is being developed
or marketed under this Agreement, unless terminated earlier pursuant to Section
16.1, and PROVIDED that Cooperative Development Work may be earlier terminated
pursuant to Section 12.1. Further, upon expiration of the agreement, except as
otherwise provided herein, no Party shall be obligated to provide materials,
disposables, Blood Pack Units(R), apheresis kits, delivery systems, Instruments
and chemicals to the other Party. Upon termination of any Project by the
Management Board or by mutual consent, all licenses hereunder shall terminate
with respect to the subject matter of such Project (which shall not affect
licenses with respect to any other Project). In the event that either party
hereunder does not commence participation, or ceases participation, in the
Cooperative Development work for the Red Blood Cell Project, other than pursuant
to the proviso in the last sentence of Section 12.2, all licenses of such party
under this Agreement shall terminate except such licenses as may be necessary or
useful in connection with other then ongoing approved Projects. Any license
under Section 8.6 hereof, however, shall survive any termination of this
Agreement.

16.      BREACH.

         16.1 MATERIAL BREACH. Either party may terminate this Agreement for any
material breach by the other party sixty (60) days after providing the other
party with written details of the breach if the breach remains uncured at the
end of the sixty (60) day notice period. Notwithstanding the preceding sentence,
each party acknowledges that the ability of the other party to carry on the
Cooperative Development work will be substantially adversely affected in the
event that such party does not make payment when due to the other party.
Accordingly, in the event of the failure to make any payments that are due and
owing, or fund any equity purchase, a thirty (30) day notice period shall apply
in lieu of such sixty (60) day notice period in the preceding sentence.

         16.2 RIGHTS ON TERMINATION. In the event of termination by either party
as provided in Section 16.1, without limiting any other rights or remedies, such
party shall have the rights provided for under Section 12 of the Agreement as if
the other party had unilaterally ceased participation in the Cooperative
Development Work.

17.      REPRESENTATIONS AND INDEMNITIES.

         17.1 STERITECH REPRESENTATIONS. Steritech represents and warrants that
as of the Effective Date:

                  (a) It has granted no prior license or assignment of rights
under the Steritech Patents in the Field.

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF
1934, AS AMENDED.

                                      33.
<Page>

                  (b) There are no foreign or United States administrative,
judicial or Patent and Trademark Office proceedings contesting the inventorship
or ownership of any Steritech Patent;

                  (c) Neither the execution and delivery of this Agreement, nor
the performance of the obligations of Steritech hereunder shall result in a
violation, breach or event of default (or any event or condition which with
notice or the passage of time or both would constitute an event of default) of
or with respect to any agreement, mortgage, indenture or order of any court of
competent jurisdiction binding upon Steritech or upon the property of Steritech;

                  (c) It is party to no contract materially adverse to the
obligations undertaken and rights granted in this Agreement;

                  (e) The execution of this Agreement and delivery to Baxter
does not conflict with the terms of any agreement to which Steritech is bound.

                  (f) The Technology Transfer Agreement and the License
Agreement between Steritech and HRI Research, Inc. each dated December 13, 1991
are in full force and effect and are binding and enforceable in accordance with
their terms.

                  (g) That Steritech has advised Baxter of any knowledge of any
third party patent or Know-How that might be infringed by the incorporation of
any Steritech Patent or Steritech Know-How likely to be embodied or used in a
System; and

                  (h) Steritech is unaware of any technology not licensed to
Baxter hereunder, that it believes would be necessary to optimally use the
Steritech Compound.

         17.2 STERITECH INDEMNIFICATION - REPRESENTATIONS AND WARRANTIES.
Steritech shall indemnify Baxter for any losses sustained or expenses incurred
by Baxter as a result of a breach by Steritech of any of the foregoing
representations and warranties.

         17.3 STERITECH INDEMNIFICATION - PRODUCTS. Steritech shall defend,
indemnify and hold Baxter harmless from and against any and all claims, damages,
liability, suits, actions and expenses, including reasonable attorney's fees, by
reason of liability imposed by law upon Baxter resulting from the sale of
Systems to the extent any such liability, expressly including, but not limited
to products liability, arises from the failure to conform to Specifications for
`Steritech Compounds incorporated into Systems; PROVIDED that Baxter shall give
Steritech prompt written notice of such claim and Steritech shall have the right
to defend such claim (Baxter having the right to participate in any such defense
at Baxter's own expense).

         17.4 INSURANCE. Steritech shall, at its own expense, establish and at
all times during the period from Market Launch until three (3) years after the
last delivery of a System under this Agreement products liability insurance in
an amount not less than $5,000,000 each occurrence combined single limit bodily
injury and property damage, PROVIDED that such insurance is available on
commercially reasonable terms. The insurance policy shall be endorsed to name
Baxter as an additional insured and to provide for written notification to
Baxter by the insurer not less than thirty (30) days prior to cancellation,
non-renewal or material change. A certificate of insurance evidencing compliance
with this section and referencing this Agreement shall be furnished to Baxter by
Steritech within ten (10) days of Market Launch.

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF
1934, AS AMENDED.

                                    34.
<Page>

         17.5 BAXTER REPRESENTATIONS. Baxter represents and warrants to
Steritech that as of the Effective Date:

                  (a) It has granted no prior license or assignment of rights
under the Baxter Patents that would materially impair its ability to develop,
manufacture or sell Systems.

                  (b) There are no foreign or United States administrative,
judicial or Patent and Trademark Office proceedings contesting the inventorship
or ownership of any Baxter Patent that is likely to be embodied or used in a
System.

                  (c) neither the execution and delivery of this Agreement, nor
the performance of the obligations of Baxter hereunder shall result in a
violation, breach or event of default (or any event or condition which with
notice or the passage of time or both would constitute an event of default) of
or with respect to any agreement, mortgage, indenture, or order of any court of
competent jurisdiction binding upon Baxter or upon the property of Baxter.

                  (d) it is party to no contract materially adverse to the
obligations undertaken in this Agreement.

                  (e) The execution of this Agreement and delivery to Steritech
does not conflict with the terms of any agreement to which Baxter is bound.

                  (f) Baxter has no current agreements with other parties for
systems for the inactivation of pathogens in FFP or Red Cells.

                  (g) Baxter has advised Steritech of any knowledge of any third
party patent or know-how that might be infringed by the incorporation by Baxter
of any Baxter Patent or Baxter Know-How likely to be embodied or used in a
System.

                  (h) Baxter is unaware of any technology not licensed to Baxter
it believes would be necessary to optimally use the Baxter Patents or Baxter
Know-How in a System.

         17.6 BAXTER INDEMNIFICATION - REPRESENTATIONS AND WARRANTIES. Baxter
shall indemnify Steritech for losses sustained or expenses incurred by Steritech
as a result of a breach by Baxter of the foregoing representations and
warranties.

         17.7 BAXTER INDEMNIFICATION-PRODUCTS. Baxter shall indemnify and hold
Steritech harmless from and against any and all claims, damages, liability,
suits actions and expenses, including reasonable attorney's fees, by reason of
liability imposed by law upon Steritech resulting from the sale of Systems to
the extent any such liability, including but not limited to product liability,
arises from the failure of components of Systems by Baxter, excluding
Instruments if manufactured by a third party (PROVIDED THAT Baxter shall
contractually require any third-party manufacturer to indemnify Steritech to the
full extent that Baxter is indemnified by such manufacturer), to conform to
specifications; PROVIDED THAT Steritech shall give Baxter prompt written notice
of such claim and Baxter shall have the right to defend such claim (Steritech
having the right to participate in such defense at its own expense).

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                     35.
<Page>

         17.8 BAXTER INSURANCE. In the event that the net worth of Baxter shall
at any time be reduced to less than $2 billion U.S., Baxter shall, at its own
expense, establish and at all times that such net worth is not maintained until
three (3) years after the last delivery of a System under this Agreement
maintain products liability insurance in an amount not less than $5,000,000 each
occurrence combined single limit bodily injury and property damage, PROVIDED
that such insurance is available on commercially reasonable terms. The insurance
policy shall be endorsed to name Steritech as an additional insured and to
provide for written notification to Steritech by the insurer not less than
thirty (30) days prior to cancellation, non-renewal or material change. A
certificate of insurance evidencing compliance with this section and referencing
this Agreement shall be furnished to Steritech by Baxter within ten (10) days of
the date that Baxter becomes obligated to establish such insurance.

18.      INFRINGEMENT.

         18.1 DEFENSE OF THIRD PARTY INFRINGEMENT SUITS. In the event that a
third party shall sue either party alleging that the manufacture, use or sale of
a System, or any part thereof, infringes. a patent of such third party, then the
Management Board shall have the option to control the defense of such suit. The
parties shall provide reasonable cooperation in the defense of such suit and
furnish all evidence in their control. All attorneys' fees as well as any
judgments, settlements, or damages payable with respect to such suit shall be.
subject to cost sharing pursuant to Section 3.5 and shall be added to the Final
Project Total Budget. Neither party shall enter into any settlement that
materially affects the other party's rights or interests without such other
party's prior written consent, which consent shall not be unreasonably withheld.

         18.2 THIRD PARTY PATENT EXPENSES. If the Management Board shall approve
the payment to a third-party of Patent Royalty Payments with respect to the sale
or use of a System or any portion thereof, then Baxter and Steritech shall bear
the Patent Royalty Payment under such license proportionately to the Revenue
Sharing Formula, and Baxter may deduct Steritech's share of such Patent Royalty
Payment from Revenue Sharing Payments due to Steritech.

         18.3 SUITS FOR INFRINGEMENT BY OTHERS. In the event Baxter or Steritech
becomes aware of any actual or threatened infringement of the Steritech Licensed
Patents or the Steritech Licensed Know-How, or the Baxter Licensed Patents or
Baxter Licensed Know-How, that party shall promptly notify the Management Board
and the Management Board shall determine the most appropriate action to take.
All expenses for pursuing such suit shall be subject to cost sharing. Any award
in such suit shall be divided between the parties in proportion to the parties'
relative combined cash contributions and Noncash Contributions to the product or
process that is subject to the infringement.

In the event the accused product is not in competition with a System in the
Field,

                  (a) Steritech alone may, in its sole discretion and at its
expense, initiate and conduct an infringement action relating to alleged
infringement of Steritech Patents or Steritech Know-How and keep any settlement
or award which may be obtained.

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                     36.
<Page>

                  (b) Baxter alone may, in its sole discretion and at its
expense, initiate and conduct an infringement action relating to alleged
infringement of Baxter Patents or Baxter Know-How and keep any settlement or
award which may be obtained.

19.      GENERAL.

         19.1 ENTIRE AGREEMENT. (1) This Agreement and Schedules, (2) the
attached Schedule E Confidentiality Agreement of even date, (3) each stock
purchase agreement pursuant to Section 4.1 hereof, and (4) the Plasma
Derivatives Letter contain the entire agreement between the parties relating to
the subject matter hereof and all prior understandings, representations and
warranties between the parties are superseded; PROVIDED, HOWEVER, that this
Agreement does not Limit any agreement restricting disclosure or use of
confidential or proprietary information previously entered into between the
parties. None of the terms of this Agreement shall be deemed to be waived or
amended by either party unless such a waiver or amendment specifically
references this Agreement and is in Writing signed by the party to be bound.
Nothing in this Agreement is intended to amend or modify the Platelet Agreement,
except that this Agreement supersedes Sections 8.7 and 8.8 of such agreement,
which provisions shall cease to be effective upon the execution and delivery of
this Agreement.

         19.2 RELATIONSHIP OF PARTIES. Baxter acknowledges that it is not an
agent of Steritech and has no authority to speak for, represent, or obligate
Steritech in any way. Steritech acknowledges that it is not an agent of Baxter
and has no authority to speak for, represent, or obligate Baxter in any way.
This Agreement does not and shall not be deemed to create any relationship of a
joint venture or a partnership.

         19.3 SENIOR BAXTER CONTACT. The senior Baxter contact of the purpose of
administering this Agreement is President, Fenwal, One Baxter Parkway,
Deerfield, Illinois 60015. At present, Kim Bush occupies this position.

         19.4 SENIOR STERITECH CONTACT. The senior Steritech contact for the
purpose of administering this Agreement is the President of Steritech at the
address first above written. At present, Mr. Stephen T. Isaacs occupies this
position.

         19.5 SEVERABILITY. The parties do not intend to violate any public
policy or statutory or common law. However, if any sentence, paragraph, clause
or combination of this Agreement is in violation of any law or is found to be
otherwise unenforceable by a court from which there is no appeal, or no appeal
is taken, such sentence, paragraph, clause, or combination of the same shall be
deleted and the remainder of this Agreement shall remain binding, PROVIDED that
such deletion does not alter the basic structure of this Agreement. In such
event, the parties shall renegotiate this Agreement in good faith, but should
such negotiations not result in a new agreement with ninety (90) days of the
initiation of such negotiations, then this Agreement may be terminated by either
party by thirty (30) days notice to the other.

         19.6 FORCE MAJEURE. Any party shall be excused from the performance of
its obligations under this Agreement and shall not be Liable for damages to the
other if such performance is prevented by circumstances beyond its effective
control. Such excuse from performance shall continue so long as the condition
responsible for such excuse continues and

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                     37.
<Page>

for a thirty (30) day period thereafter. For the purposes of this Agreement,
circumstances beyond the control of a party which excuse that party from
performance shall include, but shall not be limited to, acts of God, acts,
regulations or laws of any government including currency controls, war, civil
commotion, commandeer, destruction of facility or materials by fire, earthquake,
storm or other casualty, labor disturbances, judgment or injunction of any
court, epidemic, and failure of public utilities or common carrier.

         19.7 NOTICES. All notices and demands required or permitted to be given
or made pursuant to this Agreement shall be in writing and shall be effective
when personally given or made or when placed in an envelope and deposited in the
United States mail postage prepaid, addressed as follows:

IF TO BAXTER:                           IF TO STERITECH, IN CARE OF:

General Counsel                         President and Chief Executive Officer
Baxter Healthcare Corporation           Steritech, Inc.
One Baxter Parkway                      2525 Stanwell Drive
Deerfield, Illinois 60015               Concord, California 94520

WITH A COPY TO:                         WITH A COPY TO:

Kim Bush President, Fenwal              Howard G. Irvine
Baxter Healthcare Corporation           Cooley, Godward, Castro, Hudson & Tatum
One Baxter Parkway                      One Maritime Plaza, 20th Floor
Deerfield, Illinois 60015,              San Francisco, California 9411l

or to such other address as to which either party may notify the other.

         19.8 BINDING. This Agreement shall be binding upon and inure to the
benefit of the parties, their successors and assigns. This Agreement shall be
assignable: (i) by either party without the consent of the other to any
Affiliate of the party (an Affiliate being defined as any entity in which the
party or its parent owns or controls directly or indirectly, forty percent (40%)
or more of the voting securities); (ii) by either party with the written consent
of the other, (iii) by either party without the consent of the other in
connection with the purchase or other acquisition of substantially all the
assets of its business to which this Agreement relates; or (iv) by either party
in connection with a reincorporation under the laws of another state. Any
attempted assignment which does not comply with the terms .of this Section shall
be void.

         19.9 GOVERNING LAW. This Agreement is deemed to have been executed in
and shall be governed by and construed according to the laws of the State of
Illinois.

         19.10 VENUE. In the event that Baxter files suit against Steritech, it
shall do so in, and hereby agrees to submit to, the jurisdiction of a court in
U.S. District Court, N.D. California. In the event that Steritech files suit
against Baxter, it shall do so in, and hereby agrees to submit to, the
jurisdiction of the U.S. District Court N.D, Illinois.

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                     38.
<Page>

         19.11 DISBURSEMENTS. Unless otherwise agreed between the parties, all
disbursements from one party to another under this Agreement shall be paid on or
before the due date by wire transfer to the bank account specified in writing by
the party receiving the disbursement.

         IN WITNESS WHEREOF, this Agreement is signed by duly authorized
representatives of each party as of the Effective Date.

BAXTER HEALTHCARE CORPORATION             STERITECH, INC.

By:      /s/ V. Schmitt                   By:      /s/ S. T. Isaacs
   -----------------------------------       -----------------------------------
         Victor Schmitt                            Stephen T. Isaacs

Title:   President, Venture Management    Title:   President

Date:    1 April 1996                     Date:    March 15, 1996
     ---------------------------------         ---------------------------------

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                     39.
<Page>

                                   SCHEDULE A

                             INITIAL RED CELL BUDGET

                                    11 Pages

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

<Page>

                                RED CELL PROGRAM

                                 REVISED BUDGET
                                FEBRUARY 28, 1996

<Table>
<Caption>
-----------------------------------------------------------------------------------------------------------------
                          1996                   1997                  1998                  1999
-----------------------------------------------------------------------------------------------------------------
                           FTE         $         FTE          $         FTE         $         FTE         $
-----------------------------------------------------------------------------------------------------------------
<S>                      <C>         <C>       <C>           <C>      <C>         <C>       <C>         <C>
STERITECH R&D
Personnel                [***]       [***]     [***]         [***]    [***]       [***]     [***]       [***]
Out of Pocket                        [***]                   [***]                [***]                 [***]
Instrument                           [***]                   [***]                [***]                 [***]

-----------------------------------------------------------------------------------------------------------------
BAXTER R&D
Personnel                [***]       [***]     [***]         [***]    [***]       [***]     [***]       [***]
Out of Pocket                        [***]                   [***]                [***]                 [***]
Instrument                           [***]                   [***]                [***]                 [***]

-----------------------------------------------------------------------------------------------------------------
OUTSIDE
[***]                                [***]                   [***]                [***]                 [***]
[***]                                [***]                   [***]                [***]                 [***]
[***]                                [***]                   [***]                [***]                 [***]
[***]                                [***]                   [***]                [***]                 [***]
[***]                                [***]                   [***]                [***]                 [***]

-----------------------------------------------------------------------------------------------------------------
Total                                [***]                   [***]                [***]                 [***]
-----------------------------------------------------------------------------------------------------------------

-----------------------------------------------------------------------------------------------------------------

<Caption>

------------------------------------------------------------------------------------------
                          2000                   2001                    PROJECT TOTAL
------------------------------------------------------------------------------------------
                           FTE         $          FTE         $
------------------------------------------------------------------------------------------
<S>                      <C>         <C>        <C>         <C>               <C>
STERITECH R&D
Personnel                [***]       [***]      [***]       [***]             [***]
Out of Pocket                        [***]                  [***]             [***]
Instrument                           [***]                  [***]             [***]

------------------------------------------------------------------------------------------
BAXTER R&D
Personnel                [***]       [***]      [***]       [***]             [***]
Out of Pocket                        [***]                  [***]             [***]
Instrument                           [***]                  [***]             [***]

------------------------------------------------------------------------------------------
OUTSIDE
[***]                                [***]                  [***]             [***]
[***]                                [***]                  [***]             [***]
[***]                                [***]                  [***]             [***]
[***]                                [***]                  [***]             [***]
[***]                                [***]                  [***]             [***]

------------------------------------------------------------------------------------------
Total                                [***]                  [***]             [***]
------------------------------------------------------------------------------------------

------------------------------------------------------------------------------------------
</Table>

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                      1.
<Page>

                 RED CELL BUDGET, 1996 PROJECTION: STERITECH R&D

<Table>
<Caption>
--------------------------------------------------------------------------------------------------------
CATEGORY                       EXPLANATION                                               FTE/$
========================================================================================================
<S>                                                                                          <C>
Out of Pocket                                                                                 [***]
--------------------------------------------------------------------------------------------------------

[***]                          [***]                                                          [***]
--------------------------------------------------------------------------------------------------------

Instrument                     [***]                                                          [***]
--------------------------------------------------------------------------------------------------------

[***]                          [***]                                                          [***]
--------------------------------------------------------------------------------------------------------

[***]                          [***]                                                          [***]
--------------------------------------------------------------------------------------------------------

[***]                          [***]                                                          [***]
--------------------------------------------------------------------------------------------------------

[***]                          [***]                                                          [***]
--------------------------------------------------------------------------------------------------------

Project Leader                 [***]                                                          [***]
========================================================================================================
                                                                                              [***]
TOTAL                                                                                         [***]
--------------------------------------------------------------------------------------------------------
</Table>

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                      2.
<Page>

                  RED CELL BUDGET, 1996 PROJECTION: BAXTER R&D

<Table>
<Caption>
--------------------------------------------------------------------------------------------------------
CATEGORY                      EXPLANATION                                                FTE/$
========================================================================================================
<S>                           <C>                                                             <C>
Out of Pocket                                                                                 [***]
--------------------------------------------------------------------------------------------------------

Instrument                    [***]                                                           [***]
--------------------------------------------------------------------------------------------------------

[***]                         [***]                                                           [***]
--------------------------------------------------------------------------------------------------------

[***]                         [***]                                                           [***]
--------------------------------------------------------------------------------------------------------

Project Coordinator                                                                           [***]
========================================================================================================
                                                                                              [***]
TOTAL                                                                                         [***]
--------------------------------------------------------------------------------------------------------
</Table>

               RED CELL BUDGET, 1996 PROJECTION: OUTSIDE EXPENSES

<Table>
<Caption>
--------------------------------------------------------------------------------------------------------
CATEGORY                      EXPLANATION                                                  $
========================================================================================================
<S>                           <C>                                                             <C>
[***]                         [***]                                                           [***]
--------------------------------------------------------------------------------------------------------

[***]                         [***]                                                           [***]
--------------------------------------------------------------------------------------------------------

[***]                         [***]                                                           [***]
========================================================================================================
TOTAL                                                                                         [***]
--------------------------------------------------------------------------------------------------------
</Table>

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                      3.
<Page>

                 RED CELL BUDGET, 1997 PROJECTION: STERITECH R&D

<Table>
<Caption>
---------------------------------------------------------------------------------------------------------
CATEGORY                       EXPLANATION                                                FTE/$
=========================================================================================================
<S>                            <C>                                                             <C>
Out of Pocket                                                                                  [***]
---------------------------------------------------------------------------------------------------------

[***]                          [***]                                                           [***]
---------------------------------------------------------------------------------------------------------

[***]                          [***]                                                           [***]
---------------------------------------------------------------------------------------------------------

[***]                          [***]                                                           [***]
---------------------------------------------------------------------------------------------------------

[***]                          [***]                                                           [***]
---------------------------------------------------------------------------------------------------------

[***]                          [***]                                                           [***]
---------------------------------------------------------------------------------------------------------

[***]                          [***]                                                           [***]
---------------------------------------------------------------------------------------------------------

Project Leader                                                                                 [***]
=========================================================================================================
                                                                                               [***]
TOTAL                                                                                          [***]
---------------------------------------------------------------------------------------------------------
</Table>

* [Confidential Treatment Requested]

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                      4.
<Page>

                  RED CELL BUDGET, 1997 PROJECTION: BAXTER R&D
<Table>
<Caption>
---------------------------------------------------------------------------------------------------------
CATEGORY                       EXPLANATION                                                FTE/$
=========================================================================================================
<S>                            <C>                                                        <C>
Out of Pocket                                                                                  [***]
---------------------------------------------------------------------------------------------------------
Instrument                     [***]                                                           [***]
---------------------------------------------------------------------------------------------------------
[***]                          [***]                                                           [***]
---------------------------------------------------------------------------------------------------------
[***]                          [***]                                                           [***]
---------------------------------------------------------------------------------------------------------
Instrument                     [***]                                                           [***]
---------------------------------------------------------------------------------------------------------
[***]                          [***]                                                           [***]
---------------------------------------------------------------------------------------------------------
Other Technical                                                                                [***]
---------------------------------------------------------------------------------------------------------
Project Leader                                                                                 [***]
=========================================================================================================
                                                                                               [***]
TOTAL                                                                                          [***]
---------------------------------------------------------------------------------------------------------
</Table>

               RED CELL BUDGET, 1997 PROJECTION: OUTSIDE EXPENSES
<Table>
<Caption>
---------------------------------------------------------------------------------------------------------
CATEGORY                      EXPLANATION                                                  $
=========================================================================================================
<S>                           <C>                                                          <C>
[***]                         [***]                                                           [***]
---------------------------------------------------------------------------------------------------------
[***]                         [***]                                                           [***]
---------------------------------------------------------------------------------------------------------
[***]                         [***]                                                           [***]
=========================================================================================================
TOTAL                                                                                         [***]
---------------------------------------------------------------------------------------------------------
</Table>

* [Confidential Treatment Requested]

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                      5.
<Page>

                 RED CELL BUDGET, 1998 PROJECTION: STERITECH R&D
<Table>
<Caption>

---------------------------------------------------------------------------------------------------------
CATEGORY                      EXPLANATION                                                FTE/$
=========================================================================================================
<S>                           <C>                                                        <C>
Out of Pocket                                                                                 [***]
---------------------------------------------------------------------------------------------------------
[***]                         [***]                                                           [***]
---------------------------------------------------------------------------------------------------------
[***]                         [***]                                                           [***]
---------------------------------------------------------------------------------------------------------
[***]                         [***]                                                           [***]
---------------------------------------------------------------------------------------------------------
[***]                         [***]                                                           [***]
---------------------------------------------------------------------------------------------------------
[***]                         [***]                                                           [***]
---------------------------------------------------------------------------------------------------------
[***]                         [***]                                                           [***]
---------------------------------------------------------------------------------------------------------
Project Leader                                                                                [***]
=========================================================================================================
                                                                                              [***]
TOTAL                                                                                         [***]
---------------------------------------------------------------------------------------------------------
</Table>

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                      6.
<Page>

                  RED CELL BUDGET, 1998 PROJECTION: BAXTER R&D

<Table>
<Caption>
---------------------------------------------------------------------------------------------------------
CATEGORY                       EXPLANATION                                                FTE/$
=========================================================================================================
<S>                            <C>                                                        <C>
Out of Pocket                                                                                  [***]
---------------------------------------------------------------------------------------------------------
Instrument                     [***]                                                           [***]
---------------------------------------------------------------------------------------------------------
[***]                          [***]                                                           [***]
---------------------------------------------------------------------------------------------------------
Instrument                     [***]                                                           [***]
---------------------------------------------------------------------------------------------------------
[***]                          [***]                                                           [***]
---------------------------------------------------------------------------------------------------------
Other Technical                                                                                [***]
---------------------------------------------------------------------------------------------------------
Project Leader                                                                                 [***]
=========================================================================================================
                                                                                               [***]
TOTAL                                                                                          [***]
---------------------------------------------------------------------------------------------------------
</Table>

               RED CELL BUDGET, 1998 PROJECTION: OUTSIDE EXPENSES
<Table>
<Caption>
---------------------------------------------------------------------------------------------------------
CATEGORY                      EXPLANATION                                                  $
=========================================================================================================
<S>                           <C>                                                          <C>
[***]                         [***]                                                           [***]
---------------------------------------------------------------------------------------------------------
[***]                         [***]                                                           [***]
---------------------------------------------------------------------------------------------------------
[***]                         [***]                                                           [***]
---------------------------------------------------------------------------------------------------------
[***]                         [***]                                                           [***]
=========================================================================================================
TOTAL                                                                                         [***]
---------------------------------------------------------------------------------------------------------
</Table>

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                      7.
<Page>

                 RED CELL BUDGET, 1999 PROJECTION: STERITECH R&D
<Table>
<Caption>

---------------------------------------------------------------------------------------------------------
CATEGORY                      EXPLANATION                                                FTE/$
=========================================================================================================
<S>                           <C>                                                        <C>
Out of Pocket                                                                                 [***]
---------------------------------------------------------------------------------------------------------
[***]                         [***]                                                           [***]
---------------------------------------------------------------------------------------------------------
[***]                         [***]                                                           [***]
---------------------------------------------------------------------------------------------------------
[***]                         [***]                                                           [***]
---------------------------------------------------------------------------------------------------------
[***]                         [***]                                                           [***]
---------------------------------------------------------------------------------------------------------
[***]                         [***]                                                           [***]
---------------------------------------------------------------------------------------------------------
Project Leader                                                                                [***]
=========================================================================================================
                                                                                              [***]
TOTAL                                                                                         [***]
---------------------------------------------------------------------------------------------------------
</Table>

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                      8.
<Page>

                  RED CELL BUDGET, 1999 PROJECTION: BAXTER R&D

<Table>
<Caption>
---------------------------------------------------------------------------------------------------------
CATEGORY                       EXPLANATION                                                FTE/$
=========================================================================================================
<S>                            <C>                                                        <C>
Out of Pocket                                                                                  [***]
---------------------------------------------------------------------------------------------------------
Instrument                     [***]                                                           [***]
---------------------------------------------------------------------------------------------------------
[***]                          [***]                                                           [***]
---------------------------------------------------------------------------------------------------------
[***]                          [***]                                                           [***]
---------------------------------------------------------------------------------------------------------
Project Leader                                                                                 [***]
=========================================================================================================
                                                                                               [***]
TOTAL                                                                                          [***]
---------------------------------------------------------------------------------------------------------
</Table>

               RED CELL BUDGET, 1999 PROJECTION: OUTSIDE EXPENSES

<Table>
<Caption>
---------------------------------------------------------------------------------------------------------
CATEGORY                       EXPLANATION                                                  $
=========================================================================================================
<S>                            <C>                                                          <C>
[***]                          [***]                                                           [***]
---------------------------------------------------------------------------------------------------------
[***]                          [***]                                                           [***]
---------------------------------------------------------------------------------------------------------
[***]                          [***]                                                           [***]
---------------------------------------------------------------------------------------------------------
[***]                          [***]                                                           [***]
=========================================================================================================
TOTAL                                                                                          [***]
---------------------------------------------------------------------------------------------------------
</Table>

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                      9.
<Page>

                 RED CELL BUDGET, 2000 PROJECTION: STERITECH R&D

<Table>
<Caption>
---------------------------------------------------------------------------------------------------------
CATEGORY                      EXPLANATION                                                FTE/$
=========================================================================================================
<S>                           <C>                                                        <C>
Out of Pocket                                                                                 [***]
---------------------------------------------------------------------------------------------------------
[***]                         [***]                                                           [***]
---------------------------------------------------------------------------------------------------------
[***]                         [***]                                                           [***]
---------------------------------------------------------------------------------------------------------
[***]                         [***]                                                           [***]
---------------------------------------------------------------------------------------------------------
Project Leader                                                                                [***]
=========================================================================================================
                                                                                              [***]
TOTAL                                                                                         [***]
---------------------------------------------------------------------------------------------------------
</Table>

                  RED CELL BUDGET, 2000 PROJECTION: BAXTER R&D

<Table>
<Caption>
---------------------------------------------------------------------------------------------------------
CATEGORY                      EXPLANATION                                                FTE/$
=========================================================================================================
<S>                           <C>                                                        <C>
Out of Pocket                                                                                 [***]
---------------------------------------------------------------------------------------------------------
[***]                         [***]                                                           [***]
---------------------------------------------------------------------------------------------------------
[***]                         [***]                                                           [***]
=========================================================================================================
                                                                                              [***]
TOTAL                                                                                         [***]
---------------------------------------------------------------------------------------------------------
</Table>

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                      10.
<Page>

               RED CELL BUDGET, 2000 PROJECTION: OUTSIDE EXPENSES
<Table>
<Caption>
---------------------------------------------------------------------------------------------------------
CATEGORY                      EXPLANATION                                                  $
=========================================================================================================
<S>                           <C>                                                          <C>
[***]                         [***]                                                           [***]
---------------------------------------------------------------------------------------------------------
[***]                         [***]                                                           [***]
=========================================================================================================
TOTAL                                                                                         [***]
---------------------------------------------------------------------------------------------------------
</Table>

                  RED CELL BUDGET, 2001 PROJECTION: BAXTER R&D
<Table>
<Caption>
---------------------------------------------------------------------------------------------------------
CATEGORY                      EXPLANATION                                                FTE/$
=========================================================================================================
<S>                           <C>                                                        <C>
Out of Pocket                                                                                 [***]
---------------------------------------------------------------------------------------------------------
Instrument                    [***]                                                           [***]
---------------------------------------------------------------------------------------------------------
Technical Support             [***]                                                           [***]
=========================================================================================================
                                                                                              [***]
TOTAL                                                                                         [***]
---------------------------------------------------------------------------------------------------------
</Table>

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                      11.
<Page>

                                   SCHEDULE B

                             INITIAL S59 FFP BUDGET

                                    11 Pages

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

<Page>

                                   FFP PROGRAM

                                 REVISED BUDGET
                                FEBRUARY 28, 1996

<Table>
<Caption>
------------------------------------------------------------------------------------------------------------------------------------
                 1996               1997                  1998                  1999                  2000             PROJECT TOTAL
------------------------------------------------------------------------------------------------------------------------------------
                  FTE       $       FTE          $         FTE         $         FTE         $         FTE        $
------------------------------------------------------------------------------------------------------------------------------------
<S>             <C>       <C>     <C>          <C>       <C>         <C>       <C>         <C>       <C>        <C>         <C>
STERITECH R&D
Personnel       [***]     [***]   [***]        [***]     [***]       [***]     [***]       [***]     [***]      [***]       [***]
Out of Pocket             [***]                [***]                 [***]                 [***]                [***]       [***]
                                                                                                                            [***]
------------------------------------------------------------------------------------------------------------------------------------
BAXTER R&D
Personnel       [***]     [***]   [***]        [***]     [***]       [***]     [***]       [***]     [***]      [***]       [***]
Out of Pocket             [***]                [***]                 [***]                 [***]                [***]       [***]
Instrument                [***]                [***]                 [***]                 [***]                [***]       [***]
------------------------------------------------------------------------------------------------------------------------------------
OUTSIDE
[***]                     [***]                [***]                 [***]                 [***]                [***]       [***]
[***]                     [***]                [***]                 [***]                 [***]                [***]       [***]
[***]                     [***]                [***]                 [***]                 [***]                [***]       [***]
[***]                     [***]                [***]                 [***]                 [***]                [***]       [***]
------------------------------------------------------------------------------------------------------------------------------------
Total                     [***]                [***]                 [***]                 [***]                [***]       [***]
------------------------------------------------------------------------------------------------------------------------------------
</Table>

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       1

<Page>

                   FFP BUDGET, 1996 PROJECTION: STERITECH R&D
<Table>
<Caption>
--------------------------------------------------------------------------------------------------------
CATEGORY                      EXPLANATION                                                FTE/$
========================================================================================================
<S>                           <C>                                                        <C>
Out of Pocket                 [***]                                                           [***]
--------------------------------------------------------------------------------------------------------
[***]                         [***]                                                           [***]
--------------------------------------------------------------------------------------------------------
[***]                         [***]                                                           [***]
--------------------------------------------------------------------------------------------------------
[***]                         [***]                                                           [***]
--------------------------------------------------------------------------------------------------------
[***]                         [***]                                                           [***]
--------------------------------------------------------------------------------------------------------
[***]                         [***]                                                           [***]
--------------------------------------------------------------------------------------------------------
[***]                         [***]                                                           [***]
========================================================================================================
                                                                                              [***]
TOTAL                                                                                         [***]
--------------------------------------------------------------------------------------------------------
</Table>

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                      2.
<Page>

                     FFP BUDGET, 1996 PROJECTION: BAXTER R&D

<Table>
<Caption>
------------------------------ ------------------------------------------------ ------------------------
CATEGORY                       EXPLANATION                                               FTE/$
============================== ================================================ ========================
<S>                            <C>                                              <C>
Out of Pocket                  [***]                                                          [***]
------------------------------ ------------------------------------------------ ------------------------
[***]                          [***]                                                          [***]
------------------------------ ------------------------------------------------ ------------------------
[***]                          [***]                                                          [***]
------------------------------ ------------------------------------------------ ------------------------
[***]                          [***]                                                          [***]
------------------------------ ------------------------------------------------ ------------------------
Project Leader                 [***]                                                          [***]
============================== ================================================ ========================
                                                                                              [***]
TOTAL                                                                                         [***]
------------------------------ ------------------------------------------------ ------------------------
</Table>

                  FFP BUDGET, 1996 PROJECTION: OUTSIDE EXPENSES

<Table>
<Caption>
----------------------------- ------------------------------------------------- ------------------------
CATEGORY                      EXPLANATION                                                  $
============================= ================================================= ========================
<S>                           <C>                                               <C>
[***]                         [***]                                                           [***]
----------------------------- ------------------------------------------------- ------------------------
[***]                         [***]                                                           [***]
============================= ================================================= ========================
TOTAL                                                                                         [***]
----------------------------- ------------------------------------------------- ------------------------

</Table>

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                      3.
<Page>

                   FFP BUDGET, 1997 PROJECTION: STERITECH R&D

<Table>
<Caption>
------------------------------ ------------------------------------------------ ------------------------
CATEGORY                       EXPLANATION                                               FTE/$
============================== ================================================ ========================
<S>                            <C>                                              <C>
Out of Pocket                  [***]                                                          [***]
------------------------------ ------------------------------------------------ ------------------------
[***]                          [***]                                                          [***]
------------------------------ ------------------------------------------------ ------------------------
[***]                          [***]                                                          [***]
------------------------------ ------------------------------------------------ ------------------------
[***]                          [***]                                                          [***]
------------------------------ ------------------------------------------------ ------------------------
[***]                          [***]                                                          [***]
------------------------------ ------------------------------------------------ ------------------------
[***]                          [***]                                                          [***]
------------------------------ ------------------------------------------------ ------------------------
[***]                          [***]                                                          [***]
------------------------------ ------------------------------------------------ ------------------------
[***]                          [***]                                                          [***]
------------------------------ ------------------------------------------------ ------------------------
Project Leader                 [***]                                                          [***]
============================== ================================================ ========================
                                                                                              [***]
TOTAL                                                                                         [***]
------------------------------ ------------------------------------------------ ------------------------
</Table>

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                    4.
<Page>

                     FFP BUDGET, 1997 PROJECTION: BAXTER R&D

<Table>
<Caption>
----------------------------- ------------------------------------------------- ------------------------
CATEGORY                      EXPLANATION                                                FTE/$
============================= ================================================= ========================
<S>                           <C>                                               <C>
Out of Pocket                                                                          [***]
----------------------------- ------------------------------------------------- ------------------------
[***]                         [***]                                                           [***]
----------------------------- ------------------------------------------------- ------------------------
[***]                         [***]                                                           [***]
----------------------------- ------------------------------------------------- ------------------------
[***]                         [***]                                                           [***]
                                                                                              [***]
----------------------------- ------------------------------------------------- ------------------------
Project Leader                [***]                                                           [***]
============================= ================================================= ========================
                                                                                              [***]
TOTAL                                                                                         [***]
----------------------------- ------------------------------------------------- ------------------------
</Table>

                  FFP BUDGET, 1997 PROJECTION: OUTSIDE EXPENSES

<Table>
<Caption>
----------------------------- ------------------------------------------------- ------------------------
CATEGORY                      EXPLANATION                                                  $
============================= ================================================= ========================
<S>                           <C>                                               <C>
[***]                         [***]                                                           [***]
----------------------------- ------------------------------------------------- ------------------------
[***]                         [***]                                                           [***]
----------------------------- ------------------------------------------------- ------------------------
[***]                         [***]                                                           [***]
============================= ================================================= ========================
TOTAL                                                                                         [***]
----------------------------- ------------------------------------------------- ------------------------
</Table>

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                         5.
<Page>

                   FFP BUDGET, 1998 PROJECTION: STERITECH R&D

<Table>
<Caption>
------------------------------- -------------------------------------------------- ---------------------
CATEGORY                        EXPLANATION                                               FTE/$
=============================== ================================================== =====================
<S>                             <C>                                                <C>
Out of Pocket                   [***]                                                         [***]
------------------------------- -------------------------------------------------- ---------------------
[***]                           [***]                                                         [***]
------------------------------- -------------------------------------------------- ---------------------
[***]                           [***]                                                         [***]
------------------------------- -------------------------------------------------- ---------------------
[***]                           [***]                                                         [***]
------------------------------- -------------------------------------------------- ---------------------
[***]                           [***]                                                         [***]
------------------------------- -------------------------------------------------- ---------------------
[***]                           [***]                                                         [***]
------------------------------- -------------------------------------------------- ---------------------
Project Leader                  [***]                                                         [***]
=============================== ================================================== =====================
                                                                                              [***]
TOTAL                                                                                         [***]
------------------------------- -------------------------------------------------- ---------------------
</Table>

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       6.
<Page>

                     FFP BUDGET, 1998 PROJECTION: BAXTER R&D

<Table>
<Caption>
----------------------------- ------------------------------------------------- ------------------------
CATEGORY                      EXPLANATION                                                FTE/$
============================= ================================================= ========================
<S>                           <C>                                               <C>
Out of Pocket                 [***]                                                           [***]
----------------------------- ------------------------------------------------- ------------------------
[***]                         [***]                                                           [***]
----------------------------- ------------------------------------------------- ------------------------
[***]                         [***]                                                           [***]
                                                                                              [***]
----------------------------- ------------------------------------------------- ------------------------
Project Leader                [***]                                                           [***]
============================= ================================================= ========================
                                                                                              [***]
TOTAL                                                                                         [***]
----------------------------- ------------------------------------------------- ------------------------
</Table>

                  FFP BUDGET, 1998 PROJECTION: OUTSIDE EXPENSES

<Table>
<Caption>
----------------------------- ------------------------------------------------- ------------------------
CATEGORY                      EXPLANATION                                                  $
============================= ================================================= ========================
<S>                           <C>                                               <C>
[***]                         [***]                                                           [***]
----------------------------- ------------------------------------------------- ------------------------
[***]                         [***]                                                           [***]
============================= ================================================= ========================
TOTAL                                                                                         [***]
----------------------------- ------------------------------------------------- ------------------------
</Table>

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                      7.
<Page>

                   FFP BUDGET, 1999 PROJECTION: STERITECH R&D

<Table>
<Caption>
----------------------------- ------------------------------------------------- ------------------------
CATEGORY                      EXPLANATION                                                FTE/$
============================= ================================================= ========================
<S>                           <C>                                               <C>
Out of Pocket                 [***]                                                           [***]
----------------------------- ------------------------------------------------- ------------------------
[***]                         [***]                                                           [***]
----------------------------- ------------------------------------------------- ------------------------
[***]                         [***]                                                           [***]
----------------------------- ------------------------------------------------- ------------------------
[***]                         [***]                                                           [***]
============================= ================================================= ========================
                                                                                              [***]
TOTAL                                                                                         [***]
----------------------------- ------------------------------------------------- ------------------------
</Table>

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                      8.
<Page>

                     FFP BUDGET, 1999 PROJECTION: BAXTER R&D

<Table>
<Caption>
----------------------------- ------------------------------------------------- ------------------------
CATEGORY                      EXPLANATION                                                FTE/$
============================= ================================================= ========================
<S>                           <C>                                               <C>
Out of Pocket                 [***]                                                           [***]
----------------------------- ------------------------------------------------- ------------------------
[***]                         [***]                                                           [***]
----------------------------- ------------------------------------------------- ------------------------
[***]                         [***]                                                           [***]
----------------------------- ------------------------------------------------- ------------------------
[***]                         [***]                                                           [***]
----------------------------- ------------------------------------------------- ------------------------
Project Leader                [***]                                                           [***]
============================= ================================================= ========================
                                                                                              [***]
TOTAL                                                                                         [***]
----------------------------- ------------------------------------------------- ------------------------
</Table>

                  FFP BUDGET, 1999 PROJECTION: OUTSIDE EXPENSES

<Table>
<Caption>
----------------------------- ------------------------------------------------- ------------------------
CATEGORY                      EXPLANATION                                                  $
============================= ================================================= ========================
<S>                           <C>                                               <C>
[***]                         [***]                                                           [***]
============================= ================================================= ========================
TOTAL                                                                                         [***]
----------------------------- ------------------------------------------------- ------------------------
</Table>

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                        9.
<Page>

                   FFP BUDGET, 2000 PROJECTION: STERITECH R&D

<Table>
<Caption>
----------------------------- ------------------------------------------------- ------------------------
CATEGORY                      EXPLANATION                                                FTE/$
============================= ================================================= ========================
<S>                           <C>                                               <C>
Out of Pocket                 [***]                                                           [***]
----------------------------- ------------------------------------------------- ------------------------
[***]                         [***]                                                           [***]
----------------------------- ------------------------------------------------- ------------------------
Project Leader                [***]                                                           [***]
============================= ================================================= ========================
                                                                                              [***]
TOTAL                                                                                         [***]
----------------------------- ------------------------------------------------- ------------------------
</Table>

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       10.
<Page>

                     FFP BUDGET, 2000 PROJECTION: BAXTER R&D

<Table>
<Caption>
----------------------------- ------------------------------------------------- ------------------------
CATEGORY                      EXPLANATION                                                FTE/$
============================= ================================================= ========================
<S>                           <C>                                               <C>
[***]                         [***]                                                           [***]
----------------------------- ------------------------------------------------- ------------------------
[***]                         [***]                                                           [***]
----------------------------- ------------------------------------------------- ------------------------
Project Leader                [***]                                                           [***]
============================= ================================================= ========================
                                                                                              [***]
TOTAL                                                                                         [***]
----------------------------- ------------------------------------------------- ------------------------
</Table>

                  FFP BUDGET, 2000 PROJECTION: OUTSIDE EXPENSES

<Table>
<Caption>
----------------------------- ------------------------------------------------- ------------------------
CATEGORY                      EXPLANATION                                                [***]
============================= ================================================= ========================
<S>                           <C>                                               <C>
[***]                         [***]                                                           [***]
============================= ================================================= ========================
TOTAL                                                                                         [***]
----------------------------- ------------------------------------------------- ------------------------
</Table>

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                    11.
<Page>

                                   SCHEDULE C

                   [...***...] INTERIM DETERMINATION CRITERIA

The results of the [***] will be evaluated on an interim basis. [***] will be
evaluated. In accord with the [***] each will have received a [***] of the
specified [***] (should such [***] be specified in the [***]). [***] following
[***] will be compared. The definition of a successful outcome is defined as a
[***] to the mean reference product corrected count increments. [***] values
shall be at least [***]

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

<Page>

                                   SCHEDULE D

                            PLASMA DERIVATIVES LETTER

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

<Page>

      Kim C. Bush         Baxter Healthcare Corporation     Phone:  708.270.4110
      President           Route 120 and Wilson Road           Fax:  708.270.3855
      Fenwal Division     Round Lake, Illinois 60073
      Biotech Group

                                   SCHEDULE D
BAXTER

January 18, 1996

Mr. Stephen T. Isaacs
President and CEO
Steritech, Inc.
2525 Stanwell Drive
Suite 300
Concord, CA  94520

RE:      [***]

Dear Steve:

Thank you for your letter of December 26, 1995 discussing the rescission of your
Notice dated November 10, 1995. As we discussed on several occasions, Baxter is
[***] It has always been the position of Baxter that the Steritech
decontamination technology would be [***] With this in mind, this letter
confirms the agreement of Baxter and Steritech that:

(i) Steritech is entitled to negotiate and enter into agreements with third
parties for the development and/or licensing to such third parties of [***] free
of any rights of Baxter and without obligation to Baxter, except as set forth in
clause (ii) below.

(ii) In those cases where Steritech licenses [***] other than Baxter, Steritech
shall, at Baxter's written request, license such Steritech technology to Baxter
for such product on terms no less favorable than the terms received by such
other manufacturer.

Steritech will notify Baxter of the names of the third-party manufacturers with
whom Steritech is negotiating for licenses to Steritech's [***]

This letter agreement supersedes [***] of the Development Manufacturing and
Marketing Agreement between Steritech and Baxter, dated as of December 10, 1993,
insofar as such section concerns [***] (For the purposes of this letter, the
term [***] used in such section.)

Upon the execution and delivery by Steritech of this letter where indicated
below, the Notice dated November 10, 1996 is rescinded.

Sincerely,

/s/ Kim C. Bush

Kim C. Bush
President, Fenwal Division
Biotech Group

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

<Page>

Mr. Stephen T. Isaacs
January 18, 1996
Page 2

AGREED AS SET FORTH ABOVE

Steritech, Inc.

By:  /s/ Stephen Isaacs
     ---------------------------------------
         Stephen T. Isaacs
         President

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

<Page>

                                   SCHEDULE E

                            CONFIDENTIALITY AGREEMENT

         THIS AGREEMENT, made on March 18, 1996 with respect to the Development,
Manufacturing and Marketing Agreement ("Agreement") between Baxter and Steritech
dated as of April 1, 1996 between STERITECH, INC. ("Steritech"), having a
principal place of business at 2525 Stanwell Drive, Concord, California and
BAXTER HEALTHCARE CORPORATION ("Baxter"), a corporation having a principal place
of business at One Baxter Parkway, Deerfield, Illinois 60015, to assure the
protection and preservation of Proprietary Information disclosed or to be
disclosed or made available to each other in connection with the Agreement.

         WHEREAS, the parties have entered into a development, manufacturing and
marketing collaboration pursuant to the Agreement;

         WHEREAS, the parties desire to assure the confidential status of the
information which may be disclosed to each other in connection with the
Agreement;

         NOW, THEREFORE, in reliance upon and in consideration of the following
undertakings, the parties agree as follows:

         1. All information disclosed to the other party shall be deemed to be
"Proprietary Information." In particular, Proprietary Information shall be
deemed to include any information, process, techniques, algorithm, program,
design, drawing, formula or test data relating to any research project, work in
progress, future development, engineering, manufacturing, marketing, servicing,
financing or personnel matter relating to the disclosing party, its present or
future products, sales, suppliers, clients, customers, employees, investors, or
business. Any Proprietary Information outside the scope of the Agreement shall
be identified by the disclosing party in writing and marked "Confidential" or if
such Proprietary Information is disclosed orally, within 30 days after such
disclosure the Proprietary Information shall be reduced to writing and marked
"Confidential" by the disclosing party and such writing forwarded to the
receiving party.

         2. The term "Proprietary Information" shall not be deemed to include
information which: (i) is now, or hereafter becomes, through no act or failure
to act on the part of the receiving party, generally known or available; (ii) is
known by the receiving party at the time of receiving such information as
evidenced by its records; (iii) is furnished to the receiving party by a third
party whom the receiving party believes has a right to disclose such
information; (iv) is independently developed by the receiving party without any
breach of this Confidentiality Agreement; and (v) is the subject of a written
permission to disclose provided by the disclosing party.

         3. Each party shall maintain in trust and confidence and not disclose
to any third party or use for any unauthorized purpose any Proprietary
Information received from the other party. However, each party may disclose
Proprietary Information to its affiliates who are bound by this Agreement
(affiliates include: any company owning 40% or more of a party, or a subsidiary
of the party, or a subsidiary of a party owning 40% or more of the party). Each
party may use such Proprietary Information only to the extent required under the
Agreement.

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

<Page>

         4. The responsibilities of the parties with respect to the Proprietary
Information are limited to using the same degree of care used to protect their
own Proprietary Information from unauthorized use or disclosure. Both parties
shall advise their employees or agents who might have access to such Proprietary
Information of the confidential nature thereof.

         5. This Confidentiality Agreement shall continue in full force and
effect for so long as the parties continue to exchange Proprietary Information
under the Agreement. The termination of the Agreement shall not relieve either
party of the obligations imposed by this Confidentiality Agreement with respect
to Proprietary Information disclosed prior to the effective date of such
termination, which obligations shall survive the termination of the Agreement
for a period of two (2) years from the date of disclosure.

         6. Each party hereby acknowledges and agrees that in the event of any
breach of this Confidentiality Agreement by the other party, including, without
limitation, the actual or threatened disclosure of a disclosing party's
Proprietary Information without the prior express written consent of the
disclosing party, the disclosing party will suffer an irreparable injury, such
that no remedy at law will afford it adequate protection against, or appropriate
compensation for such injury. Accordingly, each party hereby agrees that the
other party shall be entitled to any injunctive relieve as may be granted by a
court of competent jurisdiction.

AGREED TO:                                   AGREED TO:

STERITECH, INC.                              BAXTER HEALTHCARE CORPORATION

By:  Stephen T. Isaacs                       By:  Kim Bush
     President                                    President, Fenwal Division

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

<Page>

                                   SCHEDULE F

                          BAXTER PARTICIPATION IN 1996

<Table>
<Caption>

<S>                                                                                         <C>
   RED CELL                                                                                 ESTIMATED FTES
      1.         Consult on [***]                                                                [***]

      2.         Consult on [***]                                                                [***]

      3.         Consult on [***]                                                                [***]

FRESH FROZEN PLASMA

      1.         Consultants to review and comment on [***]                                       TBD

      2.         [***] Baxter-I.V. Systems and/or Baxter Fenwal Europe will consult              [***]

      3.         Disposable/Device - Final phase development of a disposable for use             [***]
                 in toxicology and clinical trials.  Ongoing production of bags for
                 use in [***] work/toxicology trials/clinical trials

      4.         [***] - Development and validation of [***]                                     [***]
</Table>

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

<Page>

                                   SCHEDULE G

                            STOCK PURCHASE AGREEMENT

                                    SEE TAB 2

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.<Page>

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                                                   EXHIBIT 10.32

                           DEVELOPMENT, MANUFACTURING
                                       AND
                               MARKETING AGREEMENT

                                     BETWEEN
                          BAXTER HEALTHCARE CORPORATION
                                       AND
                                CERUS CORPORATION

                                  APRIL 1, 1996

                             AS AMENDED AND RESTATED

                                  JUNE 30, 1998

<Page>

                                TABLE OF CONTENTS

<Table>
<Caption>
                                                                                                               PAGE
<S>      <C>                                                                                                   <C>

1.       BACKGROUND...............................................................................................1

2.       DEFINITION OF TERMS......................................................................................1

3.       COOPERATIVE DEVELOPMENT WORK............................................................................10

         3.1      Period; Objective..............................................................................10

         3.2      Management Board...............................................................................11

                  (a)      Constitution..........................................................................11

                  (b)      Project Committees....................................................................11

                  (c)      Patent Committee......................................................................11

                  (d)      Voting................................................................................12

                  (e)      Disputes..............................................................................12

         3.3      Review Of Budget, Benchmarks; Approved Projects................................................13

                  (a)      The Red Cell Project..................................................................13

                  (b)      The S59 FFP Project...................................................................14

                  (c)      Other Projects........................................................................15

         3.4      Exchange Of Information........................................................................15

         3.5      Cost Sharing...................................................................................15

         3.6      Testing And Regulatory Expenses................................................................16

                  (a)      Testing Expenses......................................................................16

                  (b)      Regulatory Expenses...................................................................16

         3.7      Budget Contingencies...........................................................................17

                  (a)      Exceeding Initial Budget..............................................................17

                  (b)      Reconciliation Of Expenditures........................................................17

         3.8      New Technologies...............................................................................17

         3.9      Coordination and Facilitation of Communications................................................19

4.       EQUITY PURCHASE.........................................................................................19

         4.1      Baxter Purchase Of Equity In Cerus.............................................................19

         4.2      Standstill By Baxter...........................................................................21

5.       SUPPLY OF CERUS COMPOUND AND SYSTEM MANUFACTURING.......................................................24

         5.1      Cerus Responsibilities.........................................................................24

         5.2      Baxter Responsibilities........................................................................24

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

<Page>

         5.3      Instrument Production..........................................................................24

         5.4      System Specifications..........................................................................24

         5.5      Cerus Specifications...........................................................................24

         5.6      Source Of Supply...............................................................................25

         5.7      Failure Of Cerus To Meet Baxter Requirements...................................................25

         5.8      System Improvements............................................................................25

6.       MARKETING AND DISTRIBUTION RIGHTS:  EXCLUSIVE DISTRIBUTION RIGHTS.......................................25

         6.1      Commercialization..............................................................................25

         6.2      Meetings Concerning Marketing..................................................................25

         6.3      Exclusive Relationship.........................................................................26

         6.4      Competing Products.............................................................................26

         6.5      Commencement, Cessation Of Marketing...........................................................26

         6.6      Achievement Of Market Share....................................................................27

         6.7      Supply Of Baxter Goods.........................................................................27

         6.8      Requalification................................................................................27

         6.9      Management Board Access To And Review Of Marketing And Distribution Information................28

         6.10     Baxter Termination of Distribution for S59 FFP Systems.........................................28

         6.11     Baxter Termination of Supply of Goods for S59 FFP Systems......................................28

         6.12     Cerus Termination of Baxter Manufacturing Rights for S59 FFP Systems...........................28

         6.13     Cerus Termination of Distribution Rights for S59 FFP Systems...................................29

7.       REVENUE SHARING.........................................................................................29

         7.1      Revenue Sharing Payments.......................................................................29

         7.2      Baxter Sourcing Cerus Compounds................................................................29

         7.3      Cerus As Seller Of Systems.....................................................................29

         7.4      Licensing Of Rights Arising Under This Agreement...............................................30

         7.5      Distributor Sales..............................................................................30

8.       PATENTS, KNOW-HOW, LICENSE GRANTS.......................................................................30

         8.1      Cerus Sole Ownership...........................................................................30

         8.2      Baxter Sole Ownership..........................................................................30

         8.3      Joint Ownership................................................................................31

         8.4      License........................................................................................32

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                      ii

<Page>

         8.5      Cerus Rights...................................................................................32

         8.6      Cross-License As To Instruments And Compound Removal Devices; Exploitation Of Joint
                  Inventions Outside The Field...................................................................33

         8.7      Excluded Products..............................................................................33

         8.8      Notice Of Sole Rights..........................................................................33

         8.9      Other Agreements...............................................................................34

         8.10     Regulatory Files...............................................................................34

         8.11     Rights Under Government-Sponsored Research.....................................................34

9.       PROSECUTION OF PATENT RIGHTS............................................................................34

         9.1      Cerus Patents..................................................................................34

         9.2      Baxter Patents.................................................................................34

         9.3      Joint Patents..................................................................................34

         9.4      Prior Art; Review And Comment..................................................................35

         9.5      Project Patents; Licensing Payments to Third Parties...........................................35

         9.6      Patent Expenses................................................................................35

         9.7      Election Not To Pay Expenses...................................................................36

10.      TRADEMARKS..............................................................................................36

         10.1     Baxter Trademarks..............................................................................36

         10.2     Cerus Trademarks...............................................................................36

11.      CONFIDENTIAL INFORMATION................................................................................36

         11.1     Confidentiality Agreement......................................................................36

         11.2     Use Of Consultants.............................................................................36

12.      CESSATION OF COOPERATIVE DEVELOPMENT WORK...............................................................37

         12.1     Cessation......................................................................................37

         12.2     Cessation Payment..............................................................................38

         12.3     Section 12 Not Applicable to S59 FFP...........................................................38

13.      REPORTS.................................................................................................38

         13.1     Quarterly Sales Reports........................................................................38

         13.2     Cost Of Goods/Base Revenue.....................................................................39

14.      BOOKS AND RECORDS.......................................................................................39

         14.1     Records........................................................................................39

         14.2     Retention......................................................................................39

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                      iii

<Page>

         14.3     Interest.......................................................................................39

15.      TERM....................................................................................................39

16.      BREACH..................................................................................................40

         16.1     Material Breach................................................................................40

         16.2     Rights On Termination..........................................................................40

17.      REPRESENTATIONS AND INDEMNITIES.........................................................................40

         17.1     Cerus Representations..........................................................................40

         17.2     Cerus Indemnification -- Representations And Warranties........................................41

         17.3     Cerus Indemnification -- Products..............................................................41

         17.4     Insurance......................................................................................41

         17.5     Baxter Representations.........................................................................41

         17.6     Baxter Indemnification - Representations And Warranties........................................42

         17.7     Baxter Indemnification - Products..............................................................42

         17.8     Baxter Insurance...............................................................................42

18.      INFRINGEMENT............................................................................................42

         18.1     Defense Of Third Party Infringement Suits......................................................42

         18.2     Suits For Infringement By Others...............................................................43

19.      PREFERRED STOCK PURCHASE................................................................................43

20.      GENERAL.................................................................................................43

         20.1     Entire Agreement...............................................................................43

         20.2     Relationship Of Parties........................................................................44

         20.3     Senior Baxter Contact..........................................................................44

         20.4     Senior Cerus Contact...........................................................................44

         20.5     Severability...................................................................................44

         20.6     Force Majeure..................................................................................44

         20.7     Notices........................................................................................44

         20.8     Binding........................................................................................45

         20.9     Governing Law..................................................................................45

         20.10    Venue..........................................................................................45

         20.11    Disbursements..................................................................................45

         20.12    Publicity......................................................................................45

         20.13    Survival.......................................................................................45
</Table>

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                      iv

<Page>

Schedule A-1        Initial Red Cell Budget
Schedule A-2        1998 Red Cell Budget
Schedule B          Initial S59 FFP Budget
Schedule C          No Schedule C
Schedule D          Plasma Derivatives Letter
Schedule E          Confidentiality Agreement
Schedule F          No Schedule F
Schedule G          Stock Purchase Agreement
Schedule H          Example of Cost of Goods/Base Revenue
Schedule I          Amortization Schedule
Schedule J          Baxter Non-Employee Security Agreement

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                     v

<Page>

                           DEVELOPMENT, MANUFACTURING
                             AND MARKETING AGREEMENT

         THIS AGREEMENT ("Agreement") between BAXTER HEALTHCARE CORPORATION, a
Delaware corporation ("BHC") with principal offices at One Baxter Parkway,
Deerfield, Illinois 60015, and CERUS CORPORATION, a Delaware corporation,
successor in interest to STERITECH, INC., a California corporation, with
principal offices at 2525 Stanwell Drive, Concord, California 94520, is
effective as of the 1st day of April, 1996 ("Effective Date") and is amended and
restated effective as of June 30, 1998 (the "First Amendment Effective Date").

1.       BACKGROUND.

         1.1 Cerus has substantial knowledge and expertise in the area of
inactivation of pathogens for the decontamination of blood products. Baxter has
substantial knowledge and expertise in the research, development, manufacture
and distribution of healthcare products including those relating to the
collection, preservation, processing, manipulation, storage and treatment of
blood and blood components.

         1.2 The parties are interested in the development and commercialization
of products and/or systems which provide a customer with instrumentation,
disposables and compounds for use in EX-VIVO inactivation of pathogens for the
decontamination of human blood cells and human blood components intended for
human use.

2.       DEFINITION OF TERMS.

         The words appearing in capitalized form throughout this Agreement shall
have the meanings assigned to them in this Section 2.

         APPROVED DISTRIBUTOR means any company, other than a company (or any of
its affiliates) that manufactures blood collection products or any distributor
of blood collection products identified in a letter from Baxter to Cerus dated
the Effective Date. For the purposes of this definition, an "affiliate" of a
company shall mean an entity controlling, controlled by, or under common control
with such company. "Control" for the purposes of this definition shall mean
fifty percent (50%) ownership.

         APPROVED PROJECT FIELD means (a) that subset of the Field comprising
solely the EX VIVO inactivation of pathogens for decontamination of (i) human
red blood cells through use of ALE compounds and (ii) FFP through use of
psoralens, in each case of clause (i) and (ii) otherwise meeting the limitations
set forth in the definition of the FIELD, and (b) each such other subset of the
Field as shall become the subject of a Project under this Agreement pursuant to
Section 3.8 hereof.

         ALE means anchor linker effector, as defined in that certain letter
dated March 14, 1996 from Kathryn P. Wilke of Cerus to Joseph B. Barrett of
Baxter.

         BASE REVENUE means for any Integrated Inactivation Set as of any
measurement date the average net sales price (computed using the same
adjustments as provided in paragraphs (a) and

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       1

<Page>

(b) of the definition of NET SALES) of a comparable set without an Inactivation
Package ("Base Set") during the three full calendar months preceding such date,
and in the case of each new Integrated Inactivation Set, during the three full
months preceding the first sale of such Integrated Inactivation Set ("Initial
Base Revenue"). Base Revenue shall be adjusted, with respect to the sales of
each Integrated Inactivation Set in each quarter commencing with the first full
calendar quarter after its first sale, to

         (a) an amount equal to the average net sales price (computed using the
same adjustments as provided in paragraphs (a) and (b) of the definition of NET
SALES) of a comparable Base Set during three full calendar months preceding the
first day of such calendar quarter, if there exists throughout such period a
large blood collection market for such comparable Base Set, or

         (b) if there does not exist throughout such period a large blood
collection market for such Base Set, an amount equal to:
                        x
                  y =  --- where
                        z

                  (x) equals the average Net Sales price for such Integrated
                  Inactivation Set in such quarter;

                  (y) equals the Base Revenue for such Base Set during the most
                  recent three full month period in which there continuously
                  existed a large clinical market for such Base Set, and

                  (z) equals the average Net Sales price for such Integrated
                  Inactivation Set during such three full month period (or
                  shorter period since first sale of such Integrated
                  Inactivation Set).

Baxter shall provide to Cerus information supporting such average net sales
price within sixty (60) days after the last day of the first calendar quarter in
which the first sale of each Integrated Inactivation Set occurs and sixty (60)
days after the last day of each calendar quarter thereafter. For the purposes of
this definition, a "large blood collection market" shall be deemed to exist for
any Base Set in any three-month period if Baxter has sales of such Base Set into
the blood collection (for transfusion) market of at least twenty-five percent
(25%) of the number of units of such Base Set that were sold in the three-month
period immediately preceding the first sale of the comparable Integrated
Inactivation Set. Baxter shall provide to Cerus within sixty (60) days after the
last day of each calendar quarter information for each such Base Set evidencing
whether or not there exists a large clinical market.

         BASE SET has the meaning set forth in the definition of Base Revenue.

         BAXTER means BHC and its affiliates, including, but not limited to,
divisions and subsidiaries, and also including its parent company, Baxter
International Inc. and its affiliates, including, but not limited to, divisions
and subsidiaries. A company shall be considered an affiliate of BHC if it is at
least forty percent (40%) owned or controlled by BHC or Baxter International
Inc.

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       2

<Page>

         BAXTER COMPOUNDS means any and all New Technology Compounds developed
by, licensed to, acquired by or otherwise commercially accessible to Baxter
prior to the Effective Date or in the course of the Cooperative Development
Work.

         BAXTER DESIGNATED CONSULTANTS means those persons who act on a regular
basis as consultants of Baxter, as adjuncts to Baxter management or staff, or as
members of the scientific advisory board or other boards or committees, as
distinguished from consultants or contractors who are engaged to perform
specific tasks in connection with the Cooperative Development Work.

         BAXTER INVENTION means an Invention that is solely owned by Baxter, or
which Baxter has the right to control the use of, relating to the Field and any
System, including methods for manufacture or use of Baxter Compounds and Systems
or portions thereof.

         BAXTER KNOW-HOW means Know-How proprietary to Baxter that is solely
owned by Baxter, or which Baxter has the right to control the use of, relating
to the Field and any System, including methods for manufacture or use of Baxter
Compounds and Systems or portions thereof. The term BAXTER KNOW-HOW includes,
and is limited to, any of the foregoing in existence as of the Effective Date or
created or acquired during the term of the Cooperative Development Work.

         BAXTER NONCASH CONTRIBUTION shall be deemed to be [...***...] for the
Red Cell Project, [...***...] for the S59 FFP Project and such amount as the
parties may agree for any other Project, PROVIDED THAT if the parties do not so
agree, the Baxter Noncash Contribution for such Project shall be one-half of the
Initial Budget for the total Project, the amount of the Baxter Noncash
Contribution in each case being subject to adjustment as provided herein.

         BAXTER PATENTS means all United States and foreign patent applications
and patents that relate to the Approved Project Field and have claims reading on
Baxter Compounds or compositions or formulations thereof, or otherwise reading
on a System or portion thereof, or methods for manufacture or use of such System
or Baxter Compound, owned by Baxter or licensed to Baxter with the right to
sublicense, including any continuations, divisions, reissues, re-examinations
and all foreign counterparts thereof. The term BAXTER PATENTS includes, and is
limited to, any of the foregoing in existence as of the Effective Date or
claiming an invention conceived or discovery made, or which are acquired, during
the term of the Cooperative Development Work.

         BAXTER PROJECT INVENTION means an Invention conceived by employees
and/or agents of Baxter (including Baxter Designated Consultants, but excluding
Inventions made solely by Contractors) alone or with third parties (excluding
Cerus) during the term of this Agreement pursuant to the Cooperative Development
Work. Without limiting the foregoing, Baxter Project Invention also includes any
such Invention conceived by employees or agents of a Contractor jointly with
employees or agents of Baxter (but not of Cerus).

         BULK FORM means Cerus Compounds which are not packaged in final form.

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       3

<Page>

         CERUS means Cerus Corporation, a company organized under the laws of
California and its affiliates, including, but not limited to, divisions and
subsidiaries. A company shall be considered an affiliate of Cerus if it is at
least forty percent (40%) owned or controlled by Cerus.

         CERUS COMPOUND(S) means any and all psoralen compounds, ALE compounds
and New Technology Compounds developed by, licensed to, acquired by or otherwise
commercially accessible to Cerus prior to the Effective Date or in the course of
the Cooperative Development Work.

         CERUS DESIGNATED CONSULTANTS means those persons who act on a regular
basis as consultants of Cerus, as adjuncts to Cerus management or staff, or as
members of the scientific advisory board or other boards or committees, as
distinguished from consultants or contractors who are engaged to perform
specific tasks in connection with the Cooperative Development Work.

         CERUS INVENTION means an Invention that is solely owned by Cerus, or
which Cerus has the right to control the use of, relating to the Field and any
System, including methods for manufacture or use of Cerus Compounds and Systems
or portions thereof.

         CERUS KNOW-HOW means Know-How proprietary to Cerus that is solely owned
by Cerus, or which Cerus has the right to control the use of, relating to the
Field and any System, including methods for manufacture or use of Cerus
Compounds and Systems or portions thereof. The term CERUS KNOW-HOW includes, and
is limited to, any of the foregoing in existence as of the Effective Date or
created or acquired during the term of the Cooperative Development Work.

         CERUS NONCASH CONTRIBUTION shall be deemed to be [...***...] for the
Red Cell Project, [...***...] for the S59 FFP Project and such amount as the
parties may agree for any other Project, PROVIDED THAT if the parties do not
so agree, the Cerus Noncash Contribution for such Project shall be one-half
of the Initial Budget for the total Project, the amount of the Cerus Noncash
Contribution in each case being subject to adjustment as provided herein.

         CERUS PATENTS means all United States and foreign patent applications
and patents that relate to the Approved Project Field and have claims reading on
Cerus Compounds or compositions or formulations thereof, or otherwise reading on
a System or portion thereof, or methods for manufacture or use of such System or
Cerus Compound, owned by Cerus or licensed to Cerus with the right to
sublicense, including any continuations, divisions, reissues, re-examinations
and all foreign counterparts thereof. The term CERUS PATENTS includes, and is
limited to, any of the foregoing in existence as of the Effective Date, or
claiming an invention conceived or discovery made, or which are acquired, during
the term of the Cooperative Development Work.

         CERUS PROJECT INVENTION means an Invention conceived by employees
and/or agents of Cerus (including Cerus Designated Consultants, but excluding
Inventions made solely by Contractors) alone or with third parties (excluding
Baxter) during the term of this Agreement pursuant to the Cooperative
Development Work. Without limiting the foregoing, Cerus Project Invention also
includes any such Invention conceived by employees or agents of a Contractor
jointly with employees or agents of Cerus (but not of Baxter).

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       4

<Page>

         COOPERATIVE DEVELOPMENT WORK means the Cooperative Development Work
defined in Section 3.1 of this Agreement.

         CONTRACTOR means a third party, other than a Baxter Designated
Consultant or Cerus Designated Consultant, performing a portion of the
Cooperative Development Work or investigation of New Technologies under a
contract with Baxter, Cerus, or Baxter and Cerus jointly.

         CONTRACTOR INVENTION means an Invention conceived by employees and/or
agents of a Contractor in the course of performing a portion of the Cooperative
Development Work or investigation of New Technologies under a contract with
Baxter, Cerus, or Baxter and Cerus jointly. For the purposes hereof, any such
Invention that is conceived by employees or agents of the Contractor jointly
with employees or agents of Baxter (but not of Cerus) shall be considered to be
a Baxter Project Invention, and not a Contractor Invention. Any such Invention
that is conceived by employees or agents of the Contractor jointly with
employees or agents of Cerus (but not of Baxter) shall be considered to be a
Cerus Project Invention, and not a Contractor Invention.

         COST OF GOODS means, for either party, such party's full cost of
manufacturing or acquiring such items, in accordance with GAAP and in accordance
with Baxter's normal accounting policies, all consistently applied. Cost of
Goods shall not include general corporate allocations or other allocations which
are not directly related to manufacture of the item and shall not include
amortization of development expenditures or expenses falling under the category
designated by Baxter "other costs of sales" or similar category, however
designated, unless otherwise agreed by the Management Board. Capital
expenditures for facilities and/or equipment and capitalized manufacturing
start-up costs will be amortized and included in Cost of Goods. In the event any
item is acquired by a party from an affiliate of such party, "cost of
manufacturing or acquiring" shall be deemed to mean such affiliate's cost of
manufacturing or acquiring. For the purposes of this definition, an "affiliate"
of a company shall mean an entity controlling, controlled by, or under common
control with such company. "Control" for the purposes of this definition shall
mean fifty percent (50%) ownership.

         COST OF GOODS/BASE REVENUE for Cerus means Cerus' Cost of Goods. For
Baxter COST OF GOODS/BASE REVENUE means:

                  (a) in the case in which the Inactivation Package is sold as a
stand-alone item, Baxter's Cost of Goods, or

                  (b) in the case in which the Inactivation Package is sold as a
part of an Integrated Inactivation Set in any calendar year, the [...***...]
(i) [...***...] or (ii) [...***...] An example of calculation of Cost of
Goods/Base Revenue is set forth on Schedule H to this Agreement.

         DESIGNATED CONSULTANTS means Baxter Designated Consultants and Cerus
Designated Consultants.

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       5

<Page>

         DISTRIBUTOR PORTION means, for any Inactivation Package or Integrated
Inactivation Set sold through a distributor, the amount by which Net Sales price
therefrom exceeds the revenues from the sale of such items to the Distributor.

         EUROPE means any of the countries within the definition of Europe, as
such term is defined in the Platelet Agreement.

         EXCLUDED PRODUCT has the meaning provided in Section 8.7 of this
Agreement.

         FDA means the United States Food and Drug Administration.

         FFP means human fresh frozen plasma.

         THE FIELD means, subject to the exceptions set forth in Section 8.5
hereof, [...***...] in each case that are obtained from [...***...] The Field
includes [...***...] The Field does not include, however, any [...***...] to
make, enable, or improve the [...***...]. The preceding sentence is not
intended, however, to exclude (a) the use of such [...***...] falling within
clause (i) or (ii) above, or (b) the [...***...] falling within clause (i) or
(ii) above, in which the [...***...] Cerus reserves all rights to [...***...]
using Cerus Compounds in which the intended use of the [...***...] The Field
also excludes [...***...]

         FINAL PROJECT TOTAL BUDGET means the total cost and expense of
developing a System up to and including obtaining Regulatory Approval to market
the System in the countries in which the Management Board (or Cerus in the case
of the S59 FFP Project) determines that Regulatory Approval should be sought and
any other items of cost or expense that this Agreement expressly requires to be
included in Final Project Total Budget. In the event either party, to the extent
permitted under Section 3.6(b) of this Agreement, elects not to share in the
costs of Regulatory Approval of a Project in a particular country, the Final
Project Total Budget shall be adjusted solely as to such country by adding to
the overall Final Project Total Budget the amount of the incremental
expenditures incurred by the party bearing the costs of Regulatory Approval in
such country and such party's cash contribution to the Project solely as to such
country will be increased by adding the amount of such expenditures to such
party's overall cash contribution to the Project. The preceding sentence shall
not apply, however, with respect to the S59 FFP Project.

         GAAP means generally accepted accounting principles, consistently
applied.

         INACTIVATION PACKAGE means the package containing one or more Cerus
Compounds, Baxter Compounds and/or New Technology Compounds, as well as the
delivery system (consisting of all disposables and compound removal device, if
any, associated with a System).

         INITIAL BUDGET means the budget first approved by the Management Board
for developing a particular Project to Regulatory Approval, which for Red Cell
Project means Regulatory Approval in the United States and Europe, and for the
S59 FFP Project means Regulatory Approval in the United States.

         INSTRUMENT means an instrument or instruments to be developed or
adapted under the Cooperative Development Work and may include associated data
tracking systems.

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       6

<Page>

         INTEGRATED INACTIVATION SET means an integrated set containing an
Inactivation Package and other collection or storage items.

         INVENTION means a patentable invention or discovery.

         JOINT INVENTIONS means an Invention relating to the performance of this
Agreement, conceived jointly by one or more employees or agents (including
Baxter Designated Consultants) of Baxter and one or more employees or agents
(including Cerus Designated Consultants) of Cerus.

         JOINT JAPAN FFP DISTRIBUTION PARTNER has the meaning set forth in
Section 6.1 hereof.

         JOINT PATENTS means all United States and foreign patent applications
and patents claiming an invention owned by, or licensed to both Cerus and
Baxter, including any continuations, divisions, reissues, re-examinations and
all foreign counterparts thereof. Without limiting the foregoing, Joint Patents
includes the patents and patent applications claiming a Contractor Invention of
which either Baxter or Cerus gains ownership or license, as set forth in Section
8.3(d).

         KNOW-HOW means inventions, or data, processes, compositions, techniques
and other technical information that are not patentable or for which patent
protection is not sought.

         MANAGEMENT BOARD means the Management Board created pursuant to Section
3.2 hereof.

         MARKET LAUNCH of a System in a given country is deemed to be the
earlier of (1) the date of first commercial sale following Regulatory Approval
for sale of the System in that particular country or (2) the ninetieth (90th)
day following Regulatory Approval for commercial sale of that System in that
country.

         MARKETING AND ADMINISTRATIVE EXPENSES for a party in any calendar year
is that percentage of such party's Net Sales (minus Base Revenue in the case of
sales of Integrated Inactivation Sets) for costs incurred in marketing, selling
and administering the Systems, established as follows:

<Table>
<Caption>
                  AGGREGATE NET SALES                                          PERCENTAGE APPLIED
                    OF SUCH PARTY                                              TO ALL NET SALES IN
                  IN SUCH CALENDAR YEAR                                        SUCH CALENDAR YEAR
                  -------------------------------------------------------------------------------
                  <S>                                                          <C>
                  Under [...***...]                                                [...***...]
                  [...***...] up to [...***...]                                    [...***...]
                  [...***...] up to [...***...]                                    [...***...]
                  Over [...***...]                                                 [...***...]
</Table>

(All dollar amounts in this definition are expressed in U.S. dollars, converted
from foreign currencies in accordance with Section 7.1 hereof). For the purpose
of determining Premium for the first three quarterly Revenue Sharing Payments
for any calendar year, the percentage used as set forth above to compute a
party's Marketing and Administrative Expenses will be based on

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       7

<Page>

the party's BONA FIDE forecast of Net Sales in such calendar year used for its
internal management purposes (which information will be provided to the
Management Board). If actual aggregate annual Net Sales vary from such
projections to an extent that would cause a change in the applicable percentage
rate for such calendar year, such first three quarterly Revenue Sharing Payments
will be appropriately adjusted retroactively in the final Revenue Sharing
Payment for such calendar year (I.E., the First Revenue Sharing Payment date in
the following calendar year) and additional payments will be made to the
receiving party, or amounts reimbursed from the receiving party, to yield the
actual Revenue Sharing Payment to which the receiving party is entitled based on
the level of actual Net Sales in such calendar year.

         NET SALES means

                  (a) in the case of the Inactivation Package sold as a
stand-alone item or as part of an Integrated Inactivation Set, the amount
invoiced by Baxter for sales, leases, or licenses of the stand-alone
Inactivation Package or Integrated Inactivation Set, less credits or allowances,
if any, for rejections or returns, customary trade discounts actually given,
less customs and duties paid; less separately invoiced and actually incurred
taxes and other governmental charges that are imposed directly on or measured by
the sale, transfer, transportation, delivery or use of an Inactivation Package;
and less freight paid by Baxter on shipment from Baxter to end users.

                  (b) In the event any Inactivation Package or Integrated
Inactivation Set is bundled (whether or not invoiced separately) and sold at a
discount with other products for whatever reason, including a special
promotional offer, or in the event of any transaction other than a bona fide
arms length transaction exclusively for money, or upon any use of such
Inactivation Package or Integrated Inactivation Set for purposes which do not
result in customary sales revenue, such sale or other disposal or use shall be
(unless the parties agree otherwise) deemed to constitute a sale at the then
current average selling price for the Inactivation Package or Integrated
Inactivation Set, as the case may be.

                  (c) In the case of sales by Baxter to a distributor, the Net
Sales shall be computed on the distributor's invoice price to the ultimate
purchaser or user. In the event that Baxter is not able to determine the price
charged by a distributor to the ultimate purchaser or user, such price shall be
the recommended price which Baxter, at the direction of the Management Board,
recommends the distributor to charge to its end customers (which may vary from
territory to territory).

                  (d) In the event Baxter or Cerus, in accordance with policies
established by the Management Board, supplies Instruments to end users without
charge in return for an increased price of Inactivation Packages to such end
users, Baxter or Cerus, as the case may be, may deduct from Net Sales received
from such end users the depreciation of the cost of such Instruments. In the
event such Instruments are also used in connection with products supplied by
Baxter or Cerus other than the Inactivation Packages or Integrated Inactivation
Sets developed under this Agreement, then the amount of such depreciation to be
deducted in any quarter from Net Sales shall be limited to that portion of the
depreciation reasonably allocable to the use of the Instruments in connection
with Inactivation Packages and Integrated Inactivation Sets, in accordance with
policies established by the Management Board. In the case of such Instruments
that are supplied into facilities using both platelet pathogen inactivation
systems and S59 FFP Systems, Baxter or Cerus as the case may be, may [...***...]

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       8

<Page>

                  (e) In the event that the ultimate purchaser or end user is
assessed a charge by Baxter on a per-inactivation or other usage basis, the
amount of such charge shall be included in Net Sales.

                  (f) If the term "Net Sales" is used in reference to Systems
sold by Cerus, the word "Baxter" in this definition shall be deemed to mean
"Cerus," except with respect to paragraph (c) above for the sale by Cerus of S59
FFP Systems. Paragraph (c) above also does not apply to sale by a Joint Japan
FFP Distribution Partner of S59 FFP Systems. In the case of sales of S59 FFP
Systems by Cerus through a distributor or by a Joint Japan FFP Distribution
Partner, Net Sales will be the [...***...] subject to adjustment as provided in
paragraphs (a) and (b) of this definition, or if the distributor or Joint Japan
FFP Distribution Partner is [...***...]

         NEW TECHNOLOGY means New Technology as defined in Section 3.8 hereof.

         NEW TECHNOLOGY COMPOUND(S) means any compound employed in a New
Technology to which rights are acquired pursuant to Section 3.8 hereof.

         NONCASH CONTRIBUTION means the Baxter Noncash Contribution and/or the
Cerus Noncash Contribution, as the context requires.

         PATENT COMMITTEE means a committee established by the Management Board
to review and report to the Management Board on patent matters pertaining to
this Agreement, and which will be comprised of an equal number of Baxter members
and Cerus members.

         PATENT FEE PAYMENT means an upfront license fee, milestone payment or
other financial consideration to a third party, other than a royalty on
percentage-of-sales or per-unit basis, for manufacture, use or sale of a System
or portion thereof.

         PATENT ROYALTY PAYMENT means a patent royalty payment on a
percentage-of-sales or per-unit basis made to a third party for manufacture, use
or sale of a System or portion thereof. Under this Agreement, the term PATENT
ROYALTY PAYMENT includes minimum royalty payments, but does not include any
Patent Fee Payment.

         PLATELET AGREEMENT means that certain Development, Manufacturing and
Marketing Agreement between the parties dated as of December 10, 1993, as the
same may be amended from time to time.

         PLATELET PROJECT means the "Cooperative Development Work" provided for,
and as defined in, the Platelet Agreement.

         PREMIUM means the Net Sales price of an Inactivation Package or
Integrated Inactivation Set minus each Party's Cost of Goods/Base Revenue in the
Inactivation Package or Integrated Inactivation Set, minus Marketing and
Administrative Expenses and [...***...] on [...***...] on [...***...] PROVIDED,
HOWEVER, that on sales through a Joint Japan FFP Distribution Partner,
[...***...] in computing Premium.

         PROJECT means the Cooperative Development Work performed by the Parties
to develop, obtain Regulatory Approval of, and market a System for a specific
application within the Field.

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       9

<Page>

         PROJECT PATENT(S) means any Baxter Patent, Cerus Patent or Joint Patent
that the Management Board has designated a Project Patent pursuant to Section
9.5 hereof.

         RED CELL means, when used in reference to a Project, the Cooperative
Development Work to develop a System for inactivation of pathogens in human red
blood cells and, when used in reference to a System, Inactivation Package,
Instrument, or other item, the System, Inactivation Package, Instrument or other
item, developed or under development pursuant to such Cooperative Development
Work.

         REGULATORY APPROVAL means (1) in the United States, approval from the
FDA for marketing and promotion of the System, or (2) outside of the United
States, an analogous order by a non-U.S. governmental agency which requires
regulatory approval prior to marketing and promotion of a System in such
non-U.S. country.

         REVENUE SHARING FORMULA means the relative percentage interest of
Baxter and Cerus as set forth in Section 7 hereof.

         REVENUE SHARING PAYMENTS has the meaning set forth in Section 7.1
hereof.

         S59 FFP means when used in reference to a Project, the Cooperative
Development Work to develop a System for inactivation of pathogens in human
fresh frozen plasma through use of the psoralen compound designated by Cerus as
S59 and, when used in reference to a System, Inactivation Package, Instrument,
or other item, the System, Inactivation Package, Instrument or other item,
developed or under development pursuant to such Cooperative Development Work.

         SPECIAL PREFERRED STOCK means that Preferred Stock issued by Cerus to
Baxter pursuant to that certain Series A Preferred Stock Purchase Agreement
dated as of the First Amendment Effective Date and that Preferred Stock, if any,
issued by Cerus to Baxter pursuant to Section 19 of this Agreement.

         STAND-ALONE OR STAND-ALONE, in reference to an Inactivation Package,
means an Inactivation Package that is not integrated with other collection or
storage items, and which may take the form, for example, of a bag and tube set
that may be sterile docked, a syringe or ampule.

         SYSTEM(S) means a pathogen inactivation system developed pursuant to
the Cooperative Development Work for use in the Field, incorporating one or more
Cerus Compounds, Baxter Compounds and/or New Technology Compounds in an
Inactivation Package, and the following, if any, designed for or adapted for use
with such compound(s): an Instrument, and associated computer software, and any
other disposables, delivery systems or other components.

         SYSTEM IMPROVEMENTS means those improvements of commercial Systems
approved by the Management Board. The Management Board shall approve and manage
a budget for all System Improvements (System Improvement Costs).

         SYSTEM SPECIFICATIONS means the performance, cost, quality and
reliability requirements as the Management Board agrees must be met by a System
in order for the System to be acceptable for marketing and distribution
hereunder.

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       10

<Page>

3.       COOPERATIVE DEVELOPMENT WORK.

         3.1 PERIOD; OBJECTIVE. From the Effective Date, Baxter and Cerus shall
work together to develop and obtain Regulatory Approval for (the "Cooperative
Development Work"), and thereafter market, Systems in the Field. As of the First
Amendment Effective Date, the approved Projects are the Red Cell Project and the
S59 FFP Project, each directed towards the development of Systems to be sold to
customers. The parties agree also to consider and negotiate in good faith the
terms (including, without limitation, funding, license and appropriate revenue
sharing) for the potential central processing and sale of human red blood cells
that have been subjected to pathogen inactivation using processes and compounds
in the Approved Project Field. The Management Board may from time-to-time
approve specific other Projects within the Field.

3.2      MANAGEMENT BOARD.

         (a) CONSTITUTION. Cerus and Baxter will appoint a five (5) person
Management Board consisting of two (2) senior executives designated by each
company and one (1) independent member chosen by mutual agreement of the
Parties. The purpose of the Management Board will be to facilitate the overall
relationship of the parties under this Agreement and to manage the research,
development and marketing of Projects within the Field. System Specifications
recommended by the Parties shall not be deemed finalized until they are approved
by the Management Board. The Management Board shall meet from time to time as
appropriate, but no less frequently than four (4) times during each calendar
year, alternating between the offices of the parties, unless the parties shall
agree otherwise. The Management Board shall review and approve budgets, resource
allocations, Projects undertaken within the Field, sales and marketing plans and
expenditures.

         (b) PROJECT COMMITTEES. The Management Board shall create a project
committee for each Project approved by the Management Board under this
Agreement. The purpose of a project committee will be to oversee the Project for
which such committee is responsible and to manage the day-to-day operational
aspects of the Cooperative Development Work relating to that Project. A project
committee shall have only that authority specifically granted to it by the
Management Board, which authority shall include, without limitation, the
following responsibilities with respect to such Project:

                  (i) prioritization of specific aspects of the Cooperative
Development Work;

                  (ii) allocation of financial, administrative, human and other
resources;

                  (iii) preparation of a proposed budget for consideration by
the Management Board at such times as requested by the Management Board (but not
less than annually); and

                  (iv) conducting bi-monthly reviews of the Cooperative
Development Work.

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       11

<Page>

Notwithstanding the foregoing, a project committee shall never have the
authority to disburse funds or reimburse expenses without the express prior
approval of the Management Board.

                  (c) PATENT COMMITTEE. The Management Board shall create a
Patent Committee to manage all patent matters relating to this Agreement. The
Patent Committee shall have only that authority specifically granted to it by
the Management Board, which authority shall include, without limitation, the
following responsibilities:

                           (i) prior review and approval of all patent

applications and prosecutions regardless of whether the application or
prosecution relates to a Baxter Patent, Cerus Patent or Joint Patent;

                           (ii) consulting with the Management Board with
respect to the periodic reviews of Project Patents pursuant to Section 9.5 of
this Agreement; and

                           (iii) conducting semi-annual reconciliations of the
expenses of preparing, filing, prosecuting and maintaining Project Patents and
Joint Patents pursuant to Section 9.6 of this Agreement.

                  (d) VOTING. All decisions of the Management Board (except
decisions as to S59 FFP) shall be made by majority vote or written consent, with
Baxter and Cerus each having one vote regardless of the number of
representatives attending any meeting. On all decisions as to S59 FFP, the Cerus
representatives shall cast the deciding vote, except as provided in the proviso
to the next succeeding sentence and in Section 5.8 with respect to System
Improvements for S59 FFP Systems. The independent member shall vote on all
deadlocks of the Management Board other than those relating to S59 FFP; PROVIDED
HOWEVER, the independent member shall not vote, and the Cerus representatives
shall not be entitled to cast the deciding vote, on matters pertaining to any
dispute concerning the parties' legal obligations to each other for disbursement
of funds or the reimbursement of expenses under any circumstances. In the event
of a deadlock that may be broken by the independent member, either Baxter or
Cerus may notify the other party and the independent member in writing of the
existence of such deadlock and provide to each the specific resolution that such
party proposes to be adopted by the Management Board. Each party will have
thirty (30) days from such notice to present its position to the independent
member, which shall include at least one meeting at which both parties and the
independent member are present. Either Baxter, Cerus or the independent member
may, by notice to the others, shorten such time period if such party believes
that urgent action is required on the matter at issue. The independent member
shall render his or her vote on such resolution as promptly as possible, and in
no event later than twenty (20) days after such time period. In the event of a
deadlock between the parties on a decision whether to discontinue Cooperative
Development Work on a Project or to reduce funding for a Project, the
independent member shall not break the deadlock and the Project will continue
without reduction of funding level, subject to the right of either party to
cease participation in such Project, as provided in Section 12 hereof. Any
compensation of the independent member shall be by mutual agreement of the
Parties and shall be subject to cost sharing. The independent member shall vote
on all matters in a manner that in the good faith judgment of the independent
member is in Baxter and Cerus' best interests as risk and revenue sharers under
this Agreement (I.E. in the same manner that a corporate director would vote in
the best interests of the shareholders of a corporation). Baxter and Cerus will
indemnify and hold harmless the independent member against any claim arising
from a decision

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       12

<Page>

made by the independent member, so long as such decision was made in good faith.
The independent member may be removed and/or replaced by mutual written consent
of Baxter and Cerus.

                  (e) DISPUTES.

                           (i) In the event that there is a deadlock on any
issue within the authority of the Management Board as to which the independent
member would be authorized to break the deadlock, and at that time there is not
an independent member (or for any reason the independent member does not break
such deadlock), either party may apply to the AAA to appoint an individual, in
accordance with the rules of the AAA who will act in the capacity of independent
member solely for the purpose of breaking such deadlock and resolving such
issue. Prior to making such application, a party will provide to the other party
ten (10) days' advance written notice of its intent to do so. During such ten
(10) day period, the parties will use their good faith best efforts to resolve
such issue in a meeting between the chief executive officer of Cerus and the
highest ranking officer of Baxter, Fenwal Division or comparable successor
division or entity, or failing such resolution, to agree upon appointment of an
independent member. Each party will in all cases cooperate in providing the
independent member such information as the independent member may request in
considering any matter.

                           (ii) With respect to any issue that is not within the
authority of the Management Board to resolve or with respect to which the
independent member is not authorized to break the deadlock, other than an issue
concerning S59 FFP on which the Cerus representatives are entitled to cast the
deciding vote, then the matter shall be finally settled by arbitration, to be
held in Chicago, Illinois, in accordance with the Commercial Arbitration Rules
of the American Arbitration Association ("AAA"). Any such dispute or controversy
shall be arbitrated before three arbitrators selected in accordance with the
rules of the AAA. The arbitrators' decision shall be final and binding upon the
parties. The parties shall be entitled to full discovery in any such
arbitration. Each party shall bear one half of the cost of such arbitration,
unless the arbitrators otherwise allocate such costs. During the period of any
arbitration, each party shall pay to the other party any amounts that are or
become due and owing to such other party, other than amounts being contested in
good faith in the arbitration.

         3.3 REVIEW OF BUDGET, BENCHMARKS; APPROVED PROJECTS. The benchmarks,
budget and timetable for all Projects, other than the S59 FFP Project, will
be reviewable by the Management Board from time-to-time during the
Cooperative Development Work with the intent that the parties move
expeditiously and effectively toward commercialization of any System. Cerus
will inform Baxter from time-to-time of the benchmarks, budget and timetable
for the S59 FFP Project. Baxter commits that for calendar years [...***...]
Baxter will expend on the Platelet Project and the Red Cell Project an
aggregate amount of [...***...] per calendar year, all of which will be
current expenditures for project tasks, except for those limited amounts to
be applied to the accounting category of amortization in each calendar year,
as set forth on the amortization schedule attached as Schedule I to this
Agreement. Unless the parties mutually agree otherwise, such expenditures
will be applied first to [...***...], and next to [...***...] allocated
between such Projects in such amounts as the Management Boards under the
Platelet Agreement and this Agreement shall determine. Such committed amount
will be increased in any calendar year only if, and to the extent, the
combined project budgets approved

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       13

<Page>

by the Management Boards under the Platelet Agreement and for the Red Cell
Project exceed such committed amount for such calendar year. If, for any
reason, such full amount cannot usefully be spent in pursuit of the
[...***...] any amounts not so spent ("Excess Funds") shall be applied to
fund New Technologies selected by the Management Board pursuant to Section
3.8 hereof. If the Management Board determines that any such Excess Funds
cannot usefully be spent on New Technologies selected by the Management Board
pursuant to Section 3.8 hereof, such Excess Funds shall be released from the
funding commitment of this paragraph.

                  (a) THE RED CELL PROJECT. The Initial Budget for one Project
approved, as of the Effective Date, by the Management Board is the Red Cell
Project, attached hereto as Schedule A-1. The approved budget for 1998 for the
Red Cell Project, as amended, is attached hereto as Schedule A-2. The parties
agree to establish a reasonable budget for subsequent periods for the Red Cell
Project, unless the Management Board determines to discontinue such Project.
Each party shall perform the respective tasks set forth on Schedules A-1 and
A-2, except as the Management Board shall otherwise determine.

                           (i) All funding of the Red Cell Project was provided
by Cerus, until Regulatory Approval to commence Phase III clinical trials in the
United States or Europe under the Platelet Agreement (the "Platelet Milestone").
Baxter commenced participation as of January 1, 1997, and Baxter shall continue
to participate, in the Red Cell Project in accordance with this Agreement,
including without limitation, the obligation to share fifty percent (50%) of the
costs and expenses of the Cooperative Development Work incurred on or after
January 1, 1997, and to market and sell the Systems for Red Cells developed
under this Agreement; PROVIDED THAT Baxter's obligation to bear fifty percent
(50%) of the costs and expenses for 1998 is subject to Section 3.3(a)(iii)
hereof. Subsequent to the date of achievement of the Platelet Milestone, Baxter
paid to Cerus, subject to final reconciliation, fifty percent (50%) of the
amount expended by Cerus under the Project budget from January 1, 1997 through
December 31, 1997. Baxter shall pay to Cerus on July 1, 1998, and on each
January 1 and July 1 thereafter, the amount by which Cerus' budgeted
expenditures under the then current Project budget for the then current calendar
year (including amounts budgeted to be expended by Cerus on outside expenses)
exceeds fifty percent (50%) of the budgeted expenditures for such period;
PROVIDED THAT for 1998 such payment obligations will be subject to Section
3.3(a)(iii) hereof. Such excess budgeted expenditures to be paid to Cerus for
any calendar year will be divided between the January 1 payment and the July 1
payment in amounts that approximate the expected excess expenditure levels over
the course of such year, as the parties may agree. Failing such agreement, 50%
of such excess budgeted amount shall be paid on January 1, and 50% shall be paid
on July 1.

                           (ii) The parties acknowledge that the Platelet
Milestone was achieved on September 30, 1997.

                           (iii) Notwithstanding the foregoing provisions of
this Section 3.3.(a), to the extent the approved budget for 1998 for the Red
Cell Project exceeds Eight Million Three Hundred Thousand Dollars ($8,300,000),
Cerus will fund all expenses for the Red Cell Project in 1998 in excess of such
amount, up to the amount of the approved budget ("Cerus 1998 Excess
Expenditures"). To compensate for the Cerus 1998 Excess Expenditures, Baxter
will fully fund the first expenditures under the approved budget for the Red
Cell Project for 1999 in an amount

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       14

<Page>

equal to the Cerus 1998 Excess Expenditures (such amounts being included in
Baxter's funding commitment pursuant to Section 3.3 hereof), after which the
parties shall equally share the expenses of the Red Cell Project. If there is
for any reason not an approved budget for the Red Cell Project for 1999, Baxter
will fully fund the first expenditures for 1999 under the approved budget for
such other Cerus-Baxter program or programs as Cerus shall designate in an
amount equal to the Cerus 1998 Excess Expenditures. If by July 1, 1999, however,
there is not an approved budget for such other Cerus-Baxter program or programs
that is at least equal to such Excess Expenditures, Baxter will promptly pay to
Cerus one-half of the amount by which the Excess Expenditures exceed the amount
of expenditures to be funded by Baxter under the preceding sentence.

                  (b) THE S59 FFP PROJECT. The Initial Budget for one Project
approved, as of the Effective Date, by the Management Board is the S59 FFP
Project, attached hereto as Schedule B.

                           (i) All funding of the S59 FFP Project was provided
by Cerus, until achievement of the Platelet Milestone. Baxter commenced
participation as of January 1, 1997, and Baxter shall continue to participate in
the S59 FFP Project in accordance with this Agreement, including without
limitation, the obligation to share fifty percent (50%) of the costs and
expenses of the Cooperative Development Work incurred on or after January 1,
1997 and through December 31, 1997, and to market and sell the S59 FFP Systems
developed under this Agreement. Following December 31, 1997, Baxter's obligation
to share costs shall be fixed at One Million Two Hundred Thousand Dollars
($1,200,000), Six Hundred Thousand Dollars ($600,000) of which will be paid on
January 10, 1999 and Six Hundred Thousand Dollars ($600,000) of which will be
paid on January 10, 2000. Except as set forth in the preceding sentence, Cerus
will bear all expenses of the Cooperative Development Work for the S59 FFP
Project after December 31, 1997. Subsequent to the date of achievement of the
Platelet Milestone, Baxter paid to Cerus (subject to final reconciliation) fifty
percent (50%) of the amount expended by Cerus under the Project budget from
January 1, 1997 through December 31, 1997.

                           (ii) The parties acknowledge that the Platelet
Milestone was achieved on September 30, 1997.

                           (iii) Baxter will supply such support of its
technical personnel as Cerus shall reasonably request from time to time for
development of the S59 FFP System. Cerus shall reimburse Baxter the cost of
providing such support, accounted for on average cost per full time equivalent
basis consistent with Section 3.5(a) hereof; PROVIDED THAT Cerus will be
entitled to a credit against any such costs for expenses incurred by Cerus in
support of the methylene blue project, accounted for in the same manner. Such
expenses will be paid at the time of semi-annual reconciliation pursuant to
Section 3.7(b).

                  (c) OTHER PROJECTS. The budget for any other project the
parties agree to cooperate on (other than the Red Cell Project and the S59 FFP
Project) shall be approved by the Management Board. Upon the approval of the
Initial Budget for each such project and upon each anniversary of the date
thereof, Baxter shall pay to Cerus, or Cerus shall pay to Baxter, the amount by
which such party's budgeted expenditures under the then current budget for the

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       15

<Page>

succeeding twelve-month period (including amounts budgeted to be expended by
such party on outside expenses) exceeds 50% of the total then budgeted
expenditures for such period.

         3.4 EXCHANGE OF INFORMATION. During the term of the Cooperative
Development Work, the parties shall exchange all material information developed
pursuant to the Cooperative Development Work including the exchange of Baxter
Know-How and information concerning Baxter Patents and Cerus Know-How and
information concerning Cerus Patents relating to the Field. The exchange shall
occur pursuant to Section 11. The Systems shall embody and use such Cerus
Patents and Cerus Know-How and Baxter Patents and Baxter Know-How as shall be
determined by the Management Board.

         3.5 COST SHARING. Except as otherwise provided in this Agreement,
commencing January 1, 1997, Baxter will fund fifty percent (50%) and Cerus will
fund fifty percent (50%) of the Cooperative Development Work with respect to
each Project; PROVIDED THAT Baxter's obligation to fund Cooperative Development
Work for the S59 FFP Project shall be limited as provided in Section 3.3(b)(i).
Funding shall include all costs and expenses incurred in connection with the
Cooperative Development Work. Cost and expenses shall include only those
expenditures made in accordance with Project budgets approved by the Management
Board related to research, development, clinical trials, Regulatory Approval and
other expenses that this Agreement expressly provides shall be subject to cost
sharing; PROVIDED HOWEVER that Management Board approval shall not be required
for S59 FFP Project budgets, except with respect to System Improvements under
Section 5.8. In the event that the funding for the Cooperative Development Work
for any Project, other than the S59 FFP Project, is not shared equally
commencing January 1, 1997, then (except as otherwise provided in Section 12 or
Section 16 hereof) the Revenue Sharing Formula in Section 7.1 for such Project
shall be adjusted such that the percentage of Premium received by a party will
equal the percentage contributed by such party to the sum of (a) the cash
contributed to the Final Project Total Budget commencing January 1, 1997, PLUS
(b) Noncash Contribution to the Project. Capital expenditures for facilities
and/or equipment and capitalized manufacturing start-up costs will not be
included in costs and expenses shared.

                  (a) Each party shall maintain detailed records which
accurately identify costs and expenses incurred and paid in connection with the
Cooperative Development Work for each specific Project. Except as to expenses
incurred by Cerus after June 30, 1998 on the S59 FFP Project, each party shall
submit this information to the Management Board on the on the last business day
of February for the period ending December 31, and on the last business day of
August for the period ending June 30 (or such alternative dates as the
Management Board may establish) along with an estimate of expenses to be
incurred during the current six months. Expenses internally generated because
tasks are performed by a party's own staff will be accounted for on a uniform
average cost per full time equivalent basis.

                  (b) All costs with respect to participation on the Management
Board during the Cooperative Development Work, including travel expenses for
meetings and participation on the Management Board, shall be subject to cost
sharing.

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       16

<Page>

         3.6       TESTING AND REGULATORY EXPENSES.

                  (a) TESTING EXPENSES. All expenses incurred in connection with
any testing whose primary function is marketing of the System, rather than
developing the System or obtaining Regulatory Approval of the System, shall be
borne solely by Baxter and shall not be considered expenses subject to cost
sharing, unless the Management Board determines that such expenses should be
considered part of the Cooperative Development Work.

                  (b) REGULATORY EXPENSES. The Management Board shall determine
the countries in which Regulatory Approval will be sought and the timing of
seeking such Regulatory Approval. All expenses incurred to obtain Regulatory
Approval are expenses subject to cost sharing under Section 3.5 and shall be
part of the Final Project Total Budget, it being understood that Baxter's
obligation to share expenses for the S59 FFP Project shall be limited as
provided in Section 3.3(b)(i); PROVIDED, HOWEVER, that either party may, by
notice given to the other party within thirty (30) days after such Management
Board decision with respect to a particular country, elect to not share in the
costs of Regulatory Approval in not more than five (5) countries outside of
North America and Europe, which will result in an adjustment for each such
country of Final Project Total Budget (as further provided in the definition of
"Final Project Total Budget").

         3.7      BUDGET CONTINGENCIES.

                  (a) EXCEEDING INITIAL BUDGET. If the Management Board
establishes a budget for a new Project, or determines that the budget for an
approved Project within the Field must be increased over the previously
established budget for the Project, then Baxter will fund fifty percent (50%)
and Cerus will fund fifty percent (50%) of the new Project budget or of any
increase in the previously approved budget, excluding any budget for the S59 FFP
Project after June 30, 1998, which shall be funded solely by Cerus. In the event
of any new Project budget or budget increase (excluding for the S59 FFP
Project), however, either party may, by written notice to the other party, elect
to fund less than its full share (50%) of such new Project budget or budget
increase. In such an event, the funding party may, by written notice to the
non-funding party, elect to assume responsibility for the funding of such
unfunded amount, in which event (except as otherwise provided in Section 12 and
Section 16 hereof) the Revenue Sharing Formula in Section 7.1 for such Project
will be adjusted such that the percentage of Premium to be received by a party
will equal the percentage contributed by such party to the sum of (i) the cash
contributed to Final Project Total Budget commencing January 1, 1997 (excluding
1996 carryovers as described in Section 3.5), PLUS (ii) total Noncash
Contribution to the Project.

                  (b) RECONCILIATION OF EXPENDITURES. Unless otherwise agreed,
the Management Board shall reconcile actual cash outlays and expenses approved
by the Management Board with respect to a Project on a semi-annual basis such
that costs have been incurred in the proportion of fifty percent (50%) by Baxter
and fifty (50%) by Cerus (subject to adjustments pursuant to Section 3.3(a)(iii)
hereof and except as provided in Section 3.3(b)(i) hereof with respect S59 FFP),
or such other ratio as is established pursuant to Section 3.7(a). If they are
not in such proportion, Cerus will make a cash payment to Baxter, or Baxter will
make a cash payment to Cerus, in order to achieve such proportion. The payment
shall be made in cash within thirty (30) days following the determination by the
Management Board based upon the reports made pursuant to Section 3.5(a) of this
Agreement.

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       17

<Page>

         3.8      NEW TECHNOLOGIES.

                  (a) In the event either party learns of a possibility to
acquire ownership of, or obtain a license or option to, a technology
(including without limitation any method, Know-How, Invention or composition
of matter)

                           (i) that might enable or improve a System being
developed under the Agreement, or

                           (ii) that might form the basis for a new System that
might be developed under this Agreement in the Field,

(a "New Technology") such party will notify the other party of such
possibility, and the Management Board will consider whether to pursue the
acquisition of rights to such New Technology. If the Management Board
determines to pursue the acquisition of rights to such New Technology in the
Field, each party will have the right to become a joint owner of any New
Technology acquired, or joint licensee of any New Technology so licensed,
subject to such party sharing 50% (unless the parties agree in writing to
another percentage) of the cost of acquiring ownership of, or obtaining a
license to, such technology. Notwithstanding the foregoing, if the Management
Board determines to pursue a New Technology that has use outside the Field,
as well as within the Field, the party who identified such opportunity shall,
unless the parties agree otherwise, have exclusive rights to practice such
New Technology outside the Field, and the other party will be required to
share 50% (unless the parties agree in writing to another percentage) of only
that portion of the cost of acquiring ownership of, or obtaining a license
to, such New Technology that is allocable to its value for use within the
Field. Such allocable value shall be determined by mutual agreement, or
failing such agreement, by arbitration pursuant to Section 3.2(d)(i) hereof.
Any New Technology to which rights are jointly acquired by the parties may be
exploited by either party within the Field solely under, and in accordance
with, the terms (including, without limitation, sharing of development
expenses and revenues) of this Agreement, unless the parties otherwise
expressly agree in writing to other terms.

                  (b) If the Management Board determines not to pursue the
acquisition of rights in a New Technology, due to the negative vote of the
representatives of one party, the other party (if the representatives of such
party voted in favor of acquiring rights to the New Technology), at its sole
expense, may acquire ownership of, or obtain a license to, such New Technology
and may exploit such New Technology within or outside the Field free of any
obligations under this Agreement, other than the obligation to pay a reasonable
royalty on the practice of a Joint Invention, as provided in Section 8.6(b)
hereof. Notwithstanding the foregoing, the right of exploitation by one party
shall not be construed to grant any license to any patents or other proprietary
rights of the other party, and the only licenses hereunder that may be practiced
for such purpose are the licenses set forth in Section 8.6.

                  (c) In addition to the provisions concerning New Technologies
set forth in Sections 3.8(a) and 3.8(b) above, in the event either party
proposes to pursue development or marketing of any product within the Field,
such party will present such proposal to the Management Board, together with a
reasonably detailed business plan and a proposed budget for such project. If the
Management Board determines to pursue such project, such project shall become a
Project under the Cooperative Development Work pursuant to Section 3.3(d) of
this

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       18

<Page>

Agreement. If the Management Board determines not to pursue such project, due to
the negative vote of the representatives of one party, the other party (if the
representatives of such party voted in favor of the proposal) may pursue such
project free of any obligations under this Agreement. Notwithstanding the
foregoing, the right to pursue such project by one party shall not be construed
to grant any license to any patents or other proprietary rights of the other
party, and the only licenses hereunder that may be practiced for such purpose
are the licenses set forth in Section 8.6.

                  (d) Without limiting the foregoing, or any other provisions of
this Agreement, each party agrees that in the Approved Project Field, except as
otherwise provided in Sections 3.8(b) and 3.8(c), it will make available
exclusively for the Cooperative Development Work and for embodiment in Systems
(without any consideration other than as provided in this Agreement) any
technology (including without limitation, any method, Know-How or composition of
matter) useful within the Approved Project Field owned or controlled by such
party as of the First Amendment Effective Date or of any time thereafter, and
each party will use reasonable efforts to inform the other party of any such
technology that may reasonably appear useful within the Field. This Section
3.8(d) is not intended to limit or restrict any use or commercialization of any
such technology outside the Approved Project Field.

                  (e) Each party agrees not to unreasonably delay any vote on a
proposal pursuant to Section 3.8(a) or 3.8(c), nor to withhold or delay approval
of a reasonable budget to pursue any such proposal that is approved by the
Management Board, and each party will provide committed funding for expenditures
in accordance with such budget commencing, unless the parties otherwise agree,
not later than the calendar year following the year in which such proposal is
approved by the Management Board.

         3.9 COORDINATION AND FACILITATION OF COMMUNICATIONS. In order to
promote optimum coordination and facilitation of communications, Cerus and
Baxter agree to the placement of a Cerus employee (the "Cerus Employee") at
Baxter's facility where the Projects are managed, on a full-time basis, or such
lesser amount of time as Cerus makes such person available. Baxter shall provide
suitable office space for the Cerus Employee. Baxter shall inform the Cerus
Employee of meetings (including teleconferenced meetings) relating to the
Cooperative Development Work under this Agreement and the Platelet Agreement
(together with any evaluation or development work relating to New Technologies,
other than any New Technologies that the Management Board elects not to pursue,
the "Pathogen Inactivation Programs") and shall permit the Cerus Employee to
attend such meetings and otherwise to participate on a day-to-day basis in all
issues concerning the Pathogen Inactivation Programs; PROVIDED, HOWEVER, that
the Cerus Employee shall not be permitted to attend meetings of Baxter's board
of directors or senior management team or meetings that are subject to Baxter
attorney-client privilege. The parties do not intend for the Cerus Employee to
have access to any Baxter proprietary information (other than information
relating to the Pathogen Inactivation Programs), and the Cerus Employee shall be
required to sign a Non-Employee Security Agreement in the form of Exhibit J
attached to this Agreement at or prior to the time such person arrives at
Baxter's facility. Cerus shall exercise complete and exclusive control over the
Cerus Employee's conduct and performance and will pay and/or withhold all wages,
employee benefits, worker's compensation insurance and all applicable federal,
state and local taxes arising out of such employment. Cerus shall ensure that,
while present on Baxter's property, the Cerus

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       19

<Page>

Employee shall conform to all Baxter rules and regulations regarding the conduct
of visitors. Cerus shall, at its sole expense, maintain insurance policies
customary with those maintained for Cerus' other employees, which policies shall
cover Cerus and the Cerus Employee under this Agreement, throughout the term of
this Agreement. Any family relocation and lodging expenses incurred by Cerus for
the Cerus Employee will not be subject to cost sharing hereunder.

4.       EQUITY PURCHASE.

         4.1 BAXTER PURCHASE OF EQUITY IN CERUS. Baxter shall purchase equity in
Cerus according to the following terms and schedule:

                  (a) Either purchase five million dollars ($5,000,000.00 U.S.)
of Cerus equity upon the occurrence of both:

                           (i) with respect to the Platelet Project, the receipt
of both (a) in the United States, F.D.A. approval to commence Phase III trials
and (b) in Europe, approval from a governmental authority to commence Phase III
trials (Buffy coats), and

                           (ii) the filing of an Investigational New Drug
application ("IND") or Investigational Device Exemption ("IDE") or equivalent
with the F.D.A. to begin a Phase I study under the Red Cell Project, or
comparable filing in Europe under such Project (the "Tranche 3 Milestone")

or, at Cerus' election, purchase two million dollars ($2,000,000 U.S.) of Cerus
equity upon the receipt of both (i) in the United States, F.D.A. approval to
commence Phase III trials under the Platelet Project and (ii) in Europe,
approval from a governmental authority to commence Phase III trials (Buffy
coats) under the Platelet Project (the "Tranche 3a Milestone") and purchase
three million dollars ($3,000,000 U.S.) upon the approval of an IND or IDE or
equivalent by the F.D.A. or CE Mark or equivalent approval in Europe under the
Red Cell Project (the "Tranche 3b Milestone") consisting of Common Stock at a
purchase price equal to open market price plus twenty percent (20%) if Cerus is
publicly traded at the time of such purchase or, if then privately held,
Preferred Stock at the lesser of (i) twenty-five dollars and ten cents ($25.10
U.S.) per share or (ii) fifty percent (50%) premium over last private
third-party financing round PROVIDED THAT this clause (ii) shall apply only if
there has been a third-party private financing round of at least five million
dollars ($5,000,000) since the date of the last equity purchase by Baxter
pursuant to this Section 4.1. Such purchase will be consummated and the purchase
price paid not later than within fifteen (15) days after such Tranche 3
Milestone, Tranche 3a Milestone or Tranche 3b Milestone, as the case may be. The
purchase price stated in clause (i) above, however, shall be increased from
$25.10 to twenty-seven dollars ($27.00 U.S.) if both the Tranche 3a Milestone
and Tranche 3b Milestone are achieved by January 31, 1998. If a closing under
this Section 4.1 has previously occurred at the $25.10 price, the price per
share shall be retroactively increased to $27.00, and Baxter shall promptly make
an additional payment to Cerus to yield an effective price of $27.00 per share
on such purchase. For the purposes of this Section, the "Platelet Interim
Determination" means the point in the clinical trials under the Platelet
Agreement set forth on Schedule C to this Agreement. As used in this Section
4.1, "open market" means the average closing price of the Cerus stock, as
reported in the Wall Street Journal, for the thirty (30) trading days prior to
and including the trading day that is two (2) trading days prior to the date

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       20
<Page>

the purchase is consummated. A "trading day" is a day when the Cerus stock may
be traded on the relevant exchange or over the counter.

                  (b) The purchase prices set forth above in Subsection (a),
excluding prices set by open market price, will be appropriately adjusted for
stock splits, stock dividends and the like.

                  (c) The purchases of equity set forth above will be made in
accordance with an agreement substantially in the form of the Stock Purchase
Agreement in the form of Schedule G to this Agreement, with appropriate changes
to reflect share price, class and series of stock being purchased and to make
accurate representations and warranties as of the date of the subsequent equity
purchases; such changes shall not affect the equity purchase and sale
obligations hereunder. While it is anticipated that the parties will separately
execute and deliver such Stock Purchase Agreements and associated documents for
subsequent equity purchases, the obligation to purchase and sell equity as set
forth in this Section are enforceable obligations upon the signing of this
Agreement irrespective of whether there is a separate execution and delivery of
such Stock Purchase Agreements and associated documents. It is understood that
from and after the date of Cerus' initial public offering or other conversion of
Cerus' outstanding Preferred Stock to Common Stock, the shares purchased
hereunder will be shares of Cerus Common Stock. Prior to such time, the shares
purchased hereunder will be shares of Cerus Preferred Stock. Cerus will use
reasonable efforts to provide Baxter fifteen (15) days prior notice of the
expected date of achievement of milestones under Subsection (a).

                  (d) Notwithstanding Subsection (a) above, in the event that
any purchase of equity pursuant to such subsection would cause Baxter to own in
excess of twenty and one-tenth percent (20.1%) of issued and outstanding voting
capital stock of Cerus, Cerus may limit such purchase of equity by Baxter to a
number of shares of voting capital stock that would cause Baxter to own not more
than twenty and one-tenth percent (20.1%) of such issued and outstanding voting
capital stock. Notwithstanding Subsection (a) above, in the event that Baxter at
any time owns in excess of twenty and one-tenth (20.1%) of the issued and
outstanding voting capital stock of Cerus, Cerus may limit Baxter's further
purchases of voting capital stock pursuant to such subsection. Nothing in this
clause (d) will limit or restrict Baxter's right to convert the Special
Preferred Stock in accordance with its terms.

                  (e) Notwithstanding Subsection (a) above, in the event that
any purchase pursuant to such subsection would cause Baxter to own in excess of
nineteen and nine-tenths percent (19.9%) of issued and outstanding voting
capital stock of Cerus, Baxter may limit such purchase of equity to a number of
shares of capital stock that would cause Baxter to own not more than nineteen
and nine-tenths percent (19.9%) of the issued and outstanding voting capital
stock of Cerus; PROVIDED THAT in each such instance, upon the written request of
Cerus, Baxter shall pay to Cerus as a research and development payment an amount
equal to the difference between five million dollars ($5,000,000 U.S.) and the
dollar amount of capital stock being purchased. Such research and development
payment will be made to Cerus on the date for consummation of purchase of such
capital stock. Unless Cerus notifies Baxter, as set forth below, that Cerus
elects to repay to Baxter the amount of such research and development payment,
such research and development payment will be treated as if Baxter had made an
additional contribution of cash to the Final Project Total Budget for the
purposes of the fourth sentence of Section 3.5 (allocated among then ongoing
Projects (except for the S59 FFP Project)

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       21

<Page>

in proportion to the size of the then approved budget for each Project). (Such
research and development payment shall not, however, change the actual approved
budget for any Project nor Cerus' contribution thereto.) Cerus must notify
Baxter in writing at the time of such research and development payment whether
or not Cerus elects to repay to Baxter the amount of such research and
development payment. If Cerus notifies Baxter that Cerus elects to repay such
amount, Cerus will, if such amount is not earlier repaid, pay to Baxter fifty
percent (50%) of the Revenue Sharing Payments received by Cerus hereunder, until
such amount is repaid. In the event that Baxter makes any such research and
development payment to Cerus pursuant to this subsection (e), Cerus will grant
to Baxter a warrant to purchase capital stock of Cerus on the following terms:
(i) the exercise price will be the price per share to Baxter established under
Subsection (a) above (I.E., the subsection applicable to the then current Baxter
equity purchase); (ii) the term of the warrant shall extend until two (2) years
following Market Launch (as defined in the Platelet Agreement) in the U.S. or
Europe of the first product developed under the Platelet Agreement, but not to
exceed seven (7) years from the date such research and development payment was
made, subject to earlier termination in the event of merger or acquisition of
Cerus; and (iii) the number of shares subject to the warrant shall be equal to
ten percent (10%) times the amount of such research and development payment
divided by such exercise price. The number of shares subject to the warrant will
be appropriately adjusted from time to time for stock splits, stock dividends
and the like. Repayment of the amount of the research and development payment
will not terminate the warrant.

         4.2 STANDSTILL BY BAXTER. Baxter agrees that it will not at any time,
nor will it permit any of its Affiliates to, without the prior written consent
of Cerus:

                  (a)

                           (i) acquire, directly or indirectly, by purchase or
otherwise, of record or beneficially, other than by the transactions set forth
in Section 4.1 of this Agreement or conversion of the Special Preferred Stock,
any securities of Cerus or rights or options to acquire any securities from any
holder of such securities if after such acquisition (and giving effect to the
exercise of any such rights or options) Baxter and its Affiliates would own
capital stock of Cerus having twenty and one-tenth percent (20.1%) or more of
the voting power of the outstanding capital stock of Cerus; PROVIDED, HOWEVER,
that subsequent reductions in the number of shares of outstanding voting capital
stock of Cerus (or rights or options therefor) shall not be deemed to have
caused a violation of this Section 4.2(a).

                           (ii) To the extent Baxter and/or its Affiliates owns,
beneficially or of record, securities of Cerus constituting twenty and one-tenth
percent (20.1%) or more of the voting power of the outstanding capital stock of
Cerus and such securities include securities of Cerus other than those purchased
pursuant to Section 4.1, Baxter and/or its Affiliates shall be deemed to own
"Prohibited Securities." By way of example, to the extent that exercise of the
conversion rights of the Special Preferred Stock might cause Baxter to own
twenty and one tenth percent (20.1%) or more of the voting power of the
outstanding capital stock of Cerus, the shares received on exercise of such
conversion rights would be "Prohibited Securities" to the extent of such excess.
Baxter agrees that neither it nor any of its Affiliates shall (and neither it
nor any of its Affiliates shall be entitled to) vote any Prohibited Securities
with respect to any matter subject to the vote or written consent of Cerus'
stockholders (PROVIDED, HOWEVER, that the foregoing shall

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       22

<Page>

not be deemed to limit Cerus' remedies in the event that the Prohibited
Securities were acquired in violation of this Section);

                           (iii) Baxter hereby covenants and agrees that it will
provide written notice to Cerus of any purchase, sale or other acquisition or
disposition, on the open market or in private transactions, by Baxter or any of
its Affiliates of any securities of Cerus (or if Baxter or such Affiliates shall
direct any third party to take any such actions on behalf of Baxter or such
Affiliates). Such notice shall be transmitted to Cerus by facsimile (with
telephonic notice) within three (3) business days after any such transaction on
the open market or within ten (10) business days after any such private
transaction, and shall specify the person or entity effecting the transaction,
the date of such transaction, the number of securities and the price per
security with respect to such transaction;

                  (b) solicit proxies with respect to any securities of Cerus
under any circumstances for change in the directors or management of Cerus or
relating to merger or acquisition of the Company or deposit any securities of
Cerus in a voting trust or subject them to a voting agreement or other agreement
of similar effect (other than subjecting shares owned by Baxter to a revocable
proxy);

                  (c) initiate, propose or otherwise solicit any stockholder for
the approval of one or more stockholder proposals at any time, or induce or
attempt to induce any other person to initiate any stockholder proposal for
change in the directors or management of Cerus or relating to merger or
acquisition of the Company; or

                  (d) take any action individually or jointly with any
partnership, limited partnership, syndicate, or other group or assist any other
person, corporation, entity or group in taking any action it could not take
individually under the terms of this Section 4.2.

         The preceding provisions of this Section 4.2 shall terminate in the
event (i) any Person (defined below) or 13D Group (defined below) other than an
Affiliate of Baxter) shall have commenced a tender offer for a majority of the
outstanding shares of Common Stock (including any other outstanding voting
securities) of Cerus or (ii) Cerus' Board of Directors (the "Board") shall
determine to (A) approve any transaction set forth in clause (i) immediately
preceding, (B) liquidate Cerus or sell all or substantially all of the assets of
Cerus to another person, (C) approve a merger or consolidation of Cerus with any
other person that would result in the voting securities of Cerus outstanding
immediately prior thereto continuing to represent less than a majority of the
combined voting power of the voting securities of Cerus or such surviving entity
outstanding immediately after such merger or consolidation or (D) sell to any
person a majority of Cerus' outstanding voting securities. In the event of any
determination by the Board pursuant to the immediately preceding clause (ii),
Cerus shall notify Baxter at least 15 days prior to the final approval of such
transaction, and any such Board determination shall be conditioned upon the
notification by Cerus of Baxter in compliance with this sentence. For purposes
of this Section 4.2, a "13D Group" means any group formed for the purpose of
acquiring, holding, voting or disposing of securities of Cerus that would be
required under the Securities Exchange Act of 1934, as amended (the "Exchange
Act"), and the rules and regulations promulgated thereunder, to file a statement
on Schedule 13D with the (United States Securities Exchange Commission) as a
"Person" within the meaning of Section 13(d)(3) of the Exchange Act if such
group beneficially owned sufficient securities to require such a filing. All of
the provisions of

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       23

<Page>

this Section 4.2 shall be reinstated and shall apply in full force according to
their terms in the event that: (x) if the preceding provisions of this Section
4.2 shall have terminated as a result of a tender offer, such tender offer (as
originally made or as extended or modified) shall have terminated (without
closing) prior to the commencement of a tender offer by Baxter or any of its
Affiliates that would have been permitted to be made pursuant to the preceding
provisions of this paragraph as a result of such third-party tender offer, (y)
any tender offer by Baxter or any of its Affiliates (as originally made or as
extended or modified) that was permitted to be made pursuant to the preceding
provisions of this paragraph shall have terminated (without closing), or (z) if
the preceding provisions of this Section 4.2 shall have terminated as a result
of a Board determination referred to in the preceding clause (ii), the Board
shall have determined not to take any of such actions (and no such transaction
considered by the Board shall have closed) prior to the commencement of a tender
offer by Baxter or any of its Affiliates that would have been permitted to be
made pursuant to the preceding provisions of this paragraph as a result of the
initial Board determination referred to in the preceding clause (ii), unless
prior to such Board determination not to take any of such actions, any of the
events described in the preceding clause (i) shall have occurred. Upon
reinstatement of the provisions of this Section 4.2, the preceding provisions of
this paragraph shall continue to govern (including, without limitation, those
that provide for the termination of the preceding provisions of this Section
4.2) in the event that any of the events described in the preceding clauses (i)
or (ii) shall occur. Upon the closing of any tender offer for, or acquisition by
Baxter or its Affiliates of, any securities of Cerus or rights or options to
acquire any such securities that would have been prohibited by the preceding
provisions of this Section 4.2 but for the provisions of this paragraph, all
provisions of this Section 4.2 shall terminate.

5.       SUPPLY OF CERUS COMPOUND AND SYSTEM MANUFACTURING.

         5.1 CERUS RESPONSIBILITIES. Cerus shall at all times use commercially
reasonable efforts to supply, or have supplied, Baxter's demand for the Cerus
Compounds and New Technology Compounds that the Management Board determines are
to be supplied by Cerus, used in each System, and S59 removal devices for S59
FFP Systems. The Parties shall agree in good faith upon a forecasting, order,
supply and delivery mechanism for the Cerus Compounds, such New Technology
Compounds and S59 removal devices for S59 FFP Systems. All Cerus Compounds, New
Technology Compounds and S59 removal devices for S59 FFP Systems supplied by
Cerus shall comply with the requirements for such compounds and components
established pursuant to Section 5.5 of this Agreement.

         5.2 BAXTER RESPONSIBILITIES. Baxter shall be responsible for all
aspects relating to scale-up, production, marketing and distribution of each
System, but not including manufacturing of the Cerus Compounds, New Technology
Compounds that the Management Board determines are to be provided by Cerus or
S59 Removal Devices for S59 FFP Systems. Such products shall meet the
requirements for Systems as finally approved in writing by the Management Board.
Any change in requirements must be approved in writing by the Management Board.
Such requirements shall include a provision that such products be made according
to Good Manufacturing Practices in a facility licensed by the FDA (or if Baxter
shall elect to manufacture outside the United States) other applicable
regulatory authority.

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       24

<Page>

         5.3 INSTRUMENT PRODUCTION. Baxter shall tool and scale up the
production model of any Instrument needed for each System. Baxter shall be
responsible for production and manufacture of the Instrument and associated
software of each System.

         5.4 SYSTEM SPECIFICATIONS. Baxter's manufacture of each System shall be
in accordance with Systems Specifications as finally approved in writing by the
Management Board. Any change in Systems Specifications must be approved in
writing by the Management Board.

         5.5 CERUS SPECIFICATIONS. Cerus shall supply Cerus Compounds, and those
New Technology Compounds that the Management Board shall determine are to be
supplied by Cerus, in Bulk Form to Baxter to be used as a component of a System
and Baxter shall obtain Cerus Compounds and such New Technology Compounds to
meet its requirements of inactivation compounds (other than Baxter Compounds and
those New Technology Compounds that the Management Board determines are to be
provided by Baxter) for use within the Field. Such Cerus Compounds and New
Technology Compounds shall meet the specifications for Cerus Compounds and New
Technology Compounds as finally approved in writing by the Management Board. Any
change in specifications for such Cerus Compounds or New Technology Compounds
must be approved in writing by the Management Board. Such specifications shall
include a provision that Cerus Compounds, and New Technology Compounds that the
Management Board determines shall be supplied by Cerus, be made according to
Good Manufacturing Practices in a facility licensed by the FDA or (if Cerus
shall elect to manufacture such compounds outside the United States) other
applicable regulatory authority.

         5.6 SOURCE OF SUPPLY. In the event Baxter recommends that Cerus change
Cerus' source of raw materials or Cerus Compound because of actual or
anticipated irregularity of supply, or failure to meet specifications and a
viable alternative source of supply is available, Cerus will support Baxter in
Cerus' obtaining such alternate source to the extent commercially reasonable.

         5.7 FAILURE OF CERUS TO MEET BAXTER REQUIREMENTS. To the extent that
Cerus cannot meet Baxter's requirements for Cerus Compounds, Baxter shall be
free to obtain Cerus Compounds from a third party. Cerus agrees to provide the
third party that Baxter selects with the necessary information and Cerus
Know-How to allow the third party to make the Cerus Compounds.

         5.8 SYSTEM IMPROVEMENTS. During the term of this Agreement, as
approved by the Management Board, the Parties will cooperate in making
improvements to each System to meet changing market needs, to yield
manufacturing cost reductions or make quality improvements. The costs for
such System Improvements of Inactivation Packages shall be budgeted by the
Management Board and subject to cost sharing pursuant to Section 3.5 and
shall be added to the Final Project Total Budget. Notwithstanding the
foregoing, Cerus will be responsible for [...***...] and Baxter will be
responsible for [...***...] of the cost of System Improvements for the S59
FFP Systems, such obligation, however, being subject to mutual agreement to
undertake such System Improvement.

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       25

<Page>

6.       MARKETING AND DISTRIBUTION RIGHTS:  EXCLUSIVE DISTRIBUTION RIGHTS.

         6.1 COMMERCIALIZATION. Baxter shall use commercially reasonable efforts
to market and sell Systems developed under this Agreement in those countries of
the world in which the Management Board determines that such Systems should be
marketed and sold. The parties agree that it is desirable to obtain a
distribution partner in Japan for S59 FFP Systems and agree to cooperate to
obtain such distribution partner. A distribution partner for S59 FFP Systems in
Japan obtained through such cooperative efforts is referred to herein as a JOINT
JAPAN FFP DISTRIBUTION PARTNER. In the event that any agreement is arranged with
a Joint Japan FFP Distribution Partner, or otherwise with a distribution partner
in Japan, Cerus will have the right to retain any up-front or milestone payments
paid by such party for distribution rights for S59 FFP Systems. In the event
that a Joint Japan FFP Distribution Partner is not obtained through such
cooperation on or before [ *** ], Cerus shall have the right to terminate
any sales or distribution rights of Baxter with respect to S59 FFP Systems in
Japan, and may take unilateral action to obtain a distributor for that product
in Japan, and such distribution will be considered distribution by Cerus
pursuant to Section 6.5 hereof.

         6.2 MEETINGS CONCERNING MARKETING. The Management Board shall meet from
time-to-time to discuss and approve marketing strategies in order to optimize
customer acceptance and effective promotion of each System. All final plans and
strategies regarding System marketing, distribution and pricing shall be
established by the Management Board reasonably and in good faith. Baxter shall
follow the plans and strategies established by the Management Board. The
Management Board will review the marketing plans and strategies, including
pricing, from time to time in the light of market conditions. Day-to-day
marketing and sales decisions will not be made by the Management Board; Baxter
will be responsible to make day-to-day marketing and sales decisions using its
best efforts to maximize Net Sales in the interest of both parties.
Notwithstanding the foregoing, it is understood and agreed that Baxter and Cerus
will not discuss marketing, distribution or pricing of products in any country
if Baxter and Cerus are marketing, or have plans to market, competing products
in such country.

         6.3 EXCLUSIVE RELATIONSHIP. The parties acknowledge that, except as
permitted under Sections 3.8(b) and 3.8(c), the relationship established by this
Agreement shall be the sole vehicle for exploitation by either party of products
and services in the Field. Accordingly, each party agrees that, except as
permitted under Sections 3.8(b) and (c), it will not research, develop or market
inactivation/decontamination products or services in the Field, including
without limitation products which compete indirectly or directly with the
Systems developed and marketed under this Agreement, except under and in
accordance with the terms of this Agreement. The foregoing sentence shall not in
any event, however, prevent either party from independently investigating or
researching New Technology to the extent reasonably necessary for presentation
of such New Technology to the Management Board under Paragraph 3.8(a).
Notwithstanding the foregoing, nothing in this Agreement shall prevent or
restrict Baxter from independently developing and marketing systems for
inactivation of pathogens in FFP using methylene blue.

         6.4 COMPETING PRODUCTS. In the event Baxter markets within a specific
country or territory an inactivation/decontamination product that competes
directly with a specific system developed under this Agreement, Baxter's rights
under this Agreement shall become co-exclusive with Cerus, or in the case of S59
FFP Systems may be terminated by Cerus, for the specific System in that specific
country or territory only, allowing Cerus to market, sell and

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       26

<Page>

distribute the System itself within the specific country or territory or, if
Cerus chooses, through a single Approved Distributor or Approved Distributors
within the specific country or territory. The sharing of Premium shall be
adjusted according to Section 7.3. With respect to S59 FFP Systems, Cerus will
notify Baxter upon receipt of Regulatory Approval of an S59 FFP System in any
country. Baxter will notify Cerus in writing within ninety (90) days after
receipt by Baxter of notice of Regulatory Approval of an S59 FFP System in a
country whether or not Baxter intends to distribute the S59 FFP System in such
country. If Baxter is then selling a competing system based on methylene blue in
such country, Baxter will have one year from the date receipt by Baxter of
notice of such Regulatory Approval to cease selling such methylene blue-based
system in such country. If Baxter ceases within such period to sell such
methylene blue-based system in such country, the first sentence of this Section
shall not apply with respect to Baxter's distribution rights in such country.

         6.5 COMMENCEMENT, CESSATION OF MARKETING. If (a) according to the
Management Board, Baxter (through its own efforts or those of its distributors)
has not marketed a specific System within a specific country or territory
following Market Launch within a reasonable time, but not less than one year nor
more than three years from Market Launch, or (b) after commencement of marketing
of a specific System in a particular country or territory, Baxter shall cease
marketing (or be prevented from marketing by governmental action concerning
Baxter) of such System in such country or territory in the manner required under
this Agreement, Cerus shall have exclusive rights to market that specific System
in that specific country or territory only, allowing Cerus to market, sell and
distribute the System itself within the specific country or territory, or if
Cerus chooses, through an Approved Distributor or Approved Distributors within
the specific country or territory. The sharing of Premium shall be adjusted
according to Section 7.3. If, according to the Management Board, Cerus (through
its own efforts or those of its distributors) has failed to gain a sufficient
market share for a particular System within a specific country or territory
within three (3) years after Cerus has obtained marketing rights in such country
or territory, or to gain or maintain sufficient market share in such country at
any time thereafter, or has ceased marketing of a specific System (other than
S59 FFP Systems) in any country or territory, Cerus' rights under this Agreement
shall become co-exclusive with Baxter, for that specific System in that specific
country or territory, allowing Baxter to market, sell and distribute the System
itself within the specific country or territory or, if Baxter chooses, through a
single Approved Distributor or Approved Distributors within the specific country
or territory.

         6.6 ACHIEVEMENT OF MARKET SHARE. If, according to the Management Board,
Baxter (through its own efforts and those of its distributors) has not gained a
sufficient market share for a particular System within a specific country or
territory within three (3) years following Market Launch, or has not gained or
maintained sufficient market share in such country at any time thereafter,
Baxter's rights under this Agreement shall become co-exclusive with Cerus, or in
the case of S59 FFP Systems may be terminated by Cerus, for that specific System
in that specific country or territory, allowing Cerus to market, sell and
distribute the System itself within the specific country or territory or, if
Cerus chooses, through a single Approved Distributor or Approved Distributors
within the specific country or territory. The sharing of Premium shall be
adjusted according to Section 7.3.

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       27

<Page>

         6.7 SUPPLY OF BAXTER GOODS. Baxter shall provide the necessary Baxter
disposables, Blood Pack Units(R), Instruments, Baxter Compounds, New Technology
Compounds that the Management Board determines will be provided by Baxter, and
other components necessary for Cerus, or Cerus' Approved Distributor, to sell
Systems under Sections 6.1, 6.5 and 6.6. Cerus shall forecast its needs for such
Baxter disposables, apheresis kits, Blood Pack Unit(R), Instruments, Baxter
Compounds, New Technology Compounds that the Management Board determines shall
be supplied by Baxter, and other components under Sections 6.1, 6.5 and 6.6.
Baxter's Cost of Goods/Base Revenue under this section shall be reimbursed under
Section 7.3, except with respect to Instruments, as provided in this Section.
Baxter shall not, however, be obligated to develop, reconfigure, modify, qualify
or seek Regulatory approval for any disposables, apheresis kits, Blood Pack
Units(R), Instruments, Baxter Compounds, New Technology Compounds that the
Management Board determines shall be supplied by Baxter, or other components
supplied to Cerus or Cerus' Approved Distributor under this Section. If Cerus
distributes S59 FFP Systems in any country, Cerus will be responsible in such
country for placement with customers of Instruments that are solely for use with
S59 FFP Systems. Cerus will pay to Baxter [...***...] if such Instruments are
manufactured by a third-party supplier, or [...***...] if such Instruments are
manufactured by Baxter. In the event Cerus terminates Baxter's distribution
rights for S59 FFP Systems with respect to a particular country, and Cerus or
another distributor takes over distribution of such Systems, Cerus will purchase
from Baxter any Instruments owned by Baxter and placed with customers in such
country solely for use with S59 FFP Systems, and Cerus will pay Baxter's book
value for any such Instruments.

         6.8 REQUALIFICATION. In the event Cerus obtains distribution rights
under Section 6.1, 6.5, 6.6, 12 or 16, or in the event Baxter does not supply
sufficient goods under Section 6.7 to meet Cerus' needs (without limiting
Baxter's obligation to supply such goods) Cerus may, or may license third
parties to, make, have made, use, sell and have sold products using the Cerus
Compounds, Baxter Compounds or New Technology Compounds, or under the Cerus
Patents or Cerus Know-How or patents or know-how pertaining to New Technology to
which rights have been acquired pursuant to Section 3.8, and under any patents
or know-how under which Cerus is licensed pursuant to Section 8.5(b) and Section
8.6 hereof, for the use and in the particular country or countries for which
Cerus has distribution rights, PROVIDED THAT such products are qualified for
regulatory approval on Cerus' or such third party's own system.

         6.9 MANAGEMENT BOARD ACCESS TO AND REVIEW OF MARKETING AND DISTRIBUTION
INFORMATION. A party marketing and distributing products under this Agreement
will provide to the Management Board all information in such party's possession
as the Management Board may reasonably require from time to time to review and
make decisions concerning marketing and distribution, including without
limitation breakdown and substantiation of any data provided pursuant to Section
13 of this Agreement. If the information requested of a party is information
that is not normally collected by the party, and requires substantial additional
expense of such party to collect and provide, such additional expense shall be
borne equally by the parties.

         6.10 BAXTER TERMINATION OF DISTRIBUTION FOR S59 FFP SYSTEMS. Baxter may
elect upon twenty-four (24) months' prior written notice to Cerus to terminate
Baxter's right and obligation to distribute S59 FFP Systems in a particular
country, provided that after receipt of such notice, Cerus may earlier terminate
such right and obligation in such country.

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       28

<Page>

         6.11 BAXTER TERMINATION OF SUPPLY OF GOODS FOR S59 FFP SYSTEMS. In
the event that Baxter's distribution rights for S59 FFP Systems terminate for
any reason, Baxter may thereafter elect upon [...***...] months' prior
written notice to terminate its right and obligation to supply goods to Cerus
pursuant to Section 6.7 hereof. Baxter will provide reasonable assistance
during such [...***...] month period to assist Cerus to make the transition
to another supplier or suppliers. In addition, Baxter will continue, even
after such [...***...] month period, to supply components that Cerus is
unable to obtain from third parties due to Baxter proprietary rights or that
are required to maintain regulatory validation for the Cerus S59 FFP Systems;
such components will be supplied by Baxter at [...***...] for such
components. Cerus will use due diligence to seek regulatory validation of
substitute components during such [...***...] month period. Following such
termination, Baxter shall cease to receive any Revenue Sharing Payments with
respect to S59 FFP Systems.

         6.12 CERUS TERMINATION OF BAXTER MANUFACTURING RIGHTS FOR S59 FFP
SYSTEMS. In the event that, during the scale-up or manufacturing stages for the
S59 FFP Project, Cerus unilaterally terminates the S59 FFP Project or Baxter's
manufacturing rights and obligations for S59 FFP Systems, other than for breach
of this Agreement by Baxter, then during the period between receipt by Baxter of
Cerus' notice of intent to terminate and the actual date of termination, Baxter
will use its best efforts, in consultation with Cerus, to reduce inventory and
limit commitments to suppliers and to wind down such operations. Following the
actual date of termination, Cerus will pay to Baxter Baxter's out of pocket
costs with respect to raw materials, work-in-process and finished goods
purchased or ordered on non-cancellable orders that cannot be disposed of or
used for other purposes, and Baxter will convey title to such goods to Cerus.
Cerus will also pay to Baxter reasonable wind-down costs of Baxter personnel
that were engaged by Baxter solely to carry out such activities and who cannot
be reassigned to other duties at Baxter. Such personnel costs shall not exceed
two weeks salary and benefits for any such individual. At Cerus' request, Baxter
will provide to Cerus books and records reflecting any costs for which Baxter is
seeking reimbursement under this Section.

         6.13 CERUS TERMINATION OF DISTRIBUTION RIGHTS FOR S59 FFP SYSTEMS.
In the event that following Market Launch for the S59 FFP Project, Cerus
unilaterally terminates Baxter's distribution rights hereunder with respect
to S59 FFP Systems, other than for breach of this Agreement by Baxter, Cerus
will provide Baxter not less than [...***...] months written notice of such
termination. During such period, the parties will cooperate to sell any
inventory held by Baxter. At the end of such period, Cerus will purchase any
inventory that has an acceptable shelf life at a purchase price equal to
Baxter's Cost of Goods. Cerus will be entitled to credit such purchase price
against any Cerus obligation under Section 7.3 hereof to Baxter arising from
Cerus' sale of inventory. At Cerus' request, Baxter will provide to Cerus
books and records reflecting any costs for which Baxter is seeking
reimbursement under this Section. In the event that agreements with customers
entered into prior to receipt of such Cerus notice of termination have
contractual commitments to customers extending beyond the termination date,
Cerus shall, at its election on a customer-by-customer basis, (a) permit
Baxter to continue to supply S59 FFP Systems to such customer beyond the
termination date, (b) assume Baxter's supply obligations under such
contractual commitments, or (c) pay any penalties owing to the customer to
terminate such contractual commitments.

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       29

<Page>

7.       REVENUE SHARING.

         7.1 REVENUE SHARING PAYMENTS. In consideration of the Cooperative
Development Work to be undertaken and other obligations set forth herein, the
parties agree to share Net Sales as follows: Subject to the provisions of
Sections 3.5, 3.7(a), 7.2, 7.3, 7.4, and 12, no later than sixty (60) days after
the first and all subsequent calendar quarters following the Market Launch of
the System, (a) Baxter shall pay to Cerus, with respect to Net Sales in such
calendar quarter, a sum equal to: (1) Cerus' Cost of Goods/Base Revenue; and (2)
fifty percent (50%) (or such other percentage as is established pursuant to
Section 3.5 hereof) for all products other than S59 FFP Systems, and
Seventy-Five percent (75%) for S59 FFP Systems, of the Premium during such
calendar quarter ("Revenue Sharing Payments"), and (b) Baxter shall retain for
itself the balance of the proceeds of Net Sales of Systems shipped during such
Calendar Quarter. On each such date a party that has received in such calendar
quarter a royalty, license fee or other consideration for licensing or
sublicensing rights hereunder shall pay to the other party the amount due to
such party under Section 7.4. The Revenue Sharing Payments due and payable
hereunder shall be computed for each calendar quarter in the currency in which
the sale was made, but shall be definitively discharged by payment to Cerus in
U.S. dollars converted from such currency using the average of spot rates for
such currency for the last business day of the second and third months of such
quarter and of the first month of the subsequent quarter, as quoted in the Wall
Street Journal (or such other mutually agreeable financial publication of
international circulation or rates published by Baxter's corporate treasury, if
mutually agreed).

         7.2 BAXTER SOURCING CERUS COMPOUNDS. In the event Baxter sources the
Cerus Compounds from an alternate source, Baxter shall retain for itself the
Cost of Goods/Base Revenue for the Cerus Compounds in the Systems shipped during
such calendar duration.

         7.3 CERUS AS SELLER OF SYSTEMS. In the event Cerus, or an Approved
Distributor appointed by Cerus, is the seller of the Systems under Sections 6.1,
6.5, 6.6 or Section 12, Cerus shall retain for itself its Cost of Goods/Base
Revenue, and the Marketing and Administrative Expenses, and pay to Baxter,
Baxter's Cost of Goods/Base Revenue and the percentage of Premium received by
each of the parties will equal the percentage contributed by such party to the
sum of (a) cash contributed to the Final Project Total Budget, PLUS (b) Noncash
Contribution to the Project, PROVIDED THAT for the purposes of computations
under this Section, Baxter's Noncash Contribution shall be reduced by (i) fifty
percent (50%) if such sales are made pursuant to Section 6.6, or (ii) by
seventy-five percent (75%) if such sales are made pursuant to Section 6.1, 6.5,
or Section 12. In the event that Cerus purchases any components from Baxter, as
provided in Section 6.7, Baxter's share of the Premium split shall be not less
than fifty percent (50%) of Baxter's Cost of Goods for such components, except
with respect to Instruments, as provided in Section 6.7. For the purpose of
clarification, with respect to S59 FFP Systems, expenditures by Cerus and
unreimbursed expenditures by Baxter after December 31, 1997 will be considered
part of such party's cash contribution to the S59 FFP Final Project Total
Budget.

         7.4 LICENSING OF RIGHTS ARISING UNDER THIS AGREEMENT. In the event
either Cerus (pursuant to Section 6.8 hereof) or Baxter (pursuant to Section 8.4
hereof) or Cerus and Baxter jointly (pursuant to a determination of the
Management Board) licenses or sublicenses to a third party rights arising under
this Agreement, all royalties, license fees and other consideration received
from such licensing or sublicensing (excluding research or development payments)

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                      30

<Page>

shall be shared by the parties according to the percentage of the sum of (a)
funding by each party in the Final Project Total Budget (or such lesser amount
as shall have been expended by Baxter and Cerus to enable the parties to license
or sublicense the rights hereunder and to comply with their development
obligations under the license or sublicense agreement), PLUS (b) Noncash
Contribution to such Project made by each party, PROVIDED THAT for the purposes
of this Section, Cerus' and Baxter's Noncash Contributions will be equitably
adjusted to reflect the relative contribution of Cerus Patents and Cerus
Know-How and Baxter Patents and Baxter Know-How to the rights being licensed or
sublicensed, but in all events Baxter's Noncash Contribution shall be reduced by
not less than seventy-five percent (75%). In the event such license or
sublicense to a third party is solely to rights to a New Technology acquired
jointly by Baxter and Cerus pursuant to Section 3.8(a), and not to rights with
respect to any Cooperative Development Work, Baxter and Cerus shall share
equally, or in such other proportion as Baxter and Cerus shall agree, all
royalties, license fees and other consideration received from such licensing or
sublicensing. Notwithstanding the foregoing, Cerus will not have any obligation
to pay any royalty, license fee or other consideration with respect to any
licensing by Cerus to third parties pursuant to the rights of Cerus under
Section 8.5(a) of this Agreement.

         7.5 DISTRIBUTOR SALES. In the event that either party sells
Inactivation Packages or Integrated Inactivation Sets through a distributor,
other than sales by Cerus of such products for S59 FFP, Net Sales shall be
computed as set forth in paragraph (c) of the definition of Net Sales, and the
Distributor Portion will not diminish the Revenue Sharing Payment receivable by
the other party.

8.       PATENTS, KNOW-HOW, LICENSE GRANTS.

         8.1 CERUS SOLE OWNERSHIP. Any Cerus Project Inventions shall be
assigned to and owned by Cerus.

         8.2 BAXTER SOLE OWNERSHIP. Any Baxter Project Inventions shall be
assigned to and owned by Baxter.

         8.3 JOINT OWNERSHIP.

                  (a) Cerus and Baxter each agrees to take all reasonable steps
to maximize the opportunity for patent protection of inventions made in the
course of this Agreement, including, without limitation, inventions that are
improvements of inventions covered by the Baxter Patents and Cerus Patents.

                  (b) Joint Inventions shall be assigned to and owned by Baxter
and Cerus jointly, except as set forth below in this Section 8.3(b).

                           (i)      Those inventions which would be
                                    unpatentable, under 35 U.S.C. Section 103,
                                    over Cerus-owned patents or patent
                                    applications that qualify as prior art
                                    solely under 35 U.S.C. Section 102(f) or 35
                                    U.S.C. Section 102(g) (other than patents or
                                    patent applications commonly owned by Cerus
                                    and Baxter) shall be owned by, and are
                                    hereby deemed assigned to, Cerus.

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       31

<Page>

                           (ii)     Those inventions which would be
                                    unpatentable, under 35 U.S.C. Section 103,
                                    over Baxter-owned patents or patent
                                    applications that qualify as prior art
                                    solely under 35 U.S.C. Section 102(f) or 35
                                    U.S.C. Section 102(g) (other than patents or
                                    patent applications commonly owned by Baxter
                                    and Cerus) shall be owned by, and are hereby
                                    deemed assigned to, Baxter.

                  (c) The parties agree that any Joint Invention previously
assigned under the terms of this Agreement as in effect prior to the First
Amendment Effective Date shall be re-assigned in accordance with the terms of
this Agreement as amended and restated on the First Amendment Effective Date.

                  (d) Any Contractor Inventions of which either Baxter or Cerus
gains ownership shall be considered Joint Inventions with ownership assigned as
provided in Section 8.3(b), irrespective of whether the contract with the
Contractor specifies Baxter or Cerus, or Baxter and Cerus jointly, as the
assignee; PROVIDED, HOWEVER, that any Contractor Inventions reading on S59 FFP
Systems will be assigned to and solely owned by Cerus, unless such Contractor
Inventions read on both S59 Systems and systems developed under the Platelet
Agreement, in which case ownership of such Contractor Inventions will be
assigned as provided in the Platelet Agreement. Each party agrees to execute
such additional documents as may be necessary to evidence or effectuate such
ownership or assignment. To the extent any such contract conveys any rights by
license, the recipient of such license rights (whether Cerus or Baxter) will use
its best efforts to obtain the right to assign an equal interest in, or
sublicense, such rights to the other party, and if obtained, such rights shall
be granted to the other party. If for any reason, such rights to equal interest
or sublicense can not be obtained, Cerus and Baxter will nonetheless arrange
between themselves for Cerus and Baxter to share the benefits of such rights in
a manner consistent with the terms of this Agreement. The parties agree that any
Contractor Invention previously assigned under the terms of this Agreement that
were in effect prior to the First Amendment Effective Date shall be re-assigned
in accordance with the terms of this Agreement as amended and restated on the
First Amendment Effective Date. Notwithstanding the foregoing, any rights
obtained by license with respect to S59 FFP Systems will be owned solely by
Cerus without any obligation to assign to Baxter or make other arrangements for
the benefit of Baxter, unless such rights read on both S59 FFP Systems and
systems developed under the Platelet Agreement, in which case ownership of such
rights will be assigned as provided in the Platelet Agreement.

                  (e) Within the Field, the parties shall exploit any Joint
Patents solely for the development, sale or licensing of Systems pursuant to
this Agreement.

         8.4      LICENSE.

         Subject to the terms and conditions of this Agreement, for Systems
whose manufacture, use or sale is covered by a claim of a Cerus Patent, or which
use Cerus Know-How, Cerus hereby grants Baxter an exclusive, paid-up, royalty
free (except as provided herein) license, with the right to sublicense (if such
sublicense is approved in advance by the Management Board), under Cerus Patents
and Cerus Know-How to make, have made, import, sell, offer for sale or have sold
such Systems, and to use such Systems solely for promotion and sale thereof,
worldwide, solely for use in the Approved Project Field. Notwithstanding the

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       32

<Page>

foregoing, for any country or territory where such marketing rights become
co-exclusive or exclusive to Cerus pursuant to Sections 6.1, 6.5 or 6.6 of the
Agreement, such license shall automatically become co-exclusive with Cerus, or
the rights shall revert exclusively to Cerus, as the case may be, for such
country or territory. Except as set forth herein in Section 5.7, such license
shall exclude the right to make or have made Cerus Compounds. As to Cerus
Compounds, such license shall be limited to the Cerus Compounds that are
selected by the Management Board for a specific Project within the Approved
Project Field. Notwithstanding anything in this Section or elsewhere in this
Agreement, Baxter shall not have any license or distribution rights in or to any
Cerus Patent or Cerus Know-How to the extent relating to (a) the inactivation of
bacteria, viruses, parasites or other pathogens through use of compounds other
than psoralens, ALE compounds or New Technology Compounds, or (b) use outside
the Approved Project Field, except as provided in Section 8.6 of this Agreement.

         8.5      CERUS RIGHTS.

                  (a) Baxter and Cerus have previously entered into a letter
agreement dated January 18, 1996 RE NON-EXCLUSIVE LICENSE FOR PLASMA DERIVATIVES
a copy of which is attached hereto as Schedule D (the "Plasma Derivatives
Letter"). The Plasma Derivatives Letter is not superseded by this Agreement. For
the purposes of clarity, the parties agree that the terms of the Plasma
Derivatives Letter apply to source plasma and recovered plasma for fractionation
in the same manner as they apply to plasma derivatives and recombinant
equivalents thereof, all of which shall be considered to be outside of the
Field, notwithstanding any other provision of this Agreement.

                  (b) The license to Baxter set forth above is subject to the
right retained by Cerus to grant licenses to third parties under Cerus Patents
and Cerus Know-How, and exercise other rights, as provided in Section 6.8 of
this Agreement. Baxter further grants to Cerus paid-up, royalty-free (except as
provided herein) license, with right to sublicense (a) co-exclusive in the
Field, to any Baxter Project Patents or Baxter Know-How developed in the course
of the Cooperative Development Work or Platelet Project, and (b) non-exclusive
in the Field to any Baxter Patents or Baxter Know-How otherwise embodied or used
within a System or a system developed under the Platelet Agreement; solely for
the purposes of granting licenses and exercising other rights pursuant to
Sections 6.1, 6.5, 6.6, 6.7, 6.8 and 8.5 or exercising Cerus' rights under
Section 12 or 16 of this Agreement, including without limitation the right to
make, have made, and use, sell or have sold any components of a System. This
clause (b) shall exclude, however, any Baxter proprietary materials or Baxter
proprietary configuration of blood bags and associated tubes and connections, or
Baxter proprietary processes to manufacture any of the same, unless Baxter shall
consent in writing to license of the same to Cerus.

         8.6      CROSS-LICENSE AS TO INSTRUMENTS AND COMPOUND REMOVAL DEVICES;
                  EXPLOITATION OF JOINT INVENTIONS OUTSIDE THE FIELD.

                  (a) Cerus hereby grants to Baxter, and Baxter hereby grants to
Cerus, a worldwide, non-exclusive, paid-up, royalty-free license, with right to
sublicense, to make, have made, import, and use, sell, offer for sale, or have
sold, outside the Field, products under any patents and know-how of the granting
party used or embodied in any Instrument or in any compound removal device
developed under this Agreement or the Platelet Agreement.

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       33

<Page>

                  (b) Either party may exploit any Joint Invention and rights to
any Joint Patent outside the Field subject to an obligation to pay the other
party a reasonable royalty to be negotiated in good faith, taking into account
the parties' relative contributions to the making of such invention, and,
failing agreement on such royalty, to be determined by arbitration pursuant to
Section 3.2(d) hereof. Such royalty will be paid by a party irrespective of
whether sole ownership of such Joint Invention or Joint Patent is assigned,
pursuant to Section 8.3(b), 8.3(c) or 8.3(d), to such party or to the other
party. Such royalty obligations shall not apply to the exercise of the rights
specifically provided in Section 8.6(a) above. Notwithstanding the foregoing or
Section 8.6(c), any exploitation by a party of a Joint Invention in the Field
shall be made solely either through a System developed pursuant to the
Cooperative Development Work and subject to revenue sharing as provided herein.

                  (c) If either party is assigned sole ownership of a Joint
Invention pursuant to Section 8.3 hereof, that party hereby grants to the other
party a worldwide, irrevocable, non-exclusive paid-up (except for the royalties
provided for in Section 8.6(b)) license, with right to sublicense, to make, have
made, import, and use, sell, offer for sale, or have sold products practicing
such invention and under any associated patent rights.

         8.7 EXCLUDED PRODUCTS. The term EXCLUDED PRODUCT means any product in
the Field that Baxter, in its sole discretion, specifically notifies Cerus in
writing that Baxter has no interest in developing and marketing. In the event
that Cerus proposes in writing a product for development under the Cooperative
Development Work, Baxter will consider such proposal in good faith and will
notify Cerus in writing if Baxter has no interest in developing and marketing
such product in the reasonably foreseeable future. Notwithstanding any other
provision of this Agreement, all rights and licenses hereunder as to any
Excluded Product shall revert to Cerus, including without limitation the right
to make, have made, and use, sell and have sold the Excluded Product. Cerus
shall not have any obligation to account to Baxter for any proceeds from sale of
any Excluded Product.

         8.8 NOTICE OF SOLE RIGHTS. After the Effective Date of this Agreement,
a party asserting sole ownership of any patent rights or know-how in the Field
developed pursuant to the Cooperative Development Work shall provide reasonable
notice to the Patent Committee of its intention to seek patent protection or to
assert proprietary interest in such Know-How. The Patent Committee shall have
the right to a reasonable opportunity to review and comment on such assertions
prior to patent applications being filed.

         8.9 OTHER AGREEMENTS. Cerus shall not terminate, alter or amend the
terms of the following agreements in a manner that would limit Cerus' or
Baxter's rights under this Agreement without the prior written approval of
Baxter: The Technology Transfer Agreement and the License Agreement between
Cerus and HRI Research, Inc. each dated December 13, 1991. Baxter shall respond
within thirty (30) days of receipt of written proposed changes to such
agreements. Baxter's approval of proposed changes shall not be unreasonably
withheld.

         8.10 REGULATORY FILES. Baxter and Cerus shall each have full access
to all materials filed and correspondence with the FDA and other regulatory
agencies in connection with the Cooperative Development Work and each System,
and shall be entitled to use and rely on such materials with respect to any
regulatory approvals for a product sought by either, whether or not such
product relates to this Agreement, PROVIDED THAT Baxter shall be entitled to
use or rely on

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       34

<Page>

any such materials relating to regulatory approvals sought for the S59 System
only for the purpose of developing and marketing Systems pursuant to this
Agreement and the Platelet Agreement. In the event that product registration
is in the name of Baxter in any country and Cerus obtains marketing rights
for such product in such country, then Baxter will, at Cerus' expense, cause
the product to be co-registered in Cerus' name or take other steps so that
Cerus may market and sell the product under such registration. Promptly
following the First Amendment Effective Date, Baxter will take all actions,
including execution and filing of all documents, necessary or appropriate to
transfer to Cerus all applications and filings relating to regulatory
approvals sought for the S59 FFP System.

         8.11 RIGHTS UNDER GOVERNMENT-SPONSORED RESEARCH. Any licenses hereunder
to any "subject invention," if any, as defined in 35 U.S.C. Section 201, shall
be subject to the rights of the United States Government under 35 U.S.C.
Section, 200 ET SEQ.

9.       PROSECUTION OF PATENT RIGHTS.

         9.1 CERUS PATENTS. Cerus shall have the right but no obligation to
timely prepare, file, prosecute and maintain, under its exclusive control and at
its expense, Cerus Patents.

         9.2 BAXTER PATENTS. Baxter shall have the right but no obligation to
timely prepare, file, prosecute and maintain, under its exclusive control and at
its expense, Baxter Patents.

         9.3 JOINT PATENTS. The parties shall jointly engage counsel for the
purpose of timely preparing, filing, prosecuting and maintaining Joint Patents;
PROVIDED, HOWEVER, that if a Joint Patent is assigned to one party or the other
pursuant to Section 8.3 hereof, the party to whom such patent is assigned shall
employ counsel subject to the other party's right to approve such counsel, which
approval shall not be unreasonably withheld. The parties shall jointly control
the preparation, filing, prosecution and maintenance of Joint Patents and all
expenses relating there to shall be subject to cost sharing pursuant to Section
9.6 hereof. Whenever possible, the parties shall file internationally under the
Patent Cooperation Treaty and/or the European Patent Convention in order to
minimize expenses. The party or parties who engage counsel to prepare or
prosecute Joint Patents shall advise such counsel, at the time of engagement,
that such counsel represents both parties.

         9.4 PRIOR ART; REVIEW AND COMMENT. Each party shall cooperate with the
other to ensure that all prior art that is pertinent to the examination of a
patent or application relating to a Joint Invention or an invention covered by
Section 8.3(d) hereof is brought to the attention of the other party. The
parties to this Agreement shall have the right to review and comment on
substantive documents prepared in connection with the preparation, filing,
prosecution and maintenance of patents and applications relating to a Joint
Invention or an invention covered by Section 8.3(d) hereof prior to the filing
of such papers; however, such review and comment shall be performed
expeditiously so as not to negatively affect patent rights.

         9.5 PROJECT PATENTS; LICENSING PAYMENTS TO THIRD PARTIES.

                  (a) The Management Board will conduct a periodic review (at
least annually), in consultation with the Patent Committee, to identify those
Baxter Patents and Cerus Patents that are protective of the Systems under
development, or developed, pursuant to this Agreement.

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       35

<Page>

Any such Baxter Patents or Cerus Patents that are so identified (other than
patents or patent applications that are primarily directed toward applications
outside the Field, and only incidentally directed toward the Field) shall be
designated Project Patents. In such periodic reviews, the Management Board may
also determine that certain Baxter Patents or Cerus Patents that were previously
designated as Project Patents will be removed from such designation.

                  (b) In the event that the Management Board determines that a
license from a third party is necessary or desirable in connection with the sale
of any System developed under this Agreement, the parties will share the cost of
obtaining and maintaining such license. If a Patent Fee Payment is required to
obtain or maintain such license, the party negotiating the license will make
such payment, and the other party will reimburse the paying party for fifty
percent (50%) of the amount of such payment within sixty (60) days after such
payment is made. Patent Royalty Payments on Project Patents, and Patent Royalty
Payments approved by the Management Board for patents that are not designated as
Project Patents, will be paid by Baxter (if Baxter is the selling party) or
Cerus (if Cerus is the selling party) for any System and deducted in computing
the Premium arising from sales by such party. Notwithstanding the foregoing,
with respect to any patents obtained to support the S59 FFP System, Cerus will
solely pay any Patent Fee Payment (to the extent such Patent Fee Payment is
allocable to S59 FFP, but not to the extent it is allocable to other systems
being developed under this Agreement or the Platelet Agreement) and will also
pay Patent Royalty Payments, and charge such Patent Fee Payments and Patent
Royalty Payments as Cost of Goods in Computing Premium.

         9.6 PATENT EXPENSES. The reasonable expenses, incurred on or after
January 1, 1997 of preparing, filing, prosecuting and maintaining Project
Patents and Joint Patents in the countries of the United States, Australia,
Canada, the United Kingdom, Germany, Belgium, France, Italy, Netherlands, and
Japan, and all other countries that are agreeable to Baxter and Cerus, as
evidenced in writing shall be borne equally. The parties shall reconcile on a
semi-annual basis on or about the last business day of each February and August,
commencing August, 1998, all such expenses incurred by the respective parties
during the previous semi-annual period (or previous semi-annual periods that
have not yet been reconciled). In such reconciliation, Baxter will make a cash
payment to Cerus, or Cerus will make a cash payment to Baxter, so that such
expenses are borne equally by the parties. Unless countries other than those
expressly listed above are agreed to by the parties in writing, such other
country filings shall not be made. Except as set forth above in this Section
with respect to Project Patents, Cerus will bear the expenses of preparing,
filing, prosecuting and maintaining Cerus Patents, and Baxter will bear the
expense of preparing, filing, prosecuting and maintaining Baxter Patents.

         9.7 ELECTION NOT TO PAY EXPENSES. If either party does not for any
reason pay its share of the reasonable expenses for a particular Project Patent
or Joint Patent, then, at the option of the other party:

                  (a) the interest of that nonpaying party with respect to that
particular patent application or patent shall immediately terminate and the
paying party shall be assigned and exclusively own that particular patent or
patent application, without affecting the nonpaying party's rights under all
other patent applications and patents; or

                  (b) the application or patent shall be allowed to lapse.

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       36

<Page>

         In the event the paying party elects option (a) above, the nonpaying
party hereby agrees to execute documents necessary to transfer its interest in
such patent or patent application to the paying party.

10.      TRADEMARKS.

         10.1 BAXTER TRADEMARKS. Cerus shall make no use of any Baxter trademark
without the prior written approval by Baxter.

         10.2 CERUS TRADEMARKS. Baxter shall include the Cerus name and mark (or
successor name and mark) in a prominent manner on packaging, literature and
promotional material and advertising for the System unless Baxter makes a good
faith determination that the Cerus name cannot be used due to third party
rights. Baxter shall, to the extent practical, provide to Cerus for review
copies of all proposed uses of the Cerus name and mark and references to Cerus.
At Cerus' reasonable request, Baxter shall refer to the Cerus Compounds by the
Cerus trademark that Cerus indicates is appropriate. Baxter shall include on
material bearing such trademarks an acknowledgment that such trademarks are the
property of Cerus. If necessary in any market to maintain Cerus' rights in the
Cerus trademarks, Baxter shall enter into a registered user agreement regulating
its use of the Cerus trademarks. Except as provided in this Section, no rights
to Cerus trademarks are hereby granted to Baxter.

11.      CONFIDENTIAL INFORMATION.

         11.1 CONFIDENTIALITY AGREEMENT. The use and disclosure of information
designated by either party as confidential shall be governed by the attached
Schedule E Confidentiality Agreement. The Schedule E Confidentiality Agreement
shall survive termination of this Agreement.

         11.2 USE OF CONSULTANTS. The parties contemplate that from time to time
during the term of this Agreement third party technical consultants may be
employed by either party in connection with the development of Cerus Compounds,
Baxter Compounds, New Technology Compounds or Systems. The parties agree that
information designated as confidential may be disclosed to such consultants
PROVIDED THAT the other party is given reasonable notice of the circumstances
and nature of the intended disclosure and that the disclosure is limited to
information necessary to enable the technical consultant to provide technical
consulting services. The consultant will be required to sign an agreement
committing the consultant to protect such confidential information.

12.      CESSATION OF COOPERATIVE DEVELOPMENT WORK.

         12.1 CESSATION. Either party may unilaterally cease all participation
in the Cooperative Development Work on a specific approved Project or all
Cooperative Development Work under this Agreement upon two hundred seventy (270)
days' written notice of its intent. During such 270-day period, the party
unilaterally ceasing participation shall continue to perform the tasks
previously agreed on and shall continue to support such party's share of (a) the
approved budget for such 270-day period, as provided in Section 3 of this
Agreement, or (b) if the budget has not yet been approved for such full 270-day
period, the budgeted amount for that period for which there is an approved
budget PLUS for each month during such 270-day period for which there is

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       37

<Page>

not an approved budget, an amount equal to the average monthly budget for the
last three months for which there was an approved budget. At any time
thereafter, the party who did not unilaterally cease participation in the
Cooperative Development Work shall have the right to proceed with the
independent development of such System at its own expense. Should a party so
proceed, the following terms and conditions shall apply:

                  (a) The Premium Sharing Formula in Section 7.1 will be
adjusted. The Premium shall be split between the Parties based on the percentage
of the sum of (i) Final Project Total Budget funded by each Party, PLUS (ii)
Noncash Contributions to the Project made by each party, adjusted as provided in
clauses (b) and (c) below. Such percentage being calculated as follows: for
purposes of this Section only, after the cessation of funding by one Party, the
funds provided by the other Party thereafter to support the Cooperative
Development Work shall be considered doubled when calculating the Final Project
Total Budget and the corresponding respective percentage funded by each Party.
All funds provided by either Party pursuant to the approved Project Budget, or
pursuant to clause (b) in the first paragraph of Section 12.1 above, prior to a
Party's cessation shall be credited but not doubled.

                  (b) In the event that Cerus unilaterally ceases all
participation, then at Baxter's election by written notice, all marketing rights
and licenses of Cerus hereunder to the System(s) developed or being developed
under such Project, or under the Development Work, as the case may be, shall
terminate, and Baxter shall source the Cerus Compounds from an alternative
source with the cooperation of Cerus, and the Revenue Sharing Formula in Section
7.1 will be adjusted under Sections 7.2 and 12.1(a); in addition, Baxter (but
not Cerus) shall be released from the obligations of Sections 3.8 and 6.3 with
respect to that part of the Field that such System is intended to address.

                  (c) In the event that Baxter unilaterally ceases all
participation, then at Cerus' election by written notice, all marketing rights
and licenses of Baxter to the System(s) developed or being developed under such
Project, or under the Cooperative Development Work, as the case may be, shall
terminate and Cerus shall have exclusive rights to market, sell and distribute
such System throughout the world. Baxter shall provide the necessary Baxter
disposables, apheresis kits, Blood Pack Units(R), Instruments, Baxter Compounds,
New Technology Compounds that the Management Board determines shall be supplied
by Baxter, or other components necessary for Cerus, or Cerus' Approved
Distributor to sell Systems under Section 6.7. Revenue Sharing under Section 7.1
shall be adjusted under Sections 7.3, 7.4 and 12.1(a); in addition, Cerus (but
not Baxter) shall be released from the obligations of Sections 3.8 and 6.3 with
respect to that part of the Field that such System is intended to address.

         12.2 CESSATION PAYMENT. In the event that either party gives notice
of unilateral cessation of participation on a specific approved Project or
all Cooperative Development Work under this Agreement, such party shall, not
later than twenty (20) days after the date of such notice, pay to the other
party an amount equal to [...***...] period following the date of such
cessation, or (b) if the budget has not yet been approved for such full
[...***...] period, the [...***...] Such cessation payment need not be
applied by the receiving party to continuation of work on such Project or
Cooperative Development Work. Neither party shall be entitled to give notice
of unilateral cessation of participation on the Red Cell Project prior to
January 1, 1999 on any other Project prior to two years after the approval of
the Management Board to commence

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       38

<Page>

the Project, PROVIDED, HOWEVER, that either party shall have the right to give
notice of unilateral cessation of a Project prior to that date if such party
concludes, reasonably and in good faith, based on an unambiguous, unsuccessful
outcome in a critical test in the Project test protocol that there is no
reasonable likelihood that the Project will attain Regulatory Approval.

         12.3 SECTION 12 NOT APPLICABLE TO S59 FFP. Notwithstanding the
preceding provisions of Section 12, neither Section 12.1 nor 12.2 shall apply to
the S59 FFP Project. Cerus may, at any time, cease to pursue the S59 FFP
Project, and neither party will have any obligation under Section 12.2 to the
other with respect to the S59 FFP Project.

13.      REPORTS.

         13.1 QUARTERLY SALES REPORTS. Each quarterly payment made under Section
7 shall be accompanied by a full and accurate accounting of all Net Sales of
Systems by Baxter and Cerus, as the case may be, for the calendar quarter. Each
such report shall include at least the following information for each type of
System separately as to each of the following regions: U.S., Europe, Japan, rest
of world:

                  (a) The number of stand-alone Inactivation Packages and
Integrated Inactivation Sets sold to third parties by Baxter or Cerus, as the
case may be;

                  (b) The Net Sales, with a breakdown between Net Sales of
stand-alone Inactivation Packages and Integrated Inactivations Sets;

                  (c) Cost of Goods/Base Revenue with a breakdown between
stand-alone Inactivation Packages and Integrated Inactivation Sets;

                  (d) Computation of the Revenue Sharing Payment due to the
other party.

                  (e) Customer published price lists for Systems; and

                  (f) Any deductions from Revenue Sharing Payments.

Each report shall include the certification of the party making the report
attesting to the fact that the report is an accurate and complete accounting of
all information required hereunder.

To the extent Baxter is unable to provide any such information when due,
Baxter will provide to Cerus at such time Baxter's best estimates of such
information, and will provide actual information as soon as it is available,
PROVIDED, HOWEVER, that Baxter will, in any event, provide reports when due
of actual Net Sales and Cost of Goods/Base Revenue.

         13.2 COST OF GOODS/BASE REVENUE. To the extent not provided under
Section 13.1 above, each party will furnish quarterly reports to the other party
on such party's Cost of Goods/Base Revenue for components supplied by such
party.

14.      BOOKS AND RECORDS.

         14.1 RECORDS. Baxter and Cerus shall keep full and accurate books of
account containing all particulars that may be necessary for the purpose of
calculating all amounts owing

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       39

<Page>

to either party. Books of account maintained by the parties shall be kept at
their principal place of business. All such reports and data shall be open for
inspection on a confidential basis at all reasonable times and either party may
conduct at its own expense, once every year during normal business hours through
an independent certified public accountant, an examination of the accounts
contemplated above. If any audit shall show that the selling party underpaid
amounts due under this Agreement herein as to the period subject of the audit,
then the party which underpaid shall immediately pay to the other any such
deficiency with interest thereon in accordance with Section 14.3. If the
underpayment shall exceed ten percent (10%) of the amount owed for any calendar
year, the party underpaying shall also reimburse the other for costs related to
such audit.

         14.2 RETENTION. Books and records required to be maintained by the
parties hereunder shall be retained for at least two (2) years from the date of
the payment to which they pertain.

         14.3 INTEREST. All payments due hereunder that are not paid when due
and payable hereunder shall bear interest at an annual rate equal to 4% (four
percent) above the U.S. dollar reference rate ("prime rate") charged from time
to time by Bank of America N.T. & S.A., or any successor thereto, from the date
due until paid or at such lower rate as shall be the maximum rate permitted by
law.

15.      TERM.

         This Agreement shall continue so long as any System is being developed
or marketed under this Agreement, unless terminated earlier pursuant to Section
16.1, and PROVIDED THAT Cooperative Development Work may be earlier terminated
pursuant to Section 12.1. Further, upon expiration of the agreement, except as
otherwise provided herein, no Party shall be obligated to provide materials,
disposables, Blood Pack Units(R), apheresis kits, delivery systems, Instruments
and chemicals to the other Party. Upon termination of any Project by the
Management Board or by mutual consent, all licenses hereunder (except those
licenses granted pursuant to Section 8.6) shall terminate with respect to the
subject matter of such Project (which shall not affect licenses with respect to
any other Project). In the event that either party hereunder ceases
participation, in the Cooperative Development Work for the Red Blood Cell
Project, other than pursuant to the proviso in the last sentence of Section
12.2, all licenses of such party under this Agreement shall terminate except
such licenses as may be necessary or useful in connection with other then
ongoing approved Projects. Any license under Sections 8.5 and 8.6 hereof,
however, shall survive any termination of this Agreement.

16.      BREACH.

         16.1 MATERIAL BREACH. Either party may terminate this Agreement for any
material breach by the other party sixty (60) days after providing the other
party with written details of the breach if the breach remains uncured at the
end of the sixty (60) day notice period. Notwithstanding the preceding sentence,
each party acknowledges that the ability of the other party to carry on the
Cooperative Development work will be substantially adversely affected in the
event that such party does not make payment when due to the other party.
Accordingly, in the event of the failure to make any payments that are due and
owing, or fund any equity purchase, a thirty (30) day notice period shall apply
in lieu of such sixty (60) day notice period in the preceding sentence.

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       40

<Page>

         16.2 RIGHTS ON TERMINATION. In the event of termination by either party
as provided in Section 16.1, without limiting any other rights or remedies, such
party shall have the rights provided for under Section 12 of the Agreement as if
the other party had unilaterally ceased participation in the Cooperative
Development Work.

17.      REPRESENTATIONS AND INDEMNITIES.

         17.1 CERUS REPRESENTATIONS. Cerus represents and warrants to Baxter as
of the Effective Date that:

                  (a) It has granted no prior license or assignment of rights
under the Cerus Patents in the Field.

                  (b) There are no foreign or United States administrative,
judicial or Patent and Trademark Office proceedings contesting the inventorship
or ownership of any Cerus Patent;

                  (c) Neither the execution and delivery of this Agreement, nor
the performance of the obligations of Cerus hereunder shall result in a
violation, breach or event of default (or any event or condition which with
notice or the passage of time or both would constitute an event of default) of
or with respect to any agreement, mortgage, indenture or order of any court of
competent jurisdiction binding upon Cerus or upon the property of Cerus;

                  (d) It is party to no contract materially adverse to the
obligations undertaken and rights granted in this Agreement;

                  (e) The execution of this Agreement and delivery to Baxter
does not conflict with the terms of any agreement to which Cerus is bound.

                  (f) The Technology Transfer Agreement and the License
Agreement between Cerus and HRI Research, Inc. each dated December 13, 1991 are
in full force and effect and are binding and enforceable in accordance with
their terms.

                  (g) That Cerus has advised Baxter of any knowledge of any
third party patent or Know-How that might be infringed by the incorporation of
any Cerus Patent or Cerus Know-How likely to be embodied or used in a System;
and

                  (h) Cerus has advised Baxter of any technology not licensed to
Baxter hereunder, that it believes would be necessary to optimally use the Cerus
Compound in a System.

         17.2 CERUS INDEMNIFICATION -- REPRESENTATIONS AND WARRANTIES. Cerus
shall indemnify Baxter for any losses sustained or expenses incurred by Baxter
as a result of a breach by Cerus of any of the foregoing representations and
warranties.

         17.3 CERUS INDEMNIFICATION -- PRODUCTS. Cerus shall indemnify, hold
harmless and defend Baxter from and against any and all claims, damages,
liability, suits, actions and expenses, including reasonable attorney's fees, by
reason of liability imposed by law upon Baxter resulting from the sale of
Systems to the extent any such liability, expressly including, but

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       41

<Page>

not limited to products liability, arises from the failure to conform to
specifications for Cerus Compounds incorporated into Systems; PROVIDED THAT
Baxter shall give Cerus prompt written notice of such claim and Cerus shall have
the right to defend such claim (Baxter having the right to participate in any
such defense at Baxter's own expense).

         17.4 INSURANCE. Cerus shall, at its own expense, establish and at all
times during the period from Market Launch until three (3) years after the last
delivery of a System under this Agreement products liability insurance in an
amount not less than $5,000,000 each occurrence combined single limit bodily
injury and property damage, PROVIDED THAT such insurance is available on
commercially reasonable terms. The insurance policy shall be endorsed to name
Baxter as an additional insured and to provide for written notification to
Baxter by the insurer not less than thirty (30) days prior to cancellation,
non-renewal or material change. A certificate of insurance evidencing compliance
with this section and referencing this Agreement shall be furnished to Baxter by
Cerus within ten (10) days of Market Launch.

         17.5 BAXTER REPRESENTATIONS. Baxter represents and warrants to Cerus as
of the Effective Date that:

                  (a) It has granted no prior license or assignment of rights
under the Baxter Patents that would materially impair its ability to develop,
manufacture or sell Systems.

                  (b) There are no foreign or United States administrative,
judicial or Patent and Trademark Office proceedings contesting the inventorship
or ownership of any Baxter Patent that is likely to be embodied or used in a
System.

                  (c) neither the execution and deliver of this Agreement, nor
the performance of the obligations of Baxter hereunder shall result in a
violation, breach or event of default (or any event or condition which with
notice or the passage of time or both would constitute an event of default) of
or with respect to any agreement, mortgage, indenture, or order of any court of
competent jurisdiction binding upon Baxter or upon the property of Baxter.

                  (d) it is party to no contract materially adverse to the
obligations undertaken in this Agreement.

                  (e) The execution of this Agreement and delivery to Cerus does
not conflict with the terms of any agreement to which Baxter is bound.

                  (f) Except as previously disclosed to Cerus, Baxter has no
current agreements with other parties for the development and commercialization
of systems for the inactivation of pathogens in the Approved Project Field.

                  (g) Baxter has advised Cerus of any knowledge of any third
party patent or know-how that might be infringed by the incorporation by Baxter
of any Baxter Patent or Baxter Know-How likely to be embodied or used in a
System.

                  (h) Baxter has advised Cerus of any technology not licensed to
Baxter it believes would be necessary to optimally use the Baxter Patents or
Baxter Know-How in a System.

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       42

<Page>

         17.6 BAXTER INDEMNIFICATION - REPRESENTATIONS AND WARRANTIES. Baxter
shall indemnify Cerus for losses sustained or expenses incurred by Cerus as a
result of a breach by Baxter of the foregoing representations and warranties.

         17.7 BAXTER INDEMNIFICATION - PRODUCTS. Baxter shall indemnify, hold
harmless and defend Cerus from and against any and all claims, damages,
liability, suits, actions and expenses, including reasonable attorney's fees, by
reason of liability imposed by law upon Cerus resulting from the sale of Systems
to the extent any such liability, including but not limited to product
liability, arises from the failure of components of Systems supplied by Baxter,
excluding Instruments if manufactured by a third party (PROVIDED THAT Baxter
shall contractually require any third-party manufacturer to indemnify Cerus to
the full extent that Baxter is indemnified by such manufacturer), to conform to
specifications; PROVIDED THAT Cerus shall give Baxter prompt written notice of
such claim and Baxter shall have the right to defend such claim (Cerus having
the right to participate in such defense at its own expense).

         17.8 BAXTER INSURANCE. In the event that the net worth of Baxter shall
at any time be reduced to less than $2 billion U.S., Baxter shall, at its own
expense, establish and at all times that such net worth is not maintained until
three (3) years after the last delivery of a System under this Agreement
maintain products liability insurance in an amount not less than $5,000,000 each
occurrence combined single limit bodily injury and property damage, PROVIDED
THAT such insurance is available on commercially reasonable terms. The insurance
policy shall be endorsed to name Cerus as an additional insured and to provide
for written notification to Cerus by the insurer not less than thirty (30) days
prior to cancellation, non-renewal or material change. A certificate of
insurance evidencing compliance with this section and referencing this Agreement
shall be furnished to Cerus by Baxter within ten (10) days of the date that
Baxter becomes obligated to establish such insurance.

18.      INFRINGEMENT.

         18.1 DEFENSE OF THIRD PARTY INFRINGEMENT SUITS. In the event that a
third party shall sue either party alleging that the manufacture, use or sale of
a System, or any part thereof, infringes a patent of such third party, then the
Management Board shall have the option to control the defense of such suit. The
parties shall provide reasonable cooperation in the defense of such suit and
furnish all evidence in their control. All attorneys' fees as well as any
judgments, settlements, or damages payable with respect to such suit shall be
subject to cost sharing pursuant to Section 3.5 and shall be added to the Final
Project Total Budget. Neither party shall enter into any settlement that
materially affects the other party's rights or interests without such other
party's prior written consent, which consent shall not be unreasonably withheld.

         18.2 SUITS FOR INFRINGEMENT BY OTHERS. In the event Baxter or Cerus
becomes aware of any actual or threatened infringement of the Cerus Patents or
the Cerus Know-How licensed hereunder, or the Baxter Patents or Baxter Know-How
licensed hereunder, that party shall promptly notify the Management Board and
the Management Board shall determine the most appropriate action to take. All
expenses for pursuing such suit shall be subject to cost sharing. Any award in
such suit shall be divided between the parties in proportion to the parties'
relative combined cash contributions and Noncash Contributions to the product or
process that is subject to the infringement.

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       43

<Page>

         In the event the accused product is not in competition with a System in
the Field,

                  (a) Cerus alone may, in its sole discretion and at its
expense, initiate and conduct an infringement action relating to alleged
infringement of Cerus Patents or Cerus Know-How and keep any settlement or award
which may be obtained.

                  (b) Baxter alone may, in its sole discretion and at its
expense, initiate and conduct an infringement action relating to alleged
infringement of Baxter Patents or Baxter Know-How and keep any settlement or
award which may be obtained.

19.      PREFERRED STOCK PURCHASE.

         Baxter will, upon Cerus' written request, purchase such amount of
Preferred Stock as Cerus shall request having an aggregate purchase price not
exceeding nine million five hundred thousand dollars ($9,500,000). The terms of
such Special Preferred Stock are set forth in a Series B Preferred Stock
Purchase Agreement being executed by the parties concurrently herewith.

20.      GENERAL.

         20.1 ENTIRE AGREEMENT. (1) This Agreement and Schedules, (2) the
attached Schedule E Confidentiality Agreement of even date, (3) each stock
purchase agreement pursuant to Section 4.1 hereof, and (4) the Plasma
Derivatives Letter contain the entire agreement between the parties relating to
the subject matter hereof and all prior understandings, representations and
warranties between the parties are superseded; PROVIDED, HOWEVER, that this
Agreement does not limit any agreement restricting disclosure or use of
confidential or proprietary information previously entered into between the
parties. None of the terms of this Agreement shall be deemed to be waived or
amended by either party unless such a waiver or amendment specifically
references this Agreement and is in writing signed by the party to be bound.
Nothing in this Agreement is intended to amend or modify the Platelet Agreement,
except that this Agreement supersedes Sections 8.7 and 8.8 of such agreement,
which provisions shall cease to be effective upon the execution and delivery of
this Agreement.

         20.2 RELATIONSHIP OF PARTIES. Baxter acknowledges that it is not an
agent of Cerus and has no authority to speak for, represent, or obligate Cerus
in any way. Cerus acknowledges that it is not an agent of Baxter and has no
authority to speak for, represent, or obligate Baxter in any way. This Agreement
does not and shall not be deemed to create any relationship of a joint venture
or a partnership.

         20.3 SENIOR BAXTER CONTACT. The senior Baxter contact of the purpose of
administering this Agreement is President, Fenwal, One Baxter Parkway,
Deerfield, Illinois 60015. At present, Roberto Perez occupies this position.

         20.4 SENIOR CERUS CONTACT. The senior Cerus contact for the purpose of
administering this Agreement is the President of Cerus at the address first
above written. At present, Mr. Stephen T. Isaacs occupies this position.

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       44

<Page>

         20.5 SEVERABILITY. The parties do not intend to violate any public
policy or statutory or common law. However, if any sentence, paragraph, clause
or combination of this Agreement is in violation of any law or is found to be
otherwise unenforceable by a court from which there is no appeal, or no appeal
is taken, such sentence, paragraph, clause, or combination of the same shall be
deleted and the remainder of this Agreement shall remain binding, PROVIDED THAT
such deletion does not alter the basic structure of this Agreement. In such
event, the parties shall renegotiate this Agreement in good faith, but should
such negotiations not result in a new agreement with ninety (90) days of the
initiation of such negotiations, then this Agreement may be terminated by either
party by thirty (30) days notice to the other.

         20.6 FORCE MAJEURE. Any party shall be excused from the performance of
its obligations under this Agreement and shall not be liable for damages to the
other if such performance is prevented by circumstances beyond its effective
control. Such excuse from performance shall continue so long as the condition
responsible for such excuse continues and for a thirty (30) day period
thereafter. For the purposes of this Agreement, circumstances beyond the control
of a party which excuse that party from performance shall include, but shall not
be limited to, acts of God, acts, regulations or laws of any government
including currency controls, war, civil commotion, commandeer, destruction of
facility or materials by fire, earthquake, storm or other casualty, labor
disturbances, judgment or injunction of any court, epidemic, and failure of
public utilities or common carrier.

         20.7 NOTICES. All notices and demands required or permitted to be given
or made pursuant to this Agreement shall be in writing and shall be effective
when personally given or made or when placed in an envelope and deposited in the
United States mail postage prepaid, addressed as follows:

<Table>
<S>                                                            <C>
IF TO BAXTER:                                                  IF TO CERUS, IN CARE OF:

General Counsel                                                President and Chief Executive Officer
Baxter Healthcare Corporation                                  Cerus Corporation
One Baxter Parkway                                             2525 Stanwell Drive, Suite 300
Deerfield, Illinois  60015                                     Concord, California  94520

WITH A COPY TO:                                                WITH A COPY TO:

President, Fenwal Division                                     Howard G. Ervin
Baxter Healthcare Corporation                                  Cooley Godward LLP
One Baxter Parkway                                             One Maritime Plaza, 20th Floor
Deerfield, Illinois  60015                                     San Francisco, California  94111

or to such other address as to which either party may notify the other.
</Table>

         20.8 BINDING. This Agreement shall be binding upon and inure to the
benefit of the parties, their successors and assigns. This Agreement shall be
assignable: (i) by either party without the consent of the other to any
Affiliate of the party (an Affiliate being defined as any entity in which the
party or its parent owns or controls directly or indirectly, forty percent (40%)
or more of the voting securities); (ii) by either party with the written consent
of the other; (iii) by either party without the consent of the other in
connection with the purchase or other acquisition of substantially all the
assets of its business to which this Agreement relates; or (iv) by either

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       45

<Page>

party in connection with a reincorporation under the laws of another state. Any
attempted assignment which does not comply with the terms of this Section shall
be void.

         20.9 GOVERNING LAW. This Agreement is deemed to have been executed in
and shall be governed by and construed according to the laws of the State of
Illinois.

         20.10 VENUE. In the event that Baxter files suit against Cerus, it
shall do so in, and hereby agrees to submit to, the jurisdiction of a court in
U.S. District Court, N.D. California. In the event that Cerus files suit against
Baxter, it shall do so in, and hereby agrees to submit to, the jurisdiction of
the U.S. District Court, N.D. Illinois.

         20.11 DISBURSEMENTS. Unless otherwise agreed between the parties, all
disbursements from one party to another under this Agreement shall be paid on or
before the due date by wire transfer to the bank account specified in writing by
the party receiving the disbursement.

         20.12 PUBLICITY. Neither Baxter, Cerus, nor any of their respective
representatives shall issue or cause the publication of any press release,
announcement, or public communication with respect to this Agreement, the Series
A Preferred Stock Purchase Agreement dated the First Amendment Effective Date,
the Series B Preferred Stock Purchase Agreement or the Memorandum of Agreement
between Baxter and Cerus of even date herewith, or the transactions contemplated
hereby or thereby, without the prior written consent of the other party, which
consent will not be unreasonably withheld or delayed. Cerus, however, will not
be restricted from making any public disclosure or filing with a regulatory
agency, if its counsel advises Cerus that such disclosure or filing is required
or advisable to comply with applicable legal requirements.

         20.13 SURVIVAL. Sections 3.1(e)(ii), 8.5, 8.6, 11.1, 16.2, 17.3 and
17.7, and Section 1 to the extent it defines terms in such sections, shall
survive the termination of this Agreement. Any payment obligations accruing
prior to termination shall survive termination until paid, and Section 14 hereof
shall survive termination for a period of two years.

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       46

<Page>

         IN WITNESS WHEREOF, this Agreement is signed by duly authorized
representatives of each party as of the Effective Date.

BAXTER HEALTHCARE CORPORATION                                 CERUS CORPORATION

<Table>
<S>                                                           <C>
By:      /s/ ROBERTO PEREZ                                    By:      /s/ STEPHEN T. ISAACS
         --------------------------------------------                  -------------------------------------------
         Roberto Perez                                                 Stephen T. Isaacs
Title:   President, Fenwal Division                           Title:   President
</Table>

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

<Page>

                                  SCHEDULE A-1

                             INITIAL RED CELL BUDGET

                                    11 Pages

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

<Page>

                                RED CELL PROGRAM

                                 REVISED BUDGET
                                FEBRUARY 28, 1996

<Table>
<Caption>
----------------------------------------------------------------------------------------------------------------------------------
                      1996                   1997                  1998                  1999                  2000
----------------------------------------------------------------------------------------------------------------------------------
                       FTE         $         FTE          $         FTE         $         FTE         $         FTE         $
----------------------------------------------------------------------------------------------------------------------------------
<S>                  <C>         <C>       <C>           <C>      <C>         <C>       <C>         <C>       <C>         <C>
STERITECH R&D
Personnel            [***]       [***]     [***]         [***]    [***]       [***]     [***]       [***]     [***]       [***]
Out of Pocket                    [***]                   [***]                [***]                 [***]                 [***]
Instrument                       [***]                   [***]                [***]                 [***]                 [***]
----------------------------------------------------------------------------------------------------------------------------------
BAXTER R&D
Personnel            [***]       [***]     [***]         [***]    [***]       [***]     [***]       [***]     [***]       [***]
Out of Pocket                    [***]                   [***]                [***]                 [***]                 [***]
Instrument                       [***]                   [***]                [***]                 [***]                 [***]
----------------------------------------------------------------------------------------------------------------------------------
OUTSIDE
[***]                            [***]                   [***]                [***]                 [***]                 [***]
[***]                            [***]                   [***]                [***]                 [***]                 [***]
[***]                            [***]                   [***]                [***]                 [***]                 [***]
[***]                            [***]                   [***]                [***]                 [***]                 [***]
[***]                            [***]                   [***]                [***]                 [***]                 [***]
----------------------------------------------------------------------------------------------------------------------------------
Total                            [***]                   [***]                [***]                 [***]                 [***]
----------------------------------------------------------------------------------------------------------------------------------
</Table>

<Table>
<Caption>
---------------------------------------------------------------
                      2001                    PROJECT TOTAL
---------------------------------------------------------------
                       FTE         $
---------------------------------------------------------------
<S>                  <C>         <C>               <C>
STERITECH R&D
Personnel            [***]       [***]             [***]
Out of Pocket                    [***]             [***]
Instrument                       [***]             [***]
---------------------------------------------------------------
BAXTER R&D
Personnel            [***]       [***]             [***]
Out of Pocket                    [***]             [***]
Instrument                       [***]             [***]
---------------------------------------------------------------
OUTSIDE
[***]                            [***]             [***]
[***]                            [***]             [***]
[***]                            [***]             [***]
[***]                            [***]             [***]
[***]                            [***]             [***]
---------------------------------------------------------------
Total                            [***]             [***]
---------------------------------------------------------------
</Table>

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       1

<Page>

                 RED CELL BUDGET, 1996 PROJECTION: STERITECH R&D

<Table>
<Caption>
------------------------------------------------------------------------------------------------------------------
CATEGORY                       EXPLANATION                                                         FTE/$
==================================================================================================================
<S>                            <C>                                                        <C>
Out of Pocket                                                                                           [***]
------------------------------------------------------------------------------------------------------------------
[***]                          [***]                                                                    [***]
------------------------------------------------------------------------------------------------------------------
[***]                          [***]                                                                    [***]
------------------------------------------------------------------------------------------------------------------
[***]                          [***]                                                                    [***]
------------------------------------------------------------------------------------------------------------------
[***]                          [***]                                                                    [***]
------------------------------------------------------------------------------------------------------------------
[***]                          [***]                                                                    [***]
------------------------------------------------------------------------------------------------------------------
[***]                          [***]                                                                    [***]
------------------------------------------------------------------------------------------------------------------
Project Leader                 [***]                                                                    [***]
==================================================================================================================
                                                                                                        [***]
TOTAL                                                                                                   [***]
------------------------------------------------------------------------------------------------------------------
</Table>

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       2

<Page>

                  RED CELL BUDGET, 1996 PROJECTION: BAXTER R&D

<Table>
<Caption>
---------------------------------------------------------------------------------------
CATEGORY                      EXPLANATION                               FTE/$
=======================================================================================
<S>                           <C>                              <C>
Out of Pocket                                                                [***]
---------------------------------------------------------------------------------------
Instrument                    [***]                                          [***]
---------------------------------------------------------------------------------------
[***]                         [***]                                          [***]
---------------------------------------------------------------------------------------
[***]                         [***]                                          [***]
---------------------------------------------------------------------------------------
Project Coordinator                                                          [***]
=======================================================================================
                                                                             [***]
TOTAL                                                                        [***]
---------------------------------------------------------------------------------------
</Table>

               RED CELL BUDGET, 1996 PROJECTION: OUTSIDE EXPENSES

<Table>
<Caption>
--------------------------------------------------------------------------------------------------
CATEGORY                      EXPLANATION                                            $
==================================================================================================
<S>                           <C>                                                    <C>
[***]                         [***]                                                     [***]
--------------------------------------------------------------------------------------------------
[***]                         [***]                                                     [***]
--------------------------------------------------------------------------------------------------
[***]                         [***]                                                     [***]
==================================================================================================
TOTAL                                                                                   [***]
--------------------------------------------------------------------------------------------------
</Table>

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       3

<Page>

                 RED CELL BUDGET, 1997 PROJECTION: STERITECH R&D

<Table>
<Caption>
------------------------------------------------------------------------------------------------------
CATEGORY                       EXPLANATION                                             FTE/$
======================================================================================================
<S>                            <C>                                            <C>
Out of Pocket                                                                               [***]
------------------------------------------------------------------------------------------------------
[***]                          [***]                                                        [***]
------------------------------------------------------------------------------------------------------
[***]                          [***]                                                        [***]
------------------------------------------------------------------------------------------------------
[***]                          [***]                                                        [***]
------------------------------------------------------------------------------------------------------
[***]                          [***]                                                        [***]
------------------------------------------------------------------------------------------------------
[***]                          [***]                                                        [***]
------------------------------------------------------------------------------------------------------
[***]                          [***]                                                        [***]
------------------------------------------------------------------------------------------------------
Project Leader                                                                              [***]
======================================================================================================
                                                                                            [***]
TOTAL                                                                                       [***]
------------------------------------------------------------------------------------------------------
</Table>

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       4

<Page>

                  RED CELL BUDGET, 1997 PROJECTION: BAXTER R&D

<Table>
<Caption>
-------------------------------------------------------------------------------------------
CATEGORY                       EXPLANATION                                  FTE/$
===========================================================================================
<S>                            <C>                                 <C>
Out of Pocket                                                                    [***]
-------------------------------------------------------------------------------------------
Instrument                     [***]                                             [***]
-------------------------------------------------------------------------------------------
[***]                          [***]                                             [***]
-------------------------------------------------------------------------------------------
[***]                          [***]                                             [***]
-------------------------------------------------------------------------------------------
Instrument                     [***]                                             [***]
-------------------------------------------------------------------------------------------
[***]                          [***]                                             [***]
-------------------------------------------------------------------------------------------
Other Technical                                                                  [***]
-------------------------------------------------------------------------------------------
Project Leader                                                                   [***]
===========================================================================================
                                                                                 [***]
TOTAL                                                                            [***]
-------------------------------------------------------------------------------------------
</Table>

               RED CELL BUDGET, 1997 PROJECTION: OUTSIDE EXPENSES

<Table>
<Caption>
-------------------------------------------------------------------------------------------
CATEGORY                       EXPLANATION                                  $
===========================================================================================
<S>                            <C>                                 <C>
[***]                         [***]                                              [***]
-------------------------------------------------------------------------------------------
[***]                         [***]                                              [***]
-------------------------------------------------------------------------------------------
[***]                         [***]                                              [***]
===========================================================================================
TOTAL                                                                            [***]
-------------------------------------------------------------------------------------------
</Table>

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       5

<Page>

                 RED CELL BUDGET, 1998 PROJECTION: STERITECH R&D

<Table>
<Caption>
----------------------------------------------------------------------------------------------
CATEGORY                      EXPLANATION                                      FTE/$
==============================================================================================
<S>                           <C>                                     <C>
Out of Pocket                                                                       [***]
----------------------------------------------------------------------------------------------
[***]                         [***]                                                 [***]
----------------------------------------------------------------------------------------------
[***]                         [***]                                                 [***]
----------------------------------------------------------------------------------------------
[***]                         [***]                                                 [***]
----------------------------------------------------------------------------------------------
[***]                         [***]                                                 [***]
----------------------------------------------------------------------------------------------
[***]                         [***]                                                 [***]
----------------------------------------------------------------------------------------------
[***]                         [***]                                                 [***]
----------------------------------------------------------------------------------------------
Project Leader                                                                      [***]
==============================================================================================
                                                                                    [***]
TOTAL                                                                               [***]
----------------------------------------------------------------------------------------------
</Table>

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       6

<Page>

                  RED CELL BUDGET, 1998 PROJECTION: BAXTER R&D

<Table>
<Caption>
---------------------------------------------------------------------------------------------------
CATEGORY                       EXPLANATION                                          FTE/$
===================================================================================================
<S>                            <C>                                                  <C>
Out of Pocket                                                                            [***]
---------------------------------------------------------------------------------------------------
Instrument                     [***]                                                     [***]
---------------------------------------------------------------------------------------------------
[***]                          [***]                                                     [***]
---------------------------------------------------------------------------------------------------
Instrument                     [***]                                                     [***]
---------------------------------------------------------------------------------------------------
[***]                          [***]                                                     [***]
---------------------------------------------------------------------------------------------------
Other Technical                                                                          [***]
---------------------------------------------------------------------------------------------------
Project Leader                                                                           [***]
---------------------------------------------------------------------------------------------------
                                                                                         [***]
TOTAL                                                                                    [***]
---------------------------------------------------------------------------------------------------
</Table>

               RED CELL BUDGET, 1998 PROJECTION: OUTSIDE EXPENSES

<Table>
<Caption>
---------------------------------------------------------------------------------------------------
CATEGORY                      EXPLANATION                                            $
===================================================================================================
<S>                           <C>                                                    <C>
[***]                         [***]                                                     [***]
---------------------------------------------------------------------------------------------------
[***]                         [***]                                                     [***]
---------------------------------------------------------------------------------------------------
[***]                         [***]                                                     [***]
---------------------------------------------------------------------------------------------------
[***]                         [***]                                                     [***]
===================================================================================================
TOTAL                                                                                   [***]
---------------------------------------------------------------------------------------------------
</Table>

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       7

<Page>

                 RED CELL BUDGET, 1999 PROJECTION: STERITECH R&D

<Table>
<Caption>
--------------------------------------------------------------------------------------
CATEGORY                      EXPLANATION                              FTE/$
======================================================================================
<S>                           <C>                                      <C>
Out of Pocket                                                               [***]
--------------------------------------------------------------------------------------
[***]                         [***]                                         [***]
--------------------------------------------------------------------------------------
[***]                         [***]                                         [***]
--------------------------------------------------------------------------------------
[***]                         [***]                                         [***]
--------------------------------------------------------------------------------------
[***]                         [***]                                         [***]
--------------------------------------------------------------------------------------
[***]                         [***]                                         [***]
--------------------------------------------------------------------------------------
Project Leader                                                              [***]
======================================================================================
                                                                            [***]
TOTAL                                                                       [***]
--------------------------------------------------------------------------------------
</Table>

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       8

<Page>

                  RED CELL BUDGET, 1999 PROJECTION: BAXTER R&D

<Table>
<Caption>
----------------------------------------------------------------------------------------------------------
CATEGORY                       EXPLANATION                                                 FTE/$
==========================================================================================================
<S>                            <C>                                                         <C>
Out of Pocket                                                                                   [***]
----------------------------------------------------------------------------------------------------------
Instrument                     [***]                                                            [***]
----------------------------------------------------------------------------------------------------------
[***]                          [***]                                                            [***]
----------------------------------------------------------------------------------------------------------
[***]                          [***]                                                            [***]
----------------------------------------------------------------------------------------------------------
Project Leader                                                                                  [***]
==========================================================================================================
                                                                                                [***]
TOTAL                                                                                           [***]
----------------------------------------------------------------------------------------------------------
</Table>

               RED CELL BUDGET, 1999 PROJECTION: OUTSIDE EXPENSES

<Table>
<Caption>
----------------------------------------------------------------------------------------------------------
CATEGORY                       EXPLANATION                                                   $
==========================================================================================================
<S>                            <C>                                                           <C>
[***]                          [***]                                                            [***]
----------------------------------------------------------------------------------------------------------
[***]                          [***]                                                            [***]
----------------------------------------------------------------------------------------------------------
[***]                          [***]                                                            [***]
----------------------------------------------------------------------------------------------------------
[***]                          [***]                                                            [***]
==========================================================================================================
TOTAL                                                                                           [***]
----------------------------------------------------------------------------------------------------------
</Table>

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       9

<Page>

                 RED CELL BUDGET, 2000 PROJECTION: STERITECH R&D

<Table>
<Caption>
CATEGORY                      EXPLANATION                                     FTE/$
=============================================================================================
<S>                           <C>                                             <C>
Out of Pocket                                                                      [***]
---------------------------------------------------------------------------------------------
[***]                         [***]                                                [***]
---------------------------------------------------------------------------------------------
[***]                         [***]                                                [***]
---------------------------------------------------------------------------------------------
[***]                         [***]                                                [***]
---------------------------------------------------------------------------------------------
Project Leader                                                                     [***]
=============================================================================================
                                                                                   [***]
TOTAL                                                                              [***]
---------------------------------------------------------------------------------------------
</Table>

                  RED CELL BUDGET, 2000 PROJECTION: BAXTER R&D

<Table>
<Caption>
---------------------------------------------------------------------------------------------
CATEGORY                      EXPLANATION                                     FTE/$
=============================================================================================
<S>                           <C>                                             <C>
Out of Pocket                                                                      [***]
---------------------------------------------------------------------------------------------
[***]                         [***]                                                [***]
---------------------------------------------------------------------------------------------
[***]                         [***]                                                [***]
=============================================================================================
                                                                                   [***]
TOTAL                                                                              [***]
---------------------------------------------------------------------------------------------
</Table>

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       10

<Page>

               RED CELL BUDGET, 2000 PROJECTION: OUTSIDE EXPENSES

<Table>
<Caption>
-------------------------------------------------------------------------------------------------------
CATEGORY                      EXPLANATION                                                 $
=======================================================================================================
<S>                           <C>                                                         <C>
[***]                         [***]                                                          [***]
-------------------------------------------------------------------------------------------------------
[***]                         [***]                                                          [***]
=======================================================================================================
TOTAL                                                                                        [***]
-------------------------------------------------------------------------------------------------------
</Table>

                  RED CELL BUDGET, 2001 PROJECTION: BAXTER R&D

<Table>
<Caption>
-------------------------------------------------------------------------------------------------------
CATEGORY                      EXPLANATION                                               FTE/$
=======================================================================================================
<S>                           <C>                                                       <C>
Out of Pocket                                                                                [***]
-------------------------------------------------------------------------------------------------------
[***]                         [***]                                                          [***]
-------------------------------------------------------------------------------------------------------
[***]                         [***]                                                          [***]
=======================================================================================================
                                                                                             [***]
TOTAL                                                                                        [***]
-------------------------------------------------------------------------------------------------------
</Table>

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       11

<Page>

                                  SCHEDULE A-2

                    1998 RED CELL PROGRAM BUDGET DEVELOPMENT

                                   [...***...]

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

<Page>

                                   SCHEDULE B

                             INITIAL S59 FFP BUDGET

                                    11 Pages

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

<Page>

                                   FFP PROGRAM

                                 REVISED BUDGET
                                FEBRUARY 28, 1996

<Table>
<Caption>
------------------------------------------------------------------------------------------------------------------------------------
                 1996               1997                  1998                  1999                  2000             PROJECT TOTAL
------------------------------------------------------------------------------------------------------------------------------------
                  FTE       $       FTE          $         FTE         $         FTE         $         FTE        $
------------------------------------------------------------------------------------------------------------------------------------
<S>             <C>       <C>     <C>          <C>       <C>         <C>       <C>         <C>       <C>        <C>         <C>
STERITECH R&D
Personnel       [***]     [***]   [***]        [***]     [***]       [***]     [***]       [***]     [***]      [***]       [***]
Out of Pocket             [***]                [***]                 [***]                 [***]                [***]       [***]
                                                                                                                            [***]
------------------------------------------------------------------------------------------------------------------------------------
BAXTER R&D
Personnel       [***]     [***]   [***]        [***]     [***]       [***]     [***]       [***]     [***]      [***]       [***]
Out of Pocket             [***]                [***]                 [***]                 [***]                [***]       [***]
Instrument                [***]                [***]                 [***]                 [***]                [***]       [***]
------------------------------------------------------------------------------------------------------------------------------------
OUTSIDE
[***]                     [***]                [***]                 [***]                 [***]                [***]       [***]
[***]                     [***]                [***]                 [***]                 [***]                [***]       [***]
[***]                     [***]                [***]                 [***]                 [***]                [***]       [***]
[***]                     [***]                [***]                 [***]                 [***]                [***]       [***]
------------------------------------------------------------------------------------------------------------------------------------
Total                     [***]                [***]                 [***]                 [***]                [***]       [***]
------------------------------------------------------------------------------------------------------------------------------------
</Table>

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       1

<Page>

                   FFP BUDGET, 1996 PROJECTION: STERITECH R&D

<Table>
<Caption>
--------------------------------------------------------------------------------------------------
CATEGORY                      EXPLANATION                                          FTE/$
==================================================================================================
<S>                           <C>                                                  <C>
Out of Pocket                 [***]                                                     [***]
--------------------------------------------------------------------------------------------------
[***]                         [***]                                                     [***]
--------------------------------------------------------------------------------------------------
[***]                         [***]                                                     [***]
--------------------------------------------------------------------------------------------------
[***]                         [***]                                                     [***]
--------------------------------------------------------------------------------------------------
[***]                         [***]                                                     [***]
--------------------------------------------------------------------------------------------------
[***]                         [***]                                                     [***]
--------------------------------------------------------------------------------------------------
[***]                         [***]                                                     [***]
==================================================================================================
                                                                                        [***]
TOTAL                                                                                   [***]
--------------------------------------------------------------------------------------------------
</Table>

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       2

<Page>

                     FFP BUDGET, 1996 PROJECTION: BAXTER R&D

<Table>
<Caption>
---------------------------------------------------------------------------------------------------------------------------
CATEGORY                       EXPLANATION                                                                  FTE/$
===========================================================================================================================
<S>                            <C>                                                                          <C>
Out of Pocket                  [***]                                                                             [***]
---------------------------------------------------------------------------------------------------------------------------
[***]                          [***]                                                                             [***]
---------------------------------------------------------------------------------------------------------------------------
[***]                          [***]                                                                             [***]
---------------------------------------------------------------------------------------------------------------------------
[***]                          [***]                                                                             [***]
---------------------------------------------------------------------------------------------------------------------------
Project Leader                 [***]                                                                             [***]
===========================================================================================================================
                                                                                                                 [***]
TOTAL                                                                                                            [***]
---------------------------------------------------------------------------------------------------------------------------
</Table>

                  FFP BUDGET, 1996 PROJECTION: OUTSIDE EXPENSES

<Table>
<Caption>
---------------------------------------------------------------------------------------------------------------------------
CATEGORY                      EXPLANATION                                                                     $
===========================================================================================================================
<S>                           <C>                                                                             <C>
[***]                         [***]                                                                              [***]
---------------------------------------------------------------------------------------------------------------------------
[***]                         [***]                                                                              [***]
===========================================================================================================================
TOTAL                                                                                                            [***]
---------------------------------------------------------------------------------------------------------------------------
</Table>

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       3

<Page>

                   FFP BUDGET, 1997 PROJECTION: STERITECH R&D

<Table>
<Caption>
-----------------------------------------------------------------------------------------------------------------------------------
CATEGORY                       EXPLANATION                                                                          FTE/$
===================================================================================================================================
<S>                            <C>                                                                                  <C>
Out of Pocket                  [***]                                                                                     [***]
-----------------------------------------------------------------------------------------------------------------------------------
[***]                          [***]                                                                                     [***]
-----------------------------------------------------------------------------------------------------------------------------------
[***]                          [***]                                                                                     [***]
-----------------------------------------------------------------------------------------------------------------------------------
[***]                          [***]                                                                                     [***]
-----------------------------------------------------------------------------------------------------------------------------------
[***]                          [***]                                                                                     [***]
-----------------------------------------------------------------------------------------------------------------------------------
[***]                          [***]                                                                                     [***]
-----------------------------------------------------------------------------------------------------------------------------------
[***]                          [***]                                                                                     [***]
-----------------------------------------------------------------------------------------------------------------------------------
[***]                          [***]                                                                                     [***]
-----------------------------------------------------------------------------------------------------------------------------------
Project Leader                 [***]                                                                                     [***]
===================================================================================================================================
                                                                                                                         [***]
TOTAL                                                                                                                    [***]
-----------------------------------------------------------------------------------------------------------------------------------
</Table>

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       4

<Page>

                     FFP BUDGET, 1997 PROJECTION: BAXTER R&D

<Table>
<Caption>
------------------------------------------------------------------------------------------------------------------------------------
CATEGORY                      EXPLANATION                                                                             FTE/$
====================================================================================================================================
<S>                           <C>                                                                                     <C>
Out of Pocket                                                                                                              [***]
------------------------------------------------------------------------------------------------------------------------------------
[***]                         [***]                                                                                        [***]
------------------------------------------------------------------------------------------------------------------------------------
[***]                         [***]                                                                                        [***]
------------------------------------------------------------------------------------------------------------------------------------
[***]                         [***]                                                                                        [***]
                                                                                                                           [***]
------------------------------------------------------------------------------------------------------------------------------------
Project Leader                [***]                                                                                        [***]
====================================================================================================================================
                                                                                                                           [***]
TOTAL                                                                                                                      [***]
------------------------------------------------------------------------------------------------------------------------------------
</Table>

                  FFP BUDGET, 1997 PROJECTION: OUTSIDE EXPENSES

<Table>
<Caption>
------------------------------------------------------------------------------------------------------------------------------------
CATEGORY                      EXPLANATION                                                                               $
====================================================================================================================================
<S>                           <C>                                                                                       <C>
[***]                         [***]                                                                                        [***]
------------------------------------------------------------------------------------------------------------------------------------
[***]                         [***]                                                                                        [***]
------------------------------------------------------------------------------------------------------------------------------------
[***]                         [***]                                                                                        [***]
====================================================================================================================================
TOTAL                                                                                                                      [***]
------------------------------------------------------------------------------------------------------------------------------------
</Table>

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       5

<Page>

                   FFP BUDGET, 1998 PROJECTION: STERITECH R&D

<Table>
<Caption>
-----------------------------------------------------------------------------------------------------------------------------
CATEGORY                        EXPLANATION                                                                    FTE/$
=============================================================================================================================
<S>                             <C>                                                                            <C>
Out of Pocket                   [***]                                                                              [***]
-----------------------------------------------------------------------------------------------------------------------------
[***]                           [***]                                                                              [***]
-----------------------------------------------------------------------------------------------------------------------------
[***]                           [***]                                                                              [***]
-----------------------------------------------------------------------------------------------------------------------------
[***]                           [***]                                                                              [***]
-----------------------------------------------------------------------------------------------------------------------------
[***]                           [***]                                                                              [***]
-----------------------------------------------------------------------------------------------------------------------------
[***]                           [***]                                                                              [***]
-----------------------------------------------------------------------------------------------------------------------------
Project Leader                  [***]                                                                              [***]
=============================================================================================================================
                                                                                                                   [***]
TOTAL                                                                                                              [***]
-----------------------------------------------------------------------------------------------------------------------------
</Table>

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       6

<Page>

                     FFP BUDGET, 1998 PROJECTION: BAXTER R&D

<Table>
<Caption>
------------------------------------------------------------------------------------------------------------------------------
CATEGORY                      EXPLANATION                                                                      FTE/$
==============================================================================================================================
<S>                           <C>                                                                              <C>
Out of Pocket                 [***]                                                                                 [***]
------------------------------------------------------------------------------------------------------------------------------
[***]                         [***]                                                                                 [***]
------------------------------------------------------------------------------------------------------------------------------
[***]                         [***]                                                                                 [***]
                                                                                                                    [***]
------------------------------------------------------------------------------------------------------------------------------
Project Leader                [***]                                                                                 [***]
==============================================================================================================================
                                                                                                                    [***]
TOTAL                                                                                                               [***]
------------------------------------------------------------------------------------------------------------------------------
</Table>

                  FFP BUDGET, 1998 PROJECTION: OUTSIDE EXPENSES

<Table>
<Caption>
------------------------------------------------------------------------------------------------------------------------------
CATEGORY                      EXPLANATION                                                                        $
==============================================================================================================================
<S>                           <C>                                                                                <C>
[***]                         [***]                                                                                 [***]
------------------------------------------------------------------------------------------------------------------------------
[***]                         [***]                                                                                 [***]
==============================================================================================================================
TOTAL                                                                                                               [***]
------------------------------------------------------------------------------------------------------------------------------
</Table>

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       7

<Page>

                   FFP BUDGET, 1999 PROJECTION: STERITECH R&D

<Table>
<Caption>
------------------------------------------------------------------------------------------------------------------------------
CATEGORY                      EXPLANATION                                                                      FTE/$
==============================================================================================================================
<S>                           <C>                                                                              <C>
Out of Pocket                 [***]                                                                                 [***]
------------------------------------------------------------------------------------------------------------------------------
[***]                         [***]                                                                                 [***]
------------------------------------------------------------------------------------------------------------------------------
[***]                         [***]                                                                                 [***]
------------------------------------------------------------------------------------------------------------------------------
[***]                         [***]                                                                                 [***]
==============================================================================================================================
                                                                                                                    [***]
TOTAL                                                                                                               [***]
------------------------------------------------------------------------------------------------------------------------------
</Table>

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       8

<Page>

                     FFP BUDGET, 1999 PROJECTION: BAXTER R&D

<Table>
<Caption>
------------------------------------------------------------------------------------------------------------------------------
CATEGORY                      EXPLANATION                                                                      FTE/$
==============================================================================================================================
<S>                           <C>                                                                              <C>
Out of Pocket                 [***]                                                                                 [***]
------------------------------------------------------------------------------------------------------------------------------
[***]                         [***]                                                                                 [***]
------------------------------------------------------------------------------------------------------------------------------
[***]                         [***]                                                                                 [***]
------------------------------------------------------------------------------------------------------------------------------
[***]                         [***]                                                                                 [***]
------------------------------------------------------------------------------------------------------------------------------
Project Leader                [***]                                                                                 [***]
==============================================================================================================================
                                                                                                                    [***]
TOTAL                                                                                                               [***]
------------------------------------------------------------------------------------------------------------------------------
</Table>

                  FFP BUDGET, 1999 PROJECTION: OUTSIDE EXPENSES

<Table>
<Caption>
------------------------------------------------------------------------------------------------------------------------------
CATEGORY                      EXPLANATION                                                                        $
==============================================================================================================================
<S>                           <C>                                                                                <C>
[***]                         [***]                                                                                 [***]
==============================================================================================================================
TOTAL                                                                                                               [***]
------------------------------------------------------------------------------------------------------------------------------
</Table>

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       9

<Page>

                   FFP BUDGET, 2000 PROJECTION: STERITECH R&D

<Table>
<Caption>
------------------------------------------------------------------------------------------------------------------------------------
CATEGORY                      EXPLANATION                                                                               FTE/$
====================================================================================================================================
<S>                           <C>                                                                                       <C>
Out of Pocket                 [***]                                                                                          [***]
------------------------------------------------------------------------------------------------------------------------------------
[***]                         [***]                                                                                          [***]
------------------------------------------------------------------------------------------------------------------------------------
Project Leader                [***]                                                                                          [***]
====================================================================================================================================
                                                                                                                             [***]
TOTAL                                                                                                                        [***]
------------------------------------------------------------------------------------------------------------------------------------
</Table>

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       10

<Page>

                     FFP BUDGET, 2000 PROJECTION: BAXTER R&D

<Table>
<Caption>
----------------------------------------------------------------------------------------------------------------------
CATEGORY                      EXPLANATION                                                              FTE/$
======================================================================================================================
<S>                           <C>                                                                      <C>
[***]                         [***]                                                                         [***]
----------------------------------------------------------------------------------------------------------------------
[***]                         [***]                                                                         [***]
----------------------------------------------------------------------------------------------------------------------
Project Leader                [***]                                                                         [***]
======================================================================================================================
                                                                                                            [***]
TOTAL                                                                                                       [***]
----------------------------------------------------------------------------------------------------------------------
</Table>

                  FFP BUDGET, 2000 PROJECTION: OUTSIDE EXPENSES

<Table>
<Caption>
----------------------------------------------------------------------------------------------------------------------
CATEGORY                      EXPLANATION                                                                $
======================================================================================================================
<S>                           <C>                                                                        <C>
[***]                         [***]                                                                         [***]
======================================================================================================================
TOTAL                                                                                                       [***]
----------------------------------------------------------------------------------------------------------------------
</Table>

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       11

<Page>

                                   SCHEDULE C

                                  NO SCHEDULE C

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

<Page>

                                   SCHEDULE D

                            PLASMA DERIVATIVES LETTER

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

<Page>

                          <Table>
                          <S>                               <C>                                 <C>
                          Kim C. Bush                       Baxter Healthcare Corporation       Phone:  708.270.4110
                          President                         Route 120 and Wilson Road             Fax:  708.270.3855
                          Fenwal Division                   Round Lake, Illinois 60073
                          Biotech Group
</Table>

                                   SCHEDULE D
BAXTER

January 18, 1996

Mr. Stephen T. Isaacs
President and CEO
Steritech, Inc.
2525 Stanwell Drive
Suite 300
Concord, CA  94520

RE:    [***]

Dear Steve:

Thank you for your letter of December 26, 1995 discussing the rescission of your
Notice dated November 10, 1995. As we discussed on several occasions, Baxter is
[***] It has always been the position of Baxter that the Steritech
decontamination technology would be [***] With this in mind, this letter
confirms the agreement of Baxter and Steritech that:

(i) Steritech is entitled to negotiate and enter into agreements with third
parties for the development and/or licensing to such third parties of [***] free
of any rights of Baxter and without obligation to Baxter, except as set forth in
clause (ii) below.

(ii) In those cases where Steritech licenses [***] other than Baxter, Steritech
shall, at Baxter's written request, license such Steritech technology to Baxter
for such product on terms no less favorable than the terms received by such
other manufacturer.

Steritech will notify Baxter of the names of the third-party manufacturers with
whom Steritech is negotiating for licenses to Steritech's [***]

This letter agreement supersedes [***] of the Development Manufacturing and
Marketing Agreement between Steritech and Baxter, dated as of December 10, 1993,
insofar as such section concerns [***] (For the purposes of this letter, the
term [***] used in such section.)

Upon the execution and delivery by Steritech of this letter where indicated
below, the Notice dated November 10, 1996 is rescinded.

Sincerely,

Kim C. Bush
President, Fenwal Division
Biotech Group

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

<Page>

Mr. Stephen T. Isaacs
January 18, 1996
Page 2

AGREED AS SET FORTH ABOVE

Steritech, Inc.

By:
   -----------------------------------------
         Stephen T. Isaacs
         President

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

<Page>

                                   SCHEDULE E

                            CONFIDENTIALITY AGREEMENT

         THIS AGREEMENT, made on March 18, 1996 with respect to the Development,
Manufacturing and Marketing Agreement ("Agreement") between Baxter and Steritech
dated as of April 1, 1996 between STERITECH, INC. ("Steritech"), having a
principal place of business at 2525 Stanwell Drive, Concord, California and
BAXTER HEALTHCARE CORPORATION ("Baxter"), a corporation having a principal place
of business at One Baxter Parkway, Deerfield, Illinois 60015, to assure the
protection and preservation of Proprietary Information disclosed or to be
disclosed or made available to each other in connection with the Agreement.

         WHEREAS, the parties have entered into a development, manufacturing and
marketing collaboration pursuant to the Agreement;

         WHEREAS, the parties desire to assure the confidential status of the
information which may be disclosed to each other in connection with the
Agreement;

         NOW, THEREFORE, in reliance upon and in consideration of the following
undertakings, the parties agree as follows:

         1. All information disclosed to the other party shall be deemed to be
"Proprietary Information." In particular, Proprietary Information shall be
deemed to include any information, process, techniques, algorithm, program,
design, drawing, formula or test data relating to any research project, work in
progress, future development, engineering, manufacturing, marketing, servicing,
financing or personnel matter relating to the disclosing party, its present or
future products, sales, suppliers, clients, customers, employees, investors, or
business. Any Proprietary Information outside the scope of the Agreement shall
be identified by the disclosing party in writing and marked "Confidential" or if
such Proprietary Information is disclosed orally, within 30 days after such
disclosure the Proprietary Information shall be reduced to writing and marked
"Confidential" by the disclosing party and such writing forwarded to the
receiving party.

         2. The term "Proprietary Information" shall not be deemed to include
information which: (i) is now, or hereafter becomes, through no act or failure
to act on the part of the receiving party, generally known or available; (ii) is
known by the receiving party at the time of receiving such information as
evidenced by its records; (iii) is furnished to the receiving party by a third
party whom the receiving party believes has a right to disclose such
information; (iv) is independently developed by the receiving party without any
breach of this Confidentiality Agreement; and (v) is the subject of a written
permission to disclose provided by the disclosing party.

         3. Each party shall maintain in trust and confidence and not disclose
to any third party or use for any unauthorized purpose any Proprietary
Information received from the other party. However, each party may disclose
Proprietary Information to its affiliates who are bound by this Agreement
(affiliates include: any company owning 40% or more of a party, or a subsidiary
of the party, or a subsidiary of a party owning 40% or more of the party). Each
party may use such Proprietary Information only to the extent required under the
Agreement.

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

<Page>

         4. The responsibilities of the parties with respect to the Proprietary
Information are limited to using the same degree of care used to protect their
own Proprietary Information from unauthorized use or disclosure. Both parties
shall advise their employees or agents who might have access to such Proprietary
Information of the confidential nature thereof.

         5. This Confidentiality Agreement shall continue in full force and
effect for so long as the parties continue to exchange Proprietary Information
under the Agreement. The termination of the Agreement shall not relieve either
party of the obligations imposed by this Confidentiality Agreement with respect
to Proprietary Information disclosed prior to the effective date of such
termination, which obligations shall survive the termination of the Agreement
for a period of two (2) years from the date of disclosure.

         6. Each party hereby acknowledges and agrees that in the event of any
breach of this Confidentiality Agreement by the other party, including, without
limitation, the actual or threatened disclosure of a disclosing party's
Proprietary Information without the prior express written consent of the
disclosing party, the disclosing party will suffer an irreparable injury, such
that no remedy at law will afford it adequate protection against, or appropriate
compensation for such injury. Accordingly, each party hereby agrees that the
other party shall be entitled to any injunctive relieve as may be granted by a
court of competent jurisdiction.

<Table>
<S>                                                           <C>
AGREED TO:                                                    AGREED TO:

STERITECH, INC.                                               BAXTER HEALTHCARE CORPORATION

By:      Stephen T. Isaacs                                    By:      Kim Bush
         President                                                     President, Fenwal Division
</Table>

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

<Page>

                                   SCHEDULE F

                                  NO SCHEDULE F

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

<Page>

                                   SCHEDULE G

                            STOCK PURCHASE AGREEMENT

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

<Page>

                                   SCHEDULE H

                      EXAMPLE OF COST OF GOODS/BASE REVENUE

                                   [...***...]

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

<Page>

                                   SCHEDULE I

                              AMORTIZATION SCHEDULE

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

<Page>

                                   SCHEDULE I

                              AMORTIZATION SCHEDULE

                        MAXIMUM AMOUNT OF AMORTIZATION TO
                            REDUCE COMMITTED FUNDING

Set forth below are the maximum amounts of amortization that may reduce the
minimum committed funding by Baxter under Section 3.3.

<Table>
<Caption>
                                                             MAXIMUM
                                       YEAR                 REDUCTION
<S>                                                         <C>
                                       1998                 [...***...]
                                       1999                 [...***...]
                                       2000                 [...***...]
                                       2001                 [...***...]
                                       2002                 [...***...]
                                       2003                 [...***...]
</Table>

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

<Page>

                                   SCHEDULE J

                     BAXTER NON-EMPLOYEE SECURITY AGREEMENT

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

<Page>

                                   SCHEDULE J

                            BAXTER HEALTH CORPORATION
                         NONEMPLOYEE SECURITY AGREEMENT

BAXTER HEALTH CORPORATION                        NONEMPLOYEE SECURITY AGREEMENT
DEERFIELD, ILLINOIS  60015

In consideration of my potential or continued business relationship or
association with Baxter Healthcare Corporation or one of its affiliated
companies, successors or assigns, (together "Baxter")

I, ________________________________ individually, and on behalf of my employer,
            (Printed Name)
_____________________________________________________________________ for which
               (Print Company Name and Address)

I am authorized to sign this agreement agree to the following terms and
conditions of association:

     (a) I understand that during the course of my association with Baxter I may
         acquire or have access to information that is confidential and of great
         value to Baxter. This information may include the nature of research
         and/or development projects as well as data relating to them; it may
         further include, without limitation, products, customers, suppliers,
         pricing, costs, know-how, strategies, programs, processes, and
         practices.

     (b) I agree to use Baxter's confidential information only for the direct
         and sole benefit of Baxter, and I will not disclose Baxter's
         confidential information to others without the express written
         authorization of Baxter, provided, however, that any information
         relating to pathogen inactivation technology or programs may be
         disclosed to Cerus Corporation ("Cerus") for use consistent with the
         terms of agreements in affect between Baxter and Cerus (the
         "Collaboration Agreements").

     (c) I agree that the foregoing restrictions on the use and disclosure of
         Baxter's confidential information shall continue for ten years
         following the date of this agreement and shall survive termination of
         my association with Baxter. I understand further that the foregoing
         restrictions do not apply to information which I can establish by my
         written records was in my possession prior to disclosure by Baxter to
         me, or is or becomes public knowledge through no fault of my own, or
         which I acquire from others not under obligation of secrecy to Baxter.

I understand that during the course of my association with Baxter I may also
acquire or have access to information that is confidential and of great value to
third parties. I will comply with the terms of any applicable confidentiality
agreement between Baxter and a third party, and will not use or disclose third
party confidential information in violation of an applicable confidentiality
agreement.

I will not remove from Baxter's premises any documents, files, records,
correspondence, notes, or other papers (including copies) relating to the
business of Baxter, except as our association shall require and with permission
of an authorized Baxter representative, and in such cases I will promptly return
such items to Baxter upon request or upon termination of my association.

If during my association with Baxter I am given, or prepare or produce, any
drawings, samples, prototypes, products or equipment according to Baxter's
specifications, or incorporating any of Baxter's ideas or technology, I agree
not to show or display to any third party, nor in any manner publicly use, or
give, distribute, transfer or sell, to any third party any of the aforesaid
items without first obtaining the express written permission of Baxter, except
disclosure to Cerus and use consistent with the Collaboration Agreement.

I understand that, except for information disclosed pursuant to the
Collaboration Agreements, Baxter is not willing to accept on a confidential
basis any information, suggestion or idea belonging to me or my employer. I
therefore agree that if I do disclose such information, suggestion or idea to
Baxter, Baxter shall have no liability to me or my employer because of Baxter's
disclosure or use of such information, suggestion or idea, except liability for
infringement of any valid patent now or hereafter issued thereon.

Dated this _______ day of _____________________

            Signature:
                       ---------------------------------------------------------

            Title:
                  --------------------------------------------------------------

ACCEPTED on  _____________________

            Baxter Healthcare Corporation

            By:
               -----------------------------------------------------------------

            Title:
                  --------------------------------------------------------------

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00029-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00029-of-00352.parquet"}]]